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Th2 Effector T-cells involved in the initiation of humoral immune responses 
TLR Toll-like receptor  
Tm°C  Melting temperature 
TMB 3, 3 ,´ 5, 5 -´tetramethylbenzidene 
TNF-α Tumor necrosis factor alpha 
Tris  Tris (hydroxymethyl) amino methane 
U  Units 
UV Ultraviolet  
vol Volume  
v/v Volume per volume  
w/v Weight per volume  
V Voltage  
WHO World Health Organsation  
YNB Yeast Nitrogen Base  
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Abstract 
Highly pathogenic avian influenza virus is a continuous threat to the global poultry industry, 
and results in occasional spill-over infections into the human population. The rapid antigenic 
shift and drift of influenza virus often results in outbreaks of novel influenza virus, such as 
the highly pathogenic H5N1 avian flu. The virus has broad reservoirs from sea mammals to 
avian species, and thus eradiation of the virus has proven difficult, therefore the prevention 
of virus spread and circulation is considered the most effective method for disease control 
[1]. 
 
The first objective of this study was to evaluate the immunogenicity of a recombinant 
influenza haemagglutinin domain 1 (rHA1) expressed in Pichia pastoris (P. pastoris). In a 
project previously carried out in my Master’s study, the HA1 genes derived from influenza 
H1N1 (A/Puerto Rico/8/34) was cloned in P. pastoris vector, and the rHA1 was successfully 
expressed as soluble secreted protein, and purified using Immobilised metal ion 
chromatography (IMAC) under native conditions. The rHA1 protein was administered into 
mice to evaluate its immunogenicity. The animal study has revealed that, immunised mice 
exhibited robust Th2-type T-lymphocyte and anti-HA1 IgG responses, and developed a 
virus-neutralising antibody response for hemagglutination inhibition (HI) at titer 7.4 log2. The 
result suggests that the Pichia-expressed rHA1 may be used as an immunogen for the 
prevention of influenza infection, and the technique developed in this study could serve as a 
cost and time effective solution for influenza virus vaccines.  
 
Salmonella have many advantages as a vaccine delivery vector, as they are easy to produce, 
easy to administer (orally), and are able to elicit both humoral immunity including serum and 
secretory IgA antibody, and strong cell mediated immune responses that include cytotoxic 
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and memory T-lymphocytes [2-4]. Furthermore, vaccinated recombinant Salmonella not only 
elicit immune responses against the heterologous antigen, but also to Salmonella itself, 
providing protective immunity against both Salmonella and the heterologous pathogen.  
 
The second objective of this study was to use Salmonella Typhimurium strain STM1 (an 
ΔaroA mutant developed at RMIT), as a delivery vector for an influenza antigen. Different 
strategies were used to present the influenza hemagglutinin (HA) antigen from various 
destinations to optimise immunogenicity. These include one to display the HA antigen on the 
outer membrane of Salmonella (utilising plasmid pHES, encoding the N-terminal signal 
peptide and the essential C-terminal translocation unit of the ShdA autotransporter from S. 
Typhimurium strain LT-2 [5]) and another to secrete it into the media (pMOhly1, encoding 
the necessary components of the E. coli α-haemolysin secretion system [6]).  
 
After successful cloned the HA1 gene into each plasmid vector and passed into STM1, the 
expression was characterised. Protein analysis indicated that rHA1 expressed using pHES 
vector was translocated to the outer membrane fraction of the STM1 surface; whereas rHA1 
expressed using pMOhly1 vector was detected in the growth medium. A chicken study was 
carried out to evaluate the immunogenicity of these STM1 clones; the vaccine strains were 
administered through oral gavaging and STM1 harbouring empty pHES and pMOhly1 
plasmids were used as control group in the study. 
 
The animal trial results indicated that STM1 expressing HA1 using pHES were unable to 
persist/colonise after administration, and neither humoral nor cell-mediated immune  
responses against influenza HA1 were elicited using the vaccine strain. On the other hand, 
STM1 expressing HA1 using pMOhly1 was able to induce a Th1-type immune response, 
indicated by the secretion of INF-γ from splenocytes after being stimulated by either 
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Pichia-expressed rHA1 or inactivated influenza PR-8 virus. However, humoral immune 
responses were not elicited using this vaccine.  
 
Taken together, these results indicated that Pichia-expressed influenza rHA1 could induce not 
only virus-specific humoral immune responses, but also stimulate a Th2-type cell-mediated 
immune response, which would likely be protective against influenza infections. The STM1 
expressing secretory rHA1 using pMOhly1 vector successfully induced Th1-biased 
cell-mediated immune responses, which are suggested to be important in delayed-type viral 
clearance [7].  
 
Even though the results acquired in these studies were not optimal, there were significant 
responses to the influenza antigen which suggested that further investigation is required. For 
this to happen, it is possible to induce a more well-balanced immune response against 
influenza virus by combining both subunit rHA1 and STM1 vaccine strain into a prime-boost 
vaccine scheme. Such a vaccine regimen could ensure the elicitation of both humoral and 
cell-mediated immune responses against influenza infections.  
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1.1 Introduction 
The prevention of infectious diseases has been one of the most difficult tasks for humanity. 
The burden associated with disease and infection is diverse and inevitable. Before the era of 
vaccination, diseases and infections were often managed by improved education, hygiene, 
and drug treatment. However, in terms of disease management, it is always more beneficial 
for the public to prevent diseases rather than to treat and cure them. The prevention of 
disease is often done by immunisation, otherwise known as vaccination, which modulates 
the host immune system to inhibit disease progression. Currently, there are many successful 
vaccines available for the prevention of a variety of diseases in humans and animals, but 
there are still diseases that kill millions of lives globally which urgently demand a vaccine. 
Vaccine development is dependent on the understanding of disease etiology; the immune 
responses associated with the disease and most importantly, to sustain long-lasting 
immunity for ongoing protection. This review will discuss the evolution of vaccines from its 
first documented practice to the more advanced novel vaccines, and the modern 
achievements used in the prevention of influenza infections.  
 
1.2 Evolution of Vaccine Development 
Variolation is the most primitive procedure of disease control in recorded history. The 
procedure involves the deliberate inoculation of infectious material such as purulent 
discharge, saliva or blood from an infected person into a healthy individual via direct contact 
[8]. The procedure is believed to have originated in India or China, but was introduced to the 
United Kingdom in 1721 by Lady Wortley-Montagu, who was the wife of a British 
ambassador to the Sublime Porte. Despite the initial skepticism, variolation slowly became 
regular practice in the United Kingdom, and in 1757, an 8-year-old boy named Edward 
Jenner was variolated with smallpox. The procedure was a success, as the boy became 
immune to smallpox after recovering from a mild case of the disease. Jenner later became 
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well-known around the world for his innovative contribution in immunisation against 
smallpox using matter taken from cowpox lesions [9]. Variolation ultimately spared 
countless lives from smallpox - the deadliest disease of the time. Despite its great success, 
there were several risks associated within the procedure: 1) the procedure could weaken or 
even kill the recipient if incorrectly administered, or if the recipient was physically unfit to 
withstand the infection, and 2) the recipient could became contagious after variolation, 
risking an epidemic [10, 11].  
 
Jenner’s pioneering work of infecting people with cowpox to confer protective immunity to 
smallpox was widely considered as the basis of modern immunology. Since then, the term 
vaccine has been used for any preparation of dead or attenuated pathogens or their 
products, where these preparations when introduced into the body conferred the elicitation 
of protective immune responses without causing disease. The next huge leap in regards to 
the understanding of infectious disease and immunity was achieved by the separate work of 
Louis Pasteur and Robert Koch and germ theory.  
 
Louis Pasteur demonstrated that virulence of Pasteurella multocida could be attenuated and 
evidenced the concept of immunity and generalised the principle of vaccination [12], while 
Robert Koch developed general microbiology methods, diagnosis of tuberculosis, and public 
control measures for cholera. Together with his fellow scientist Jacob Henle, they compiled 
the Koch-Henle postulate for the definition of microbial pathogens [13, 14]. After Pasteur’s 
vaccine studies, Salmon and Smith developed the first inactivated whole-cell vaccine for the 
prevention of Salmonella infections in 1886 [10].  
 
The field of vaccine development is still rapidly evolving three centuries after Jenner’s 
pioneering discovery. Over the centuries, vaccines have achieved many great successes, 
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including the eradication of smallpox, the close eradication of polio, and the prevention of 
many other infectious diseases with significant morbidities and mortalities [15]. However, 
there are still a considerable number of diseases which require an effective vaccine such as 
AIDS, tuberculosis, and malaria. Recent advances in molecular immunology, structure and 
computational biology, nanotechnology, and vaccine formulations have heralded in a new 
era of vaccine discovery in the 21st century [15].  
 
1.3 Vaccine Delivery 
Vaccine delivery is a crucial part in vaccine development, which encompasses: the route of 
vaccine administration and specific vaccine formulation for the activation of appropriate 
immune response [16]. Vaccine formulations can be administered to different sites of the 
body by intramuscular (i.m.), subcutaneous (s.c.), transcutaneous (t.c.), oral and nasal 
delivery. Each of these administration routes would require different vaccine formulations to 
optimise their immunogenicity [16]. Furthermore, vaccine dosage and number of 
vaccinations are also crucial to the successful elicitation of protective immune responses. 
Prior to licensing, these factors have to be carefully considered and evaluated in a 
randomised trial, which examines the vaccine efficacy at the individual level [17]. In general, 
the vaccine dosage should be kept to a minimum, but still sufficient to elicit a protective 
immune response in the majority of the test subjects. This could reduce the possibility of 
adverse effects caused by vaccine overdose [18-20], and increase the cost-effectiveness [17]. 
On the other hand, protective immunity following a single vaccine dosage can sometimes be 
incomplete and/or short-lived. Multiple doses of vaccines can be used to overcome these 
obstacle, which could improve the percentage of vaccinees who develop protective immune 
responses and prolong the duration of such immunity [21]. 
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1.3.1 Intramuscular and subcutaneous administration 
Subcutaneous administration is the oldest method for delivering vaccine, whereas 
intramuscular vaccination is a relatively new technique and is commonly used for modern 
vaccines such as Gardasil® and the seasonal influenza vaccine. Although i.m. vaccinations are 
routinely used in developed countries, there are several drawbacks in regards to this method 
of delivery which include: 1) trained personnel are required to administer the vaccines, 2) 
possible needle injuries 3) biohazardous waste – needle and syringe, 4) risk of bloodborne 
pathogen transmission, 5) cold storage and transportation for liquid-based vaccines 6) 
needle phobia, and 7) unable to induce mucosal immunity [16].  
 
1.3.2 Intranasal and oral administration 
In general, mucosal vaccine delivery is advantageous over i.m. and s.c. vaccinations as it 
eliminates risks associate with needle injections, and is more likely to induce both systemic 
and mucosal immune responses. Furthermore, mass vaccinations in Third World countries 
are more likely to be achieved [22-24]. Region-specific mucosa-associated lymphoid tissue 
(MALT) consists of inductive and effector sites, and mucosa-draining lymph nodes (LNs), and 
these specific mucosal inductive sites are crucial for eliciting both humoral and cell-mediated 
immune (CMI) responses [25-27]. Intranasal vaccines are usually administered by spraying, 
which allows a large contact surface of the nasal mucosa underlined with 
nasopharynx-associated lymphoid tissue (NALT), to be stimulated [22, 23]. One of the 
well-known intranasal vaccines is FluMist®, which is a trivalent live attenuated influenza 
vaccine given by nasal spray and licensed in the U.S. for persons aged between 5 ~ 50 years 
[28]. A large clinical study concluded that intranasal delivery was well tolerated, and after 
two doses of vaccine, 61% of initially seronegative children had antibodies to influenza A 
(H1N1), and 96% had antibodies to each of the other vaccine subtypes (A (N3N2) and Type B) 
[28]. However, there is an increased risk of developing Bell’s palsy, a paralysis or weakness 
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on one side of the facial muscles, associated with this vaccine [29]. Furthermore, the vaccine 
recipient may experience an unpleasant taste and nasal discomfort, which could discourage 
repeated use [30].  
 
Oral vaccination inherits the advantages of mucosal vaccines. However, the development of 
oral vaccines is complicated by the fact that vaccines must be able to withstand the harsh 
conditions of the gastrointestinal tract [24]. Antigen uptake by intestinal epithelial cells and 
antigen presenting cells (APCs) is inefficient, which often leads to limited immunogenic 
properties [31]. However, a wide variety of antigen delivery particulates are under 
investigation to overcome these obstacles, including polymer- or nano-based microparticles, 
immun-stimulating complexes and liposomes [24, 32-35]. 
 
1.4 Adjuvants 
Adjuvants are broadly defined as compounds that enhance the potency and longevity of a 
specific immune response to vaccine antigens. This can potentially make an ineffective 
vaccine become effective and has also been known as the “dirty little secret of 
immunologists” [36, 37]. 
 
Modern vaccines generally require the assistance of appropriate adjuvants to induce potent 
and long-lasting, specific immune responses to vaccine antigens [38]. Currently, there are 
three main types of vaccines: live-attenuated, inactivated, and subunit vaccines. Unlike 
live-attenuated vaccines, inactivated and subunit vaccines are usually less immunogenic, 
hence assistance from adjuvant is often required for enhancing, sustaining and directing 
vaccine immunogenicity [39, 40].  
 
 
CHAPTER 1 
7 
 
A good adjuvant or adjuvant formulation should be: 1) non-toxic or have minimal toxicity at 
the dosage to induce effective adjuvanticity, 2) capable of eliciting the desired humoral 
and/or cell-mediated immunity, 3) capable of conferring long-lasting immunity, 4) safe, 
without causing disease such as autoimmunity and cancer, and 5) assist in vaccine stability 
[37]. 
 
Modern adjuvants can be generally classified into two different categories according to their 
mechanism of adjuvanticity – immunostimulants and vehicles [38]. The functions of 
immunostimulants are to potentiate the specific immune response by directing an antigen to 
immune cells, facilitating phagocytosis and/or activating APCs [41]. Such a system can be 
achieved by formulating vaccine antigens together with naturally occurring 
immunostimulating proteins such as the E. coli heat-labile toxin (LT) or cholera toxin (CT) [42]. 
Other Immunostimulants such as lipopolysaccharides (LPS) derived from the bacterial outer 
membrane of gram-negative bacteria may be directly recognised by toll-like receptors (TLRs) 
on APCs, and initiate innate immune responses [35, 43].  
 
Vehicle adjuvants, also known as the “depot delivery system”, are used to slow the release of 
vaccine antigens from the site of injection, hence optimising vaccine immunogenicity [39, 44]. 
This is often accomplished by entrapping the vaccine antigen in a poorly metabolised and 
slow-degrading compound such as aluminium-salt-based adjuvant (Alum) [38, 41]. Alum has 
been the most commonly used adjuvant. It was first published in 1929, and it’s the only 
adjuvant that is currently licensed for the use in human vaccines [45, 46]. Alum promotes 
antigen phagocytosis via APCs such as dendritic cells (DCs), macrophages and B-lymphocytes, 
and it also enhances MHC class II expression and antigen presentation [47, 48]. However, 
Alum is unable to elicit Th1 and cytotoxic T-lymphocyte (CTL) responses, which are crucial in 
controlling most intracellular pathogens such as TB, malaria and AIDS [38]. Moreover, 
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formation of granulomas due to repeated injection of Alum-adjuvanted vaccine is also of 
concern [39].  
 
1.5 Traditional vaccines 
The traditional approaches to vaccine development have focused on using attenuated, 
inactivated or modified pathogens. There are numerous successful vaccines developed using 
these approaches (as summarised in Table 1.1). The traditional vaccines can be generally 
classified into three types: 1) attenuated vaccines; 2) inactivated vaccines; and 3) subunit 
vaccines (Figure 1.1).  
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Table 1.1: Examples of conventional vaccines 
 
 
 
 
 
 
 
 
 
 
 
Type of vaccine  Target pathogens  Type of immunity 
Attenuated     
Bacterial  Salmonella, Tuberculosis  IgA, CMI 
Viral  Measles, Mumps, Rubella, Polio  IgA, CMI 
Inactivated     
Bacterial  Salmonella, Yersinia, Leptospires  IgG 
Viral  Polio, influenza   IgG 
Sub-unit     
Bacterial  Clostridial Fusiformis-toxoid  IgG 
Viral  FMDV-capsid  IgG 
Table adapted from [49] 
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Figure 1.1: Traditional vaccine methodologies. 
Traditional vaccines were designed empirically using: a) Killed (inactivated) pathogen; b) 
attenuated pathogen; and c) subunit of target pathogen. Many successful vaccines were 
developed using these approaches. Image adapted from [50] 
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1.5.1 Attenuated vaccines 
Upon attenuation, a pathogen is subjected to altered growth temperature, serial passage in 
cell-lines or cultures, or genetic modification. These procedures are performed to reduce or 
eliminate virulence, but also retain their ability to replicate at a reduced rate. As the live 
pathogen is still capable of establishing infection in target cells, they are able to induce 
“targeted” immunity against the pathogen. Furthermore, attenuated vaccines usually have 
the advantage of convenient administration, such as via intranasal or oral routes [51]. The 
use of attenuated vaccines is unsafe in immunocompromised individuals as the vaccine 
pathogen may persist due to a limited immune response, and reversion of these vaccine 
strains to the pathogenic wild-type is also of great concern [52, 53]. Moreover, attenuated 
vaccines have evolved into vaccine carriers, in which heterologous antigens from unrelated 
pathogens can be genetically engineered to be expressed in these carriers [3, 54]. Details of 
vaccine carriers will be discussed subsequently.  
 
1.5.2 Inactivated vaccines 
In contrast to live attenuated vaccines, inactivated vaccines are generally more stable and 
safe, as the pathogen has lost the ability to replicate by means of treatment with heat, 
chemical or radiation. However, the drawback of these vaccines is their inability to infect 
cells and subsequent lack of cell-mediated immunity, which makes the vaccines less 
immunogenic. Therefore, multiple injections and strong adjuvants are often required to elicit 
sufficient protective immunity [55]. Repeated vaccination with adjuvanted vaccines could 
potentially cause serious adverse reactions such as autoimmune disorders and allergy [56]. 
Despite these disadvantages and safety concerns, many inactivated vaccines are still 
commonly used today, such as the seasonal influenza vaccine and the inactivated polio 
vaccine [49]. 
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1.5.3 Subunit vaccines 
A subunit vaccine relies on the use of microbial components to elicit appropriate immune 
responses against the target pathogen. Since potentially harmful pathogen components are 
not administered, it significantly improves vaccine safety [57]. Subunit vaccines are easily 
manufactured in bulk quantities with high consistency, able to induce immune responses 
against specific pathogen epitopes, and are highly stable [58], but are generally less 
immunogenic than the traditional whole-cell preparations [59]. To ensure long-lasting 
protective immunity, the incorporation of potent adjuvants along with multiple 
administrations of the vaccine is necessary [57, 60]. A successful example of a subunit 
vaccine is the hepatitis B virus (HBV) vaccine which consists of highly purified recombinant 
envelope protein found on the viral surface [61, 62]. The immunisation strategy is a course of 
three injections which confers more than 95% and 90% protection in infants and adults, 
respectively [61]. However, non-responders to the HBV vaccine account for a small yet 
significant amount of vaccinees [63].  
 
1.6 Modern vaccines 
Following the era of traditional approaches in vaccine development, more sophisticated 
vaccines have been developed. 
 
1.6.1 Conjugate vaccines  
Conjugate vaccines use molecular technology to join a weak antigen such as bacterial 
polysaccharide - generally only possessing a B-lymphocyte epitope, to a carrier protein which 
contains T-lymphocyte epitopes to boost immunogenicity [64, 65].  
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1.6.2 Synthetic peptides 
Synthetic peptides are an epitopes-based approach by synthesising small peptides containing 
regions of T-lymphocyte epitopes, and used as vaccine antigen to elicit potent cell-mediated 
immunity [66]. However, these peptides are often not as immunogenic as the whole protein, 
hence need to be optimised to enhance immunogenicity. 
 
1.6.3 Reverse vaccinology 
Reverse vaccinology is an approach used to analyse the genome of a pathogen in order to 
explore the complete repertoire of antigenic candidates [67, 68]. The selected candidates are 
then expressed recombinantly and immunogenicity is then evaluated in vivo [68]. The search 
for candidate antigens is initiated by screening for coding regions and open reading frames 
(ORFs), followed by homology searches using the potential antigens against known and 
characterised proteins. Finally, the selected potential antigens are subjected to structural and 
functional genomic analysis to identify their cellular location, and the candidate vaccine 
antigens are recombinantly expressed to examine their immunogenicity [69-72].  
 
1.6.4 DNA vaccines  
DNA vaccines use a bacterial plasmid encoding the antigen protein and equipped with a 
potent eukaryotic promoter to induce protein expression in situ [73]. The vaccine can be 
administrated via intramuscular, subcutaneous or mucosal routes, depending on which 
immune cell is to be stimulated [74]. The DNA constructs enter the cell nucleus and the 
antigenic proteins are expressed by host cell machinery, and the proteins are recognised by 
the host immune system and elicit immune responses [75, 76].  
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One key attraction to DNA vaccines is the potential to deliver antigens to both major 
histocompatibility complex (MHC) class I and class II pathways. In particularly the MHC class I 
pathway, which is responsible for the generation of cytotoxic T-lymphocyte immune 
responses (CTLs) is often unachievable by traditional inactivated and subunit vaccines [75, 
77].  
 
Currently, there are no DNA-based vaccines licensed for human use, but four veterinary 
products are available. These include West Nile virus vaccine for horses [78], hematopoietic 
necrosis virus vaccine for fish [79], a melanoma cancer vaccine for canines [80], and a growth 
hormone enhancing product for swine [81].  
 
1.6.5 RNA vaccines  
The concept of the RNA vaccine was first demonstrated by Wolff et al., 1990 [82], when mice 
immunised intramuscularly with messenger RNA (mRNA) vectors encoded with reporter 
proteins, demonstrated that in vivo protein expression from “foreign” RNA molecules was 
achievable [82]. Thereafter, Martinon et al., 1993 [83], described the induction of 
virus-specific CTLs immune responses in vivo in mice, by immunisation of 
liposome-entrapped mRNA encoding the influenza virus nucleoprotein (NP) [83]. One 
superior fact about the RNA vaccine is that a significant portion of the host innate immune 
response is responsible for sensing and counteracting viral particles with the RNA genome.  
Thus, certain forms of RNA molecules can stimulate potent innate immunity, which plays an 
important role in the subsequent generation of effective adaptive immune responses [76, 84, 
85]. 
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1.6.6 Vector vaccines  
1.6.6.1 Viral vectors 
The concept of using virus as vaccine vectors involves a highly-attenuated recombinant viral 
pathogen which infect host cells and hijacks the cellular machinery to express both viral 
proteins and vaccine antigens, subsequently inducing an immune response [86, 87].  
 
Viral vector vaccines are known to elicit strong humoral immune responses, and also have 
the potential to activate CTLs through MHC class I presentation [86]. In addition, CTLs are 
known to detect and target strain-independent highly conserved antigenic epitopes, and 
such epitopes are often inaccessible to antibodies which are restricted by their functionality 
and position [86]. One such example was demonstrated by Brewoo et al., 2013 [88], where 
the influenza structural protein nucleoprotein (NP), derived from influenza H1N1 
(A/influenza/Puerto Rico/8/34), was inserted into modified recombinant vaccinia virus 
Ankara (MVA). Immunised mice showed complete protection against lethal challenges from 
homologous H1N1 (A/Norway/3487-2/09), and heterologous H5N1 (A/Vietnam/1203/04), 
and partial protection against seasonal H3N2 (A/Aichi/68) [88]. The vaccine did not only 
induce significant levels of neutralising antibody responses, but also elicited IFN-γ secreting 
CD8+ and CD4+ T-lymphocytes and IL-2 secreting CD4+ T-lymphocytes [88]. This example 
provides a proof-of-concept that structural and highly conserved pathogenic epitopes can be 
carried by viral vectors and induce protective immunity.  
 
1.6.6.2 Bacterial vectors 
The use of attenuated bacteria to express heterologous antigens and serve as vaccine 
carriers has been extensively studied over the last 30 years [89]. Such technology provides 
versatile applications in vaccine development, and has been used to elicit immune responses 
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against bacterial, viral, protozoan and metazoan pathogens in animal models and clinical 
studies [89, 90]. Bacterial vaccine vectors possesses many advantages: 1) they are easy and 
inexpensive to manufacture with flexible scalability; 2) there are multiple vaccination routes 
available, especially oral-mucosal routes [89, 91]; 3) enteric bacterial vectors have tropism 
towards lymphoid antigen presenting cells (e.g. dendritic cells and macrophage) in the 
intestinal mucosal tract, which is a unique asset for developing mucosal vaccines [89, 92-96]; 
and 4) they are known to elicit potent innate and adaptive immune responses against 
Salmonella and heterologous antigens [97, 98].  
 
A variety of heterologous antigens expressed in bacterial vectors have been shown to confer 
protection against disease in animal models, but suboptimal results observed in humans and 
primates have stalled the development of such vaccine strategies [90, 99]. Currently, there 
are no licensed bacterial vaccine vectors, but substantial evidence suggest that recombinant 
Listeria monocytogenes, Salmonella and Shigella vaccine carriers are competent to elicit both 
humoral and cell-mediated immunity against a heterologous antigen [89].  
 
Intracellular pathogens such as Salmonella spp. are known to establish infection via the 
intestinal tract, therefore oral administration can easily be achieved. Furthermore, studies 
have shown their ability to present homologous and heterologous antigens to both 
endogenous and exogenous antigen-presenting pathways, eliciting CD4+ and CD8+ 
T-lymphocyte activities, and to stimulate humoral immune responses to induce serum and 
secretory IgA antibodies [100-107]. Nevertheless, the concerns of reversion to pathogenic 
wild-type and limited immunogenicity due to pre-existing immunity against vaccine vectors, 
must be properly addressed for the development of such vaccine systems [2, 89].  
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1.7 Salmonella-vectored vaccines 
Salmonella are Gram-negative bacilli, facultative anaerobic, motile, non-lactose fermenting, 
belonging to the Enterobacteriaceae family. Salmonella infect humans and animals generally 
by the oral-faecal route [108]. 
 
1.7.1 Pioneer study of Salmonella-vectored vaccines 
The use of attenuated Salmonella as a carrier for heterologous protein via oral delivery has 
been well documented over the last few decades. In the early 1980’s, Formal et al., 1981 
[109] conducted a Pioneering study into heterologous antigen presentation using Salmonella 
species as a vaccine carrier, where the first existing attenuated typhoid vaccine Salmonella 
enterica serovar Typhi Ty21a was used to present the form I antigen from Shigella sonnei. 
This vaccine induced protection against infection from both S. enterica and S. sonnei in 
immunised mice. Thereafter, a vast variety of recombinant attenuated Salmonella strains 
have been generated to target various infectious and non-infectious diseases [110].  
 
1.7.2 Salmonella pathogenesis and immune responses 
Salmonella is favorable over other vaccine carriers, based on the fact that upon Salmonella 
infection, both Salmonella and heterologous antigens are delivered into APCs such as DCs 
and macrophages - the natural target cells of Salmonella [111]. Furthermore, Salmonella 
pathogen-associated molecular patterns (PAMPs) elicit potent innate immune responses 
during infection [16], which stimulate the maturation of these APCs and migration to 
secondary lymph nodes, leading to the initiation of adaptive immune responses [112]. 
Therefore, Salmonella self-derived PAMPs serve as vaccine adjuvants which amplify the 
immune response against the heterologous antigen. Salmonella-based vaccine carriers also 
promise flexibility and versatility in regards to directing appropriate immunological reactions 
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including CD4+ T-lymphocytes, CD8+ T-lymphocytes and regulatory T-lymphocytes, which 
were shown to be elicited during Salmonella infection, and confer protective immunity 
against different diseases [113-118].  
 
Attenuated Salmonella has also become an attractive vector to deliver modern DNA vaccines, 
where the heterologous genes are not expressed, but carried by the vector. This is because 
Salmonella has the unique ability to transfer expression plasmids to host cells, even if the 
bacteria are unable to escape the phagocytic vacuole [119, 120]. 
 
1.7.3 Role of antigen presenting cells in Salmonella immunity 
As a facultative intracellular pathogen, T-lymphocytes are vital components of the specific 
immune response to Salmonella. The bacterial specific CD4+ and CD8+ T-lymphocytes are 
essential for complete protection against S. Typhimurium [121]. Macrophages and immature 
DCs also play an important role in the elicitation of both innate and adaptive immune 
responses to the infection. These cells capture and degrade bacteria in a defined proteolytic 
pathway, and processed bacterial antigens are displayed on the APC for antigen recognition 
[122].  
 
The MHC class I and the class II molecules expressed on APC surface present antigenic 
peptides that are accessible to CD8+ cytotoxic T-lymphocyte and CD4+ helper T-lymphocyte 
[123]. The MHC class I molecules containing antigenic fragments are transported to the 
endoplasmic reticulum before being transferred to the MHC molecule, and then the antigen 
fragment is presented via MHC molecule for recognition by CTL [123]. For MHC class II 
presentation, after endocytosis and fusion with the lysosome, degraded protein fragments 
enter the MHC class II molecule pathway [124], which suggested that the major phagocytic 
cells, neutrophils, macrophages and DCs all play a role in the induction of S. Typhimurium 
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specific T-lymphocytes responses. Nevertheless, DCs are believed to have a superior ability 
to stimulate naïve T-lymphocyte in comparison to macrophages.  
 
1.7.4 Attenuation for a Salmonella-vectored vaccine 
In the past, attenuation of bacteria has been achieved by chemical mutagenesis, for example 
Salmonella Typhi Ty21a [125]. However, most of the attenuated Salmonella strains currently 
used for experimental or clinical studies are auxotrophic strains which are generated via the 
deletion or mutation of essential genes that are accountable for biosynthesis of metabolically 
essential elements such as aromatic amino acids (aro), guanidine (gua) or purine (pur) [99]. 
These mutations attenuate the strain whilst preserving its immunogenicity. Such Salmonella 
mutants have shown promising results in animal models. For example, in guinea pigs, the 
orally administered Salmonella Typhimurium aroA mutant expressing chromosomally 
integrated Mycobacterium tuberculosis fusion antigen Ag85B-ESAT6 followed by boosting 
with a dose of purified Ag85B-ESAT6, successfully reduced the level of M. tuberculosis in the 
lung and spleen to the same extent as the BCG vaccine [126]. Another study demonstrated 
that the passenger antigen delivered could be detected in Peyer’s patches and the spleen 
several days after immunisation with the attenuated Salmonella, even if the expression 
plasmid was lost soon after administration [119]. Darji et al., 2000 [120] demonstrated that 
even though plasmid loss took place, mice that were immunised four times with attenuated 
Salmonella encoded virulence factors of L. monocytogenes through oral administration were 
protected from a lethal challenge with L. monocytogenes.  
 
1.7.5 Genetic stability and protein expression of heterologous genes 
1.7.5.1 Chromosomal integration 
Chromosomal integration of a cassette encoding the heterologous antigen gene allows 
maximum genetic stability, as chromosomal DNA rarely undergoes mutation or deletion 
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[127]. However, chromosomal integration usually results in a single copy of heterologous 
antigen per bacterium, which is a challenge that has to be resolved to ensure sufficient 
antigen is expressed to confer protective immunity [128]. Consequently, the selection of a 
potent and inducible promoter is therefore important.  
 
1.7.5.2 Plasmid-based expression systems 
Plasmid-based heterologous antigen expression on the other hand, is hindered by the 
metabolic burden associated with plasmid replication, which can over-attenuate the carrier 
or lead to spontaneous loss of plasmid [129]. There are a wide variety of strategies being 
investigated to improve plasmid retention. One of the most successful strategies for the 
prevention of plasmid loss is known as the conditional lethal system. This system maintains 
the plasmid-bearing bacterial population by encoding replication-essential proteins in the 
plasmid, so that plasmid-less daughter cells are unable to survive without the plasmids [130, 
131]. In one such approach, the asd gene which encodes aspartate β-semialdehyde 
dehydrogenase was used. It is an important enzyme for not only amino acid synthesis, but 
also for cell wall synthesis [131]. Consequently, harbouring an asd-encoding plasmid is 
essential for survival, unless the bacteria carry the chromosome-encoding asd gene. This 
particular system has been successfully demonstrated in a live attenuated S. Typhimurium to 
carry a variety of heterologous antigens including a viral peptide from HBV [132], and F1-Ag 
and V-Ag antigens derived from Yersinia pestis [133]. The S. Typhimurium vaccine induced 
potent humoral immune responses, including serum IgG and secretory IgA in mucosally 
immunised mice. 
 
Another important aspect of using a vaccine carrier to deliver heterologous antigen is how 
the protein expression is controlled and compartmentalised. Regulating the level and 
location of heterologous antigen expression can have a significant impact on the 
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immunogenicity of a vaccine carrier. Incorporating an appropriate expression promoter is the 
key to guarantee the desired level and timing of antigen delivery, and to confer the optimal 
immune responses [134]. Early studies conducted by Hohmann et al., 1995 [134] 
demonstrated that an antigenic protein expressed from a constitutive promoter encoded in S. 
Typhimurium chromosome was incapable of inducing a protective antigen-specific immune 
response. In contrast, in vivo-inducible promoters such as PpagC, which only induces antigen 
expression after the bacterial cell has been phagocytosed by macrophages, have induced a 
strong serum IgG response against the same antigen [134]. It was suggested that although 
the constitutive promoter confers high levels of heterologous antigen expression, there is an 
overall increase in metabolic burden to the vaccine carrier, which compromises 
immunogenicity [135].  
 
1.7.6 Heterologous antigen presentation 
It is known that the nature of antigen toxicity within a vaccine carrier could hinder 
colonisation and reduce overall antigen delivery. Protein folding is another essential element 
for inducing protective humoral responses against conformational epitopes. Several 
strategies have been developed to overcome these hurdles, which include the export of the 
antigen to the extracellular space and direct surface display [136, 137]. Kang and Curtiss, 
2003 [138] demonstrated that in orally immunised mice, the antigen-specific humoral 
response of an attenuated S. Typhymurium carrying PspA derived from S. pneumonia surface 
protein was enhanced 10,000-fold by incorporating the secretion signal from β-lactamase 
compared with the unfused PspA construct. Surface display is an attractive means to present 
heterologous antigen to the host immune system because of the potential to elicit potent 
humoral immunity. Currently, heterologous genes can be fused into a gene encoding 
bacterial outer membrane proteins such as OmpA [139], LamB [140] or flagellin [141]. The 
fusion protein that contains the heterologous antigen is then presented on the bacterial 
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outer membrane for immunological stimulation. Another approach for surface display is to 
utilise the bacterial autotransporter (AT) system. The ATs are the most abundant proteins 
encoding many virulence factors of Gram-negative bacteria, and are responsible for 
exporting the N-terminal domain of the fusion protein to the bacterial outer membrane 
[141].  
 
1.7.7 Immune responses against heterologous antigen 
Salmonella as a vector vaccine carrying heterologous antigen can in theory induce both local 
and systemic immune responses. The understanding of S. Typhimurium pathogenesis and the 
cross-interaction between the host immune system and associated virulence factors allowed 
the generation of live-attenuated Salmonella vaccines and their application for the delivery 
of heterologous vaccine antigen [3].  
 
1.7.7.1 Cell-mediated immune responses 
It has been demonstrated that Salmonella expressed heterologous antigens can elicit Th1, 
Th2 and CTL responses [142]. However, the level of immune stimulation may vary depending 
on several factors such as the types of strains, attenuation and antigenic protein expressed 
[143]. The activation of a Th1 response is characterised by the up-regulation of IFN-γ; 
whereas the induction of a Th2 response is characterised by IL-4 [138]. Some studies also 
demonstrated the activation of CTL responses to the passenger antigens [144-146] 
 
1.7.7.2 Humoral immune responses 
Some studies have demonstrated that protective humoral responses against a heterologous 
antigen can be elicited by Salmonella-vectored vaccine carrier, which include bacterial, viral 
and parasitic antigens [147-153]. The induction of IgA antibody responses against 
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heterologous antigen in the intestinal tract, saliva and lung have been reported in some 
studies using oral administration [154-156]. The elicitation of serum IgG responses against 
heterologous antigen has also been demonstrated when the vaccine was orally administered 
[156-158].  
 
Furthermore, the induction of both Th1 and Th2 responses against heterologous antigen has 
been observed by the presence of characteristic IgG1 and IgG2 serum antibodies, as IgG1 is 
an indicative of a Th2 response and IgG2 is indicative of a Th1 response [154, 155, 157].  
 
1.7.8 Application to livestock 
There have been studies demonstrating the use of Salmonella vaccine carriers carrying a 
heterologous antigen for application in livestock. Stokes et al., 2007 [159] demonstrated the 
use of a vector expressing a Bacillus anthracis protective antigen which conferred protection 
against aerosolised B. anthracis spores in orally immunised mice, and had previously shown 
to induce protection against spore challenge through subcutaneous delivery [160].  
 
1.8 Veterinary vaccines 
The objectives for the development of successful veterinary vaccines can be very different 
from those for human vaccines, depending on the target host. Vaccines for companion 
animals generally have similar objectives as for human vaccines, as the health and welfare of 
individual animals is the main consideration for vaccine development. In livestock animals on 
the other hand, the cost-benefit of food production and improved overall production is the 
bottom line that drives vaccine development [51, 161]. It is also driven by the requirement 
for the protection of livestock against zoonotic pathogens, and consumers against 
food-borne pathogens [51]. Vaccine development for wildlife is generally restricted to the 
pathogens that are transmittable to humans, such as the sporadic outbreaks of highly 
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pathogenic avian influenza infections in Southeast Asia, and increasing interest for the 
development of such a vaccine has been seen in recent years [51]. 
 
In terms of economic considerations of animal vaccine development, the potential returns 
are much less compared to human vaccines. This is mainly due to a low sale-price or fewer 
market requirements, hence leading to lower investment in the research and development of 
animal vaccines [161]. Nevertheless, the regulations for approval of animal vaccines are 
usually less stringent than for human vaccines, resulting in faster market launch and 
investment returns, which is advantageous over the development of human vaccines [51].  
 
Conventional veterinary vaccines are usually based on live-attenuated or inactivated 
pathogens, for example, the inactivated equine influenza virus vaccine [55]. Nowadays, 
molecular techniques are increasingly employed in the development of second generation 
veterinary vaccines, such as the DNA vaccine against infectious hematopoietic necrosis virus 
for salmon [79], and the fowl pox viral vectored vaccine against Newcastle disease virus for 
poultry [162].  
 
1.9 Influenza virus 
Influenza remains as one of the most important diseases in humans and animals, as the virus 
continuously undergoes antigenic changes and has a broad range of animal reservoirs [163]. 
There are three types of influenza virus: A, B and C, with the classification based on the 
serological reactivity of internal proteins. Influenza type B and type C are mostly restricted to 
humans and occasionally isolated from other mammalian hosts. Type A influenza virus on the 
other hand, causes disease in a wide variety of avian and mammalian species [164, 165]. As 
type B and type C influenza virus result in minor illness, they are not of much concern, 
whereas type A influenza virus has the potential to evade the human immune system and 
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result in widespread infection [166]. This review will explore the human and socioeconomic 
impacts caused by type A influenza virus infections, the viral pathogenesis and the current 
and potential control measures. 
 
1.9.1 Influenza in the poultry industry 
In 1878, a mysterious contagious disease in poultry associated with a high mortality rate was 
described in Northern Italy. The disease was initially termed “fowl plague” and was confused 
with the acute septicemic form of fowl cholera [167]. The disease subsequently spread along 
with poultry merchants to Eastern Austria, Germany, and later Belgium and France, 
eventually becoming endemic throughout Central Europe and Italy [168]. Decades after the 
first description of fowl plague, the causative agent was identified as a virus in 1901 and 
further determined to be a type A influenza virus in 1955. The term “fowl plague” was finally 
replaced by the more appropriate term “highly pathogenic avian influenza” at the First 
International Symposium on Avian Influenza in 1981 [167].  
 
Type A influenza virus is sub-typed according to serological analysis, to two 
surface-glycoproteins known as hemagglutinin (HA) and neuraminidase (NA). To date, 17 HA 
and 10 NA subtypes have been identified [169]. These avian influenza viruses (AIV) are 
further classified according to their disease manifestations, where low pathogenic AIV (LPAIV) 
causes asymptomatic to mild infections, and highly pathogenic AIV (HPAIV) results in up to 
100% morbidity and mortality [169-171]. Until now, there are only some strains of H7 or H5 
subtypes which meet the defined criteria of being highly pathogenic, and they are believed 
to have evolved from low pathogenic precursors [167].  
 
AIV have been isolated from a variety of animal species including humans, pigs, horses, mink, 
felids, marine mammals, domestic birds and free-flying wild birds [172]. As summarised by 
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Olsen et al., 2006 [172], LPAIV have been isolated from at least 105 wild birds species of 26 
different families, and it is well-documented that these LPAIV from wild birds are occasionally 
spread along their migratory route, to the major AIV reservoirs “domestic birds” (i.e. duck, 
geese, terns and wader), and cause sporadic LPAIV or HPAIV outbreaks [172]. The first 
serologically confirmed HPAIV outbreak in poultry was in a small farm in Scotland in 1959 
[173], thereafter, in excess of 28 separate HPAIV outbreaks were documented, resulting in 
significant economic losses [167, 174]. For instance, the H5N2 HPAIV outbreak in 
Pennsylvania in 1983 initiated with a low pathogenic H5N2 virus, where acute respiratory 
disease with increased mortality (0% to 2.7%), and decreased egg production (4% to 43%), 
was diagnosed in an egg-laying flock. The disease was then spread between flocks, and an 
estimated 100 flocks became infected between April and October of 1983 [175]. Later in the 
year, signs of virus mutation were seen in a layer flock, where the chickens exhibited 
significantly decreased food and water consumption, ceased egg production, and displayed 
severe comb lesions. Mortality rate increased from 50% to 89% in a 10-day observation time 
(Figure 1.2) [175]. Signs of neurological symptoms such as tremors were also observed, 
which is usually absent in LPAIV infections [175]. The virus was later isolated and identified as 
a highly pathogenic variant of the epidemic H5N2 LPAIV, which had begun earlier that year 
[175, 176]. The outbreak was eventually controlled by the mass slaughter of more than 17 
million birds with direct and indirect costs of more than USD$312 million [167]. Of particular 
interest was that it was the first documented change of an LPAIV to an HPAIV during a field 
outbreak, which emphasises the fast-changing nature of type A influenza virus [175]. 
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A) 
B) 
 
 
 
Figure 1.2: the H5N2 HPAIV outbreak in Pennsylvania in 1983. 
A) Extreme mortality in broiler chickens during the H5N2 HPAIV outbreak in Pennsylvania in 
1983. B) A layer chicken naturally infected with H5N2 HPAIV developed severe necrosis and 
ruptured vesicles in the comb caused by the infection. Images obtained from [175]. 
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Except for the 1983 Pennsylvania outbreak, most of the other HPAIV outbreaks were limited 
to the initially infected farms with little or no spread, but occasional widespread outbreaks 
were documented, resulting in massive economic losses (Table 1.2).  
 
The HPAIV H5N1 outbreak is shown in (Table 1.2) has received the most attention in recent 
years, mainly due to its far-reaching adverse effects in domestic birds, public health, and also 
poultry industries on a global scale [177]. The virus first surfaced in Hong Kong in the late 
1990s and has spread across Asia, Europe and Africa in recent years [178]. It was first isolated 
from sick geese from a flock in the Guangdong Province of China in 1996, and the outbreak 
resulted in the closing and depopulation of all live-bird markets, with 18 human cases 
reported by the end of 1997 [177-179]. Since then, sporadic outbreaks of HPAIV H5N1 have 
been reported in Hong Kong, China and other parts of Southeast Asia in poultry and 
wild-birds, and human cases related to HPAIV H5N1 resurfaced in Vietnam in 2003 [177]. The 
infected host species of this HPAIV H5N1 has since expanded beyond humans, poultry and 
wild-birds, to infect canines, felines, swine and mustelidae, further increasing the possibility 
of virus-human contact [177].  
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Table 1.2: Significant HPAIV outbreaks since 1959 
Country Year Subtype Species affected 
Approximate number of 
bird slaughtered 
References 
Pennsylvania 
USA 
1983 H5N2 chicken, turkey 17 million chickens [167, 175, 
176] 
Mexico  1994 H5N2 chicken >millions [180, 181] 
Pakistan  1994 H7N3 chicken >6,000,00 [182] 
Italy 1999 H5N2 turkey 14 million chickens, 
turkeys, guinea fowl, 
quails, ducks, pheasants, 
ostriches 
[183-185] 
Chile  2002 H7N3 chicken 2 millions [186, 187] 
Netherland 2003 H7N7 chicken >34 million [188-190] 
Canada  2004 H7N3 chicken 16 million [191, 192] 
Asia, Europe 
and Africa  
2003- 
present 
H5N1 chicken, duck >100 millions  [177] 
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The sporadic outbreaks of LPAIV remain underappreciated and should not be neglected, such 
as the LPAIV H9N2 which caused sporadic outbreaks in Europe, Asia, Africa, the Middle East 
and the U.S., and is now considered enzootic throughout Asia [174]. It is reported that LPAIV 
H9N2 sporadically causes human infections with flu-like symptoms, which is indistinguishable 
from the seasonal human influenza strains H1N1 and H3N2 [193, 194]. Although there is no 
evidence to strongly indicate human-to-human transmission, given the predicted low affinity 
of LPAIV H9N2 for human influenza receptors, the recurring transmission into the human 
population increases the possibility of influenza viral re-assortment and subsequent ability 
for human-to-human transmission [182, 195-197].  
 
1.9.2 Influenza infection in humans 
In the last 100 years, there were five unquestioned human influenza pandemics occurred in 
1918 (H1N1), 1957 (H2N2), 1968 (H3N2), 1977 (H1N1) and 2009 (H1N1) [198]. Among them, 
the “Spanish flu” is the worst known pandemic in recorded history, and claimed an estimated 
50 million human deaths or more, worldwide (Figure 1.3) [199, 200].  
 
The 1918 H1N1 influenza pandemic exhibited several unique clinical and epidemiological 
characteristics, as the clinical course was usually self-limiting, but a high percentage of 
infected victims developed severe pneumonic complications [201].  
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Figure 1.3: The H1N1 pandemic outbreak “Spanish flu” in 1918. 
Emergency military hospital during the influenza pandemic in the United States in 1918. 
Image obtained from [166]. 
 
 
 
 
 
 
 
CHAPTER 1 
32 
 
Furthermore, epidemiological features of the 1918 pandemic were unprecedented, where 
the virus struck in three separate waves between spring of 1918 and winter of 1919, and an 
unusual “W-shaped”, age-specific mortality curve characterised by an unexplained peak 
death in healthy young adults between 20 and 40 years of age [201-203]. A recent 
phylogenetic study by Worobey et al., 2013 [204] has suggested that the age-specific 
mortality in 1918 may have been due primarily to their childhood exposure to a doubly 
heterosubtypic H3N8 virus, which was estimated to have circulated between 1889 and 1900; 
whereas, all other age groups were probably partially protected by childhood exposure to H1 
or H1-related antigens.  
 
The subsequent influenza pandemic emerged in 1957-1958 and the causative virus type A 
influenza (H2N2), was a lineal descendent of the 1918 H1N1 “killer” strain that had acquired 
three novel genes from avian-like subtypes. The original surface-glycoproteins were replaced 
with H2 and N2, and a gene encoding the PB1 polymerase was also replaced with an 
avian-like gene segment [205, 206]. It is still uncertain in which intermediate host the viral 
re-assortment took place, or how long the re-assorted virus took to adapt into an efficient 
human-to-human transmission pandemic [201]. The pandemic eventually killed an estimated 
two million people worldwide [207]. The virus then became seasonal endemic and sporadic 
in 1959, and vanished within 11 years [201].  
 
Also known as the “Hong Kong flu”, type A influenza once again gained novel avian genes by 
re-assortment with the previously circulating virus, which lead to the pandemic outbreak in 
1968 [200]. The causative agent responsible for the 1968 pandemic was a type A influenza 
H3N2, where the previous H2 and PB1 genes were replaced with avian-like H3 and PB1 to 
create yet another descendent of the 1918 virus [200, 205, 206]. Despite the novelty of the 
newly re-assorted influenza H3N2 virus, the aggressiveness of the H3N2 pandemic was 
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modest in its mortality impact, and quickly became seasonally endemic with sporadic 
appearance, and remains circulating worldwide to date [201].  
 
The latest influenza pandemic emerged in Mexico in 2009. The virus was known as the type A 
influenza H1N1 “Swine flu”, where it was a genetically re-assorted strain between two 
pre-existing swine lineage viruses – a North American H1N2 and a Eurasian H1N1 [208, 209]. 
The outbreak initiated in Mexico, where severe pneumonias were reported from infected 
individuals. Nevertheless, the pathogenicity of “Swine flu” virus was mostly self-limiting and 
clinically similar to the seasonal influenza virus in other countries [210]. As of 19th March 
2010, WHO has reported at least 16,813 reported human casualties from millions of infected 
individuals [201]. 
  
Unfortunately, despite progressive accumulation of scientific knowledge of influenza viruses, 
it is still impossible to accurately predict whether or not a pandemic is imminent, when or 
where it may emerge, and what sort of subtype and global impact it may have, as evidenced 
by the completely unexpected outbreak of the 2009 H1N1 virus [211, 212]. One influenza 
subtype of concern for a possible future pandemic is the HPAIV H5N1, as it has the potential 
to have an estimated 60% mortality rate, and sporadic reappearances in avian species spill 
over into the human population [213, 214]. Moreover, although the predominant human 
cases are restricted to poultry-to-human transmission, given the fast mutating nature of type 
A influenza virus, it is possible that the virus will adapt to human-to-human transmission and 
result in another devastating influenza pandemic [214].  
 
 
 
CHAPTER 1 
34 
 
1.9.3 The virus 
1.9.3.1 Influenza viral structure 
The type A influenza virus is an RNA virus which belongs to the Orthomyxoviridae family. Its 
genome consists of eight single-stranded negative-polarity RNA segments that encode a total 
of eleven proteins (HA, NA, NP, M1, M2, NS1, NEP, PA, PB1, PB1-F2, and PB2), and virus 
subtype is based on 17 different HA and 10 different NA envelope surface-glycoproteins [169, 
215, 216]. The general structure of an infective influenza virion is made up of a lipid bilayer 
envelope derived from the infected host cell, two surface-glycoproteins, an ion channel 
protein and the RNA genome (Figure 1.4) [216].  
 
The highly antigenic surface-glycoprotein HA is responsible for viral entry by binding with the 
host cellular receptor sialic acid [217]; whereas the NA is responsible for preventing viral 
aggregation in the infected host cell and plays an important role in allowing the ready 
dispersal of newly propagated virus [163]. The M1 protein located in the viral lipid envelope 
facilitates viral assembly, and the M2 protein serves as an ion gateway. The M2 protein is 
situated between the inner and outer lipid bilayer and regulates pH to facilitate HA synthesis 
[163, 218]. The non-structural protein (NS1) is known to induce apoptosis, proteosomal 
degradation and RNA editing which is believed to play a vital role in influenza pathogenesis 
[219, 220], and the RNA segment-coating nucleoprotein (NP) and polymerase PB1, PB2 and 
PA assemble the transcriptional complex essential for viral replication [221].  
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Figure 1.4: A schematic diagram of an influenza virion. 
(Image obtained from [222])  
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1.9.3.2 Antigenic “shift” and “drift” 
As a successful pathogen, type A influenza virus relies on two evolutionary mechanisms, 
“antigenic shift” and “antigenic drift” [223]. Type A influenza viruses gain entrance to host 
cells via HA binding to “sialic acid” receptors on the cell surface, and the binding affinity of 
HA to sialic acid receptor is thought to play an important role for the host specificity of 
several type A influenza subtypes [224, 225]. The high-degree of antigenic variation of 
influenza HA leads to repeat epidemics and occasional pandemics. Expeditious HA mutation 
is facilitated via inaccurate RNA-dependent RNA polymerase during viral genesis. It is 
estimated that each replication cycle generates errors at a rate of 1 in 104 nucleotide bases, 
which is approximately 105-fold more errors compared to DNA-dependent DNA polymerase 
replication [165, 223]. These point mutations result in amino acid substitutions in the 
influenza proteome and those which occur within the surface-glycoproteins allow the virus 
to evade the host immune system despite the presence of pre-existing humoral immunity. 
This event is termed “antigenic drift”. It has been reported that a minimum of four amino 
acid substitutions distributed on minimum of two or more antigenic sites of the HA are 
sufficient to allow re-infection [226, 227].  
 
The segmented RNA genome of type A influenza virus also contributes to another antigenic 
variation known as “antigenic shift” or viral re-assortment [228]. The re-assortment could 
happen when two or more different influenza subtypes from different origins co-infect a 
single animal. Given the presence of a vast reservoir of type A influenza viruses in avian 
species thus raises the variety of viral subtypes available for re-assortment [163]. Such events 
enable the virus to evolve and become antigenically novel. The virus then has the potential 
to become a pandemic viral strain which can evade the host immune system and cause 
widespread infection, such as the 2009 H1N1 swine-origin influenza virus [223].  
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It has been documented that, human influenza has preferential tropism of binding with sialic 
acid linked to galactose by α-2,6 linkages, whereas avian viruses of this type prefer to bind to 
α-2,3 linkages. Given that many animals, including swine, chickens and humans have both 
types of linkages on their epithelial cells, animals co-infected with different subtypes of 
influenza virus may serve as “mixing vessels” for the generation of novel virus [216]. 
Moreover, the “wet market” of Southeast Asia, where humans, swine, poultry and 
occasionally other animals are in close proximity further increases the risks to public health 
[229-231].  
 
1.9.3.3 The role of Hemagglutinin in influenza pathogenesis 
Influenza HA belongs to the type-1 membrane-glycoprotein family and has three major 
activities in viral pathogenesis; 1) the HA specifically binds to cellular receptors containing 
sialic acid on target cells to initiate the virus-cell interaction, 2) the HA mediates the viral 
entry into the cell cytoplasm by membrane fusion, and 3) the HA is the major target site for 
humoral immune responses [232].  
 
To infect the host cell, the HA first binds to the host receptor and is then internalised by 
endocytosis. The low pH in the endosome drives conformational changes in HA which results 
in fusion of the viral membrane with the endosomal membrane, consequently allowing the 
viral genome to enter the cell (Figure 1.5) [233].  
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Figure 1.5: The illustration of a typical influenza viral entry.  
Influenza HA1 is responsible for initial attachement to the host cell receptor containing sialic 
acid. Image adapted from [234]. 
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Once the infection has been established, the immature HA is synthesised as a single 
polyprotein, which is a precursor of mature HA [235]. The HA precursor contains two 
domains, one sialic acid receptor binding domain (HA1) and the ectodomain (HA2), also 
known as a fusion peptide which anchors to the viral lipid bilayer [236]. The HA precursor 
polyprotein must be post-translationally cleaved by host proteolytic activities at a conserved 
arginine residue to form two domains, HA1 and HA2 which are connected by a disulfide bond 
[237]. This cleavage event is vital for viral infectivity, as the HA cleavage releases the 
hydrophobic N-terminus of HA2 which is inserted into the target membrane during fusion. 
The cleavage also allows the molecule to be structurally functional, and then activated by the 
acidic environment of the endosome to undergo the molecular rearrangements necessary 
for fusion [237]. The HA precursor contains monobasic cleavage sites for extracellular 
cleavage by trypsin-like serine proteases, which may originate from host epithelial cell 
proteases, host inflammatory proteases, as well as bacterial proteases [165]. This also 
explains why a remarkable 75% of influenza patients who developed severe pneumonia are 
diagnosed with bacterial co-infections, as bacterial proteases may assist the activation of 
functional HA [237-240].  
 
Influenza HA is the most immunogenic component of the influenza virus, as a significant 
amount of humoral immune response following influenza infection in animals and humans is 
directed toward the HA, with a population of these antibodies capable of neutralising HA 
binding and/or fusion [241-245]. Early investigations have revealed that these antibodies 
have a negative correlation with disease manifestation in animals, thus suggesting that these 
antibodies are essential for the protection against influenza infection [241, 246-250]. In 
addition, most of the influenza virus protective antigenic sites are conformational epitopes 
and located predominantly on the HA1 globular head [251, 252]. 
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1.9.4 Disease control and prevention 
Despite ongoing annual vaccine programs, seasonal influenza epidemics continue to be a 
major cause of high mortality and morbidity. The currently employed egg-based “inactivated 
whole-virus vaccine” only confers short-term and highly specific humoral immunity, which is 
incompetent to deal with the rapidly evolving influenza virus. Most importantly, the i.m. 
administered vaccine is unable to elicit protective mucosal immunity at the site of viral entry 
[1], and manufacturing of the egg-based vaccine is both time-consuming (up to nine months) 
and unsuitable for egg-allergy individuals [253]. 
 
In the poultry industry, outbreaks of HPAIV such as H5N1 are responsible for significant 
economic losses and also pose serious threats to public health, therefore control measures 
not only help to limit industrial and economic losses but also reduce risks associate with 
human infections [254-256]. Currently, the industry relies on enhancing biosecurity measures, 
frequent serological surveillance, and restricting the movement of birds to control and 
prevent an influenza epidemic in poultry [170, 177]. However, these control measures have 
not been able to prevent the virus spread since they first emerged [257]. In recent years, 
vaccines for poultry influenza have been introduced in some developing countries to limit 
the socioeconomic impact of HPAIV outbreaks in poultry [169, 258]. Nevertheless, the 
current vaccines have not been the panacea for the prevention of avian influenza in the field, 
as there are several limitations and concerns associated with vaccine efficiency, including:  
 
1) Multiple subtypes might be co-circulating in some epidemic regions [259]. 
2) Vaccine-induced antibodies could interfere with routine serological surveillance and 
differentiation of diseased birds from vaccinated birds [260]. 
3) Vaccine-induced immune pressure may accelerate viral antigenic drift to evade 
pre-existing immunity [261-263].  
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4) Regular “updates” of vaccine serotype are required to control the antigenic drifted 
variants [264, 265]. 
5) Vaccinated birds might still be infected but absent of clinical symptoms, thus leading to 
“silent” circulation of the virus [266, 267].  
6) Vaccine efficacy and response could vary between poultry species, even within the same 
species [268-271].  
7) The duration of vaccine-induced protective immunity varies [272].  
8) Young birds carrying maternally acquired immunity through vaccination could influence 
subsequent vaccination [273, 274].  
 
1.9.5 Avian influenza vaccines 
The routinely used vaccines against avian influenza in the poultry industry are for control of 
LPAIV H9N2 in Asia, LPAIV H5N2 in Central America, and HPAIV H5N1 in Asia and Africa [170]. 
Based on experimental studies and field usage, vaccines against AIV can be classified into 
four technological groups: 1) inactivated whole influenza virus, 2) in vitro expression of 
subunit HA protein, 3) in vivo expression of HA protein, and 4) nucleic acid vaccines [170]. 
Although the live-attenuated avian influenza vaccine promises to induce superior protective 
immunity, the potential to mutate into a novel HPAIV could result in considerable economic 
losses and possible human infections. Thus, live-attenuated avian influenza virus is presently 
discouraged from vaccine use in the poultry industry [275, 276].  
 
1.9.5.1 Inactivated whole-virus vaccines 
Similar to the production of human seasonal influenza vaccines, the method of developing 
an inactivated whole-virus vaccine is low cost and technologically “mature”, and has been 
used for more than 30 years [275]. In the past, the LPAIV isolated from outbreaks and/or 
serological surveillance from wild and domestic birds have been the primary viral strains 
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used in vaccine development. Nowadays, some HPAIV have been used in inactivated 
influenza vaccines such as H7N3 in Pakistan and H5N1 in Indonesia [170]. Currently, the 
overwhelming majority of avian influenza vaccines manufactured and used in the poultry 
industry are oil-adjuvanted inactivated whole-virus vaccines, which administered by 
parenteral injection [275]. However, limited use of inactivated avian influenza vaccines has 
been reported due to high labour costs for parenteral administration of the vaccine, and the 
intricacies in differentiating “diseased” and “vaccinated” birds by routine serological 
surveillance in the vaccinated population [260].  
 
1.9.5.2 DNA vaccines for influenza virus 
Plasmid-based DNA vaccines expressing the avian influenza HA gene under the control of a 
promoter have been studied as an AIV vaccine, and results showed successful elicitation of 
protective immunity in chickens upon challenge with HPAIV H5 and H7 subtypes [277-280]. 
An alternative method to deliver DNA vaccines using a bacterial vector was evaluated by Pan 
et al., 2010 [281], where complete protection from intranasal HPAIV H5N1 challenge in 
chickens was achieved by priming with a HA DNA vaccine delivered orally in attenuated  
S. Typhimurium followed by boosting with a killed viral vaccine.  
 
1.9.5.3 In vitro expression of influenza vaccine antigen 
1.9.5.3.1 Recombinant influenza HA as influenza vaccine  
Influenza HA is unquestionably the most immunogenic antigen within the influenza virus. 
Therefore, recombinantly expressed HA could be used as subunit vaccine and elicit 
protective immunity [228, 282]. Recombinant HA has been demonstrated to be expressed in 
vitro in mammalian cells, insect cells, plant cells, bacteria, viruses or yeasts [98, 283-289]. 
After expression, the protein is subjected to downstream process including extraction, 
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purification, and combining with an adjuvant. The subunit HA vaccine has a superior safety 
profile as no viable virus is involved in the manufacturing process, and it provides a more 
rapid and cost-effective production alternative [275, 289]. One such example was the use of 
baculovirus vectors to express HA from both H5 and H7 subtypes. Poultry immunised with 
purified HA were protected from H5 and H7 HPAIV challenge [284]. 
 
1.9.5.3.2 Yeast Expression System “Pichia pastoris” 
In general, yeasts are an excellent platform for expressing heterologous proteins. 
Methylotrophic yeast such as P. pastoris can be easily and rapidly grown at high cell-density 
and no sophisticated facilities are required. P. pastoris also has several advantages over other 
eukaryotic expression systems, and the most important of all for the purpose of expressing 
recombinant vaccine antigen is the diverse post-translational modifications, which including 
glycoslation, peptide-folding, proteolytic cleavages and targeting secretion [235, 290-292]. A 
study conducted by Saelens et al., 1999 [235] has demonstrated that mice immunised with P. 
pastoris expressed influenza (A/Victoria/3/75 (H3N2-subtype)) HA were completely protected 
from homologous challenges and exhibited increased surval rate in heterologous challenges. 
 
1.9.5.4 In vivo expression of influenza vaccine antigen 
1.9.5.4.1 Current status of vector vaccines for the prevention of influenza infections in 
poultry 
Various viral and bacterial vaccine vectors have been investigated for in vivo expression of 
the influenza HA gene for the purpose of creating an avian influenza vaccine. A variety of 
viral vectors have been used in vaccine development including viruses belonging to the 
Herpesviridae, Poxviridae, Adenoviridae and Retroviridae families [283, 287, 288, 293-296]. 
Among them, recombinant fowlpox virus has been the most extensively investigated viral 
vector for carrying HPAIV HA gene derived from either H5 or H7 avian influenza subtypes 
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[297-301], and fowlpox vector vaccines carrying HA derived from H5 subtypes have been 
commercialised for field applications in Mexico [302, 303]. However, there are a few 
limitations in regard to the use of recombinant fowlpox virus as an influenza vaccine, which 
are: 1) the vaccine must be administered parenterally, 2) it can only be used in chickens, and 
3) chickens must be naïve to the fowlpox vector for the vaccination to be effective [170, 272]. 
The newly developed recombinant viral vector derived from the Newcastle disease virus on 
the other hand, can overcome the limitations associated with the inter-species barrier by 
administration via aerosol spray or eye drop [296, 304-306]. However, the concerns of 
pre-existing immunity to Newcastle disease virus could hinder vaccine efficacy.  
 
On the other hand, recombinant bacterial vectors have been investigated to a lesser extent 
for the purpose of AIV vaccine development. Such a vaccine system can be achieved by 
incorporating genes encoding antigenic influenza proteins together with a potent promoter 
into either a bacterial chromosome or plasmid, and in vivo expression of immunogen after 
administration [127, 129, 307]. Georgio et al., 1997 [307] evaluated the use of L. 
monocytogenes expressing influenza nucleoprotein (NP), and showed that mice vaccinated 
intravenously cleared the influenza virus from the lungs faster after subsequent challenge. 
Moreover, Ben-Yedidia and Arnon, 2005 [308] demonstrated that both B- and T-lymphocyte 
epitopes of the influenza virus can be co-expressed within Salmonella flagellin, hence the 
recombinant flagellae served as an antigen carrier and also as an immunostimulant. Mice 
immunised Intranasally with recombinant Salmonella were protected against subsequent 
challenge.  
 
1.9.5.4.2 Salmonella-vectored vaccine for the prevention of influenza virus 
Currently, there is only limited investigation using Salmonella-vectored vaccine carriers for 
the purpose of AVI prevention in both the public health and veterinary sector. A table which 
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summarises the currently available literatures of the studies using Salmonella-vectored 
vaccines for the prevention of influenza is provided (Table 1.3). 
 
In Table 1.3, the use of attenuated Salmonella as a means to deliver a DNA vaccine carrying 
AIV HA and boosting with an inactivated vaccine confers not only a mucosal IgA response, 
but also systemic protection against lethal challenge [281, 309]. A study conducted by 
Jazayeri et al., 2012 [310], demonstrated the administration of a DNA vaccine carried by 
Salmonella enhanced the expression of cytokine secretion including IL-1β, IL-12β, IL-15 and 
IL-18 in chickens, and elevated virus-neutralising humoral response, and further studies are 
required to evaluate whether the vaccine construct protects against AIV infection. 
 
The use of a Salmonella-vectored vaccine to deliver heterologous influenza vaccine antigen 
has been studied to a lesser extent. The current studies using influenza structural proteins as 
vaccine antigens have demonstrated suboptimal protection against challenges in animal 
models, and require multiple immunisations to confer complete protection in homologous 
challenges [311], or provided only limited immunogenicity when the vaccine constructs were 
administered alone [312]. The study conducted by Liljebjelke et al., 2010 [312], using 
influenza HA1 as passenger antigen has demonstrated limited protection to low-dose 
challenges against homologous and heterologous virus, however no protection was 
conferred to high-dose challenges.  
 
Although these vaccine vectors were less than ideal for field application, the outstanding 
safety profiles and the ability to induce antigen-specific immune responses suggested that 
the development of Salmonella-vectored influenza vaccines could be achieved in the future 
by better expression of heterologous antigens from the selected Salmonella vector.  
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Table 1.3: Salmonella-vectored vaccine carriers for the prevention of influenza infection in animal model studies 
Vaccine strain Passenger protein  Animal host  Mode of antigen 
delivery  
Outcome  References 
S. Typhymurium 
aroA
-
 SL7207 
HPAIV H5N1  
(A/Goose/Jiangsu/1/2000) 
HA 
Chicken DNA vaccine Orally immunised chickens followed by inactivated vaccine provided 
complete protection against HPAIV H5N1 intranasal challenge, and 
significantly increased neutralising antibody levels and intestinal mucosal 
IgA. Elevated cell-mediated immune responses were observed.   
[281] 
S. Typhymurium 
aroA
-
 SL7207 
LPAIV H9N2  
(A/Ck/China/N/2005) 
HA 
Chicken DNA vaccine Orally immunised chickens followed by inactivated vaccine prevented virus 
shedding after intranasal challenge with the H9N2 strain. Before challenge, 
immunised chicken exhibited an elevated virus-neutralising antibody titre, 
and mucosal IgA titre. 
[309] 
S. Typhymurium 
SV4089 
HPAIV H5N1 
(A/Ck/Malaysia/5858/04) 
HA 
Chicken DNA vaccine  Orally immunised chickens had enhanced IL-1β, IL-12β, IL-15 and IL-18 
expression in the spleen, and elevated virus-neutralising antibody tire.  
[310] 
S. Typhymurium 
SV4089 
HPAIV H5N1 
(A/Ck/Malaysia/5858/04) 
HA, NA and NP 
Chicken  DNA vaccine Virus-specific immune responses were not evaluated. The study 
demonstrated orally administered S. Typhymurium SV4089 was able to 
migrate through different organs of chicken, but did not cause septicaemia. 
Furthermore, Salmonella-specific O antiserum was elicited. 
[313] 
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Table 1.3: Salmonella-vectored vaccine carriers for the prevention of influenza infection in animal model studies (Continued)  
Vaccine strain Passenger protein  Animal host  Mode of antigen 
delivery  
Outcome  References 
S. Typhymurium 
SifA
-
 mutant 
LPAIV H1N1  
(A/WSN/1933)  
NP 
Mouse Heterologous 
antigen 
Orally immunised mice followed with 3 booster immunisations were 
completely protected against lethal influenza virus challenge, and 66% 
protected from 2 booster immunisations. In addition, Th1 immune 
responses were elicited against influenza NP. 
[311] 
S. Typhymurium 
LB5010 (r
-
m
+
) & 
S. Typhymurium 
BRD509  
HPAIV H5N1  
(A/whooper 
swan/Mongolia/3/2005) 
HA1 
Chicken Heterologous 
antigen 
Orally immunised mice were completely protected against low-dose 
challenge with homologous strain, and partial protection from low-dose 
challenge from heterologous strain. However, vaccine vectors did not confer 
protection to high-dose challenge of either of these viruses. 
[312] 
Salmonella 
Enteritidis strain 
(aroA
- 
htrA
-
) 
Highly conserved avian 
influenza M2e gene, fused 
with immune-enhancing 
CD154 peptide sequence  
Chicken  Heterologous 
fusion protein 
The vaccine vector exhibited the ability to invade liver and spleen without 
noticeable adverse reactions. Orally immunised chickens elicited an 
M2e-specific antibody response, and offer significant protection against 
direct challenge with LPAIV H7N2, but not LPAIV H5N1.  
[314] 
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1.10 Concluding remarks 
Vaccine development has evolved exponentially over the last couple of centuries, from the 
primitive variolation techniques for smallpox prevention [8] to the latest nucleic acid 
vaccines [315]. There have been many successes in vaccine innovation which have improved 
the quality of life and reduced mortality for some diseases such as the polio vaccine and the 
more recent HPV vaccines [316, 317]. The quest towards an effective vaccine to induce 
long-lasting protection against recurrent disease such as the avian influenza virus would be 
of enormous value to both public health and the poultry industry. Many investigations have 
illustrated that employing an attenuated bacterial vector to deliver heterologous antigens 
can induce both innate and adapted immune responses to both the vector and the 
heterologous antigen [99, 119, 120, 318, 319]. Over the last few decades, recurrent and 
sporadic outbreaks of avian influenza virus in the poultry industry and occasional spill-over to 
the human population have raised the awareness of inadequate vaccine strategies in the 
industry. By careful selection of vaccine vectors and appropriate expression of immunogenic 
antigens, avian influenza could be controlled more easily and therefore minimise human 
spill-over infections. Vaccination would prevent potential widespread infections or 
pandemics, saving millions of dollars for the poultry industry and avoiding catastrophic 
impact to the already overstretched public health infrastructure.  
 
1.11 Rationale of the project 
In my previous study, the gene encoding HA1 derived from influenza model strain (A/Puerto 
Rico/8/34(H1N1)) was cloned into a yeast expression vector encoded with a methanol 
inducible promoter. The recombinant HA1 (rHA1) was successfully expressed from P. pastoris 
and secreted into culture media, and had been successfully purified using Nickel-charge 
immobilised-metal affinity chromatography (IMAC).  
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In this project, the first aim was to evaluate the immunogenicity of P. pastoris expressed 
rHA1 in a mouse trial. A parallel study was conducted by the collaborating institute - Institute 
of Biotechnology (IBT), Vietnam Academy of Science and Technology, where the HA1 gene 
derived from Influenza A virus (Hatay/2004/(H5N1)) was expressed in P. pastoris, and 
immunogenicity of the rHA1 was examined in chickens (personal communication). 
 
Salmonella-vectored vaccines are still in the development phase in the field of modern 
medicine for both human and animal use. Such vaccines can be delivered in the same 
manner as a natural infection, thus the elicited immune responses mimics and targets 
specific points of the natural infection. In order to translate such advantages to field 
application, an established attenuated Salmonella Typhimurium vaccine (STM1) which has 
been licensed and is commercially available to the livestock industry to prevent Salmonellosis 
in poultry [320], was chosen as the carrier vector. Previous investigation indicated that STM1 
has the ability to express the model heterologous antigen ovalbumin [4]. Upon immunisation 
in mice, the STM1 was not only taken up by the DCs but also lead to CD8+ T-lymphocyte 
responses specific to the dominant ovalbumin epitope –SIINFEKL, and mucosal IgA responses 
[3]. These promising characteristics lead to the development of a vaccine carrier using 
Salmonella STM1.  
 
In this study, Salmonella STM1 was genetically engineered to carrier and express influenza 
HA1 in vivo. The HA1 was chosen as the vaccine antigen because it has a majority of the 
protective antigenic sites, and a portion of these HA1-specific antibodies have a negative 
correlation to the manifestation of disease [241-247]. Pre-existing immunity to the 
Salmonella-vectored vaccine carrier has been documented; however, the vaccine efficacy 
was not hindered in the case of delivering ovalbumin in mice [2, 4].  
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The aims of this project includes:  
- To evaluate the immunogenicity of P. pastoris expressed rHA1 in a mouse model. 
- To clone influenza HA1 gene into expression plasmids in Salmonella STM1, where 
different expression strategies were employed to display the rHA1 in various destinations 
to optimise protein expression and immunogenicity. 
- To evaluate the immunogenicity of these Salmonella STM1 vaccine strains in chickens. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Chapter 2 
General Materals and Methods  
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2.1 General procedures 
All chemical reagents used were of analytical laboratory grade. All autoclavable materials 
including media, solutions and glassware were sterilised by autoclaving at 1210C (15 Ibs/in2) 
for 20 minutes unless otherwise stated. All solutions and media were prepared with 
deionised water acquired from a Millipore Milli-Q® water system (Millipore, Australia). 
Glassware was washed with Pyroneg detergent (JohnsonDiversey, Pty. Ltd., Australia), and 
washed with a dishwashing machine (Gallay Scientific, Australia). Prior to use, glassware was 
rinsed twice with deionised water.  
 
Solutions were dispensed using Eppendorf Research® adjustable pipettes (Eppendorf, 
Australia) which included 0.5 – 1.0 μL, 20-200 μL, 100-1000 μL digital pipettes, and 
Finnpipette® digital pipette range (Thermo Labsystems, USA) which included a 1-5 mL, 
5-10mL digital pipette, and BioPetteTM Plus Autoclavable Multichannel Pipettes (Labnet 
International, USA) which included 5-50 μL, and 20-200 μL multi-channel pipettes. Solution 
volumes of 1.5 mL or less were centrifuged with an Eppendorf microcentrifuge 5415C or 
5415D. Volumes greater and up to 50 mL was centrifuged in a Beckman Allegra 21R 
centrifuge. Sartorius analytical top loading balance was used to weigh reagents greater less 
than 2 g; whereas reagents of greater than 2 g were weighed on an ISSCO model 300 top 
loading balance. Media containing supplements were autoclaved and cooled to 550C before 
the addition of the supplements. All media was prepared using aseptic technique and stored 
at 40C until use. 
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2.2 General chemicals and equipment 
2.2.1 Equipment 
Balance:  
ISSC Model 300 (0.01-300g) Industrial & Scientific Supply, Australia 
Satorius BP210S (0.1mg-210g) Satorious Gottingen, Germany 
Biosafety class II cabonet (Aura 2000 
M.A.C.)  
BIOAIR Instrument, Italy 
Centrifuges:  
Eppendorf AG 22331 bench top  Eppendorf Hamburg, Germany 
Heraeus Multifuge 1s-r Centrifuge Thermo Electron, USA 
Beckamn Allegra. 21R Centrifuge Bechmn Coulter, Australia 
Beckman Coulter Optima L100 XP 
Ultracentrifuge 
Bechmn Coulter, Australia 
Dry block heater Ratek, Australia. 
Electrophoresis power supply – 
powerPac 300 
Biorad Laboratories, USA 
Electrophoresis units – DNA:  
Sub-Cell wide mini BioRad Laboratories, USA 
Mini-Sub® Cell GT BioRad Laboratories, USA 
Electroporation cuvette BioRad Laboratories, USA 
Gel Doc image system BioRad Laboratories, USA 
Electrophoresis units – Protein:   
Mini Protean® Tetra System BioRad Laboratories, USA.  
Trans-blot electrophoretic transfer 
cell (mini) 
Ratek, Australia. 
iBlot® Gel Transfer Device Invitrogen, USA 
iMarkTM microplate absorbance reader 
(96-well) 
BioRad Laboratories, USA 
Microscope:  
Olympus CX31 – light microscope  Olympus, Japan  
Olympus CKX41SF – inverted 
microscope 
Olympus, Japan 
Olympus E330 – Camera  Olympus, Japan 
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Microplate luminometer – LUMIstar 
Omega 
BMG LABTECH GmBH, Germany  
PCR machines:   
G-Storm GS1 Thermal Cycler  G-Storm, UK 
GeneAmp PCR system 2400 Applied Biosystem, USA 
pH meter Metrohm, USA 
Platform shaker Ratek, Australia. 
Pulse controller & Gene pulser 
apparatus 
BioRad Labortories, USA. 
Roller mixer Ratek, Australia. 
Sonifier – digital cell disruptor  Branson, USA 
Incubator (with orbital shaking) BL8500 Edwards Instrument, Australia 
Incubator (CO2 incubator) Galaxy 1705 New Brunswick
TM, USA 
Transilliminator (UV) Noves, Australia. 
Optima L80 XP Ultracentrifuge  Beckman Coulter, Australia. 
Vortex mixer Ratek, Australia. 
Waterbath Thermoline Scientific, Australia 
 
2.2.2 Consumables 
Centricon® centrifugal devices Millipore, Australia. 
Centrifuge tubes:  
Eppendorf tubes Sarstedt, Australin 
10 mL tubes  Sarstedt, Australia 
15 mL tubes  Corning, USA 
50 mL tubes  Corning, USA 
Ultra-ClearTM thinwall tube  Beckman Coulter, Australia. 
Cover slips Mediglass, Australia. 
Cryovials (1.8 mL) Nalgene Company, USA. 
Filter (0.2 μm and 0.45 μm) Sarstedt, Germany 
iBlot® Transfer Stack, nitrocellulose, 
regular 
Invitrogen, USA 
iBlot® Transfer Stack, nitrocellulose, mini Invitrogen, USA 
Microscope slide LOMB Scientific Co., Australia. 
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Microtitre plate:  Nunc, Denmark. 
96-well, flat bottom Greiner bio-one, USA 
96-well, V-shaped bottom Greiner bio-one, USA 
Needles (19, 21, and 26 gauge) Terumo Pty, Ltd., Australia. 
Pasteur pipette (sterile) Copan Innovation, USA 
Petri dishe Copan Innovation, USA 
PCR tubes – 0.2 mL flat-cap  Quantum Scientific,  
Syringe (1, 5, 10, 20, and 50 mL) Terumo Pty, Ltd, Australia. 
Tissue culture flasks (25cm2 and 75cm2) Greiner bio-one, USA 
 
2.2.3 Commercial kit for nucleic acids manipulation 
Tetro cDNA Synthesis Kit  Bioline Pty. Ltd., Australia  
TOPO® TA Cloning Kit Invitrogen, USA 
QIAprep® spin miniprep kit QIAGEN, Australia. 
QIAquick gel extraction kit  QIAGEN, Australia. 
 
2.2.4 Animals used in this study  
BALB/c mice (female) Animal Resource Centre, Canningvale, 
Western Australia. 
Brioler Chickens (mix-gender) Inghams Enterprises, Packenham, 
Victoria 
 
2.2.5 Materials  
2.2.5.1 General media 
Brain Heart Infusion (BHI) broth: 3.7% (w/v), prepared according to manufacturers 
specification (Oxoid, UK). 
Luria-Bertani (LB) broth: 0.5% (w/v) yeast extract (Oxoid, UK), 1% tryptone (Oxoid, UK), 0.5% 
sodium choride (BDH Chemicals, UK). 
Luria-Bertani (LB) agar: 0.5% (w/v) yeast extract (Oxoid, UK), 1% tryptone (Oxoid, UK), 0.5% 
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sodium chloride (BDH Chemicals, UK), 1.2% (w/v) bacteriological agar (Oxoid, UK). 
Nutrient Broth (NB): 1.3% (w/v), followed manufacturer instruction (Oxoid, UK). 
Mueller-Hinton (MH) Broth: 2.1% (w/v), followed manufacturer instruction (Oxoid, UK). 
MacConkey agar (MCA): 5.2% (w/v), followed manufacturer instruction (Oxoid, UK). 
S.O.C. medium: 0.5% (w/v) yeast extract (Oxoid, UK), 2% tryptone (w/v) (Oxoid, UK), 10 mM 
sodium chloride (BDH Chemicals, UK), 2.5 mM potassium chloride (BDH Chemicals, UK), 10 
mM magnesium chloride (BDH Chemicals, UK), 10 mM magnesium sulfate (BDH Chemicals, 
UK). Media was autoclaved and stored at 40C until use. Sterile glucose (BDH Chemicals, UK) 
solution in mH2O was prepared by passing it through a 0.2 μm filter, and 20 mM glucose was 
added before used. 
 
2.2.5.2 General solutions 
β-mercaptoethanol: for general use - electrophoresis purity (BioRad Laboratories, USA); for 
tissue culture use – tissue culture grade (Gibco®, USA) 
λ-DNA marker: PstI/λ-DNA marker was prepared by incubating 20 μg λ-DNA (New England 
Biolabs, USA), 18 μL NEBuffer 3.1 (New England Biolabs, USA), 10U PstI (New England Biolabs, 
USA) and mH2O up to 180 μL, at 37°C overnight. The digestion was ceased by heating at 80
0C 
for 20 minutes and 20 μL of 6x DNA loading buffer was then added. The marker was stored 
at -20°C and 10 μL aliquots used on a DNA agarose gel.  
Acryl/BisTM (29:1) solution: Astral, Australia  
Agarose gel: 1% (w/v) DNA grade agarose (Progen Industries, Australia) in 1x TAE buffer, 
dissolved by heating in a microwave.  
Ammonium persulphate (APS): 10% (w/v) ammonium persulphate (Sigma-Aldrich, USA) in 
deionised water stored in dark at 4°C.  
Ampicillin: 100 mg/mL ampicillin (CSL, Australia) in mH2O water, filter sterilised.  
BCIP/NBT solution for detection of alkaline phosphatase antibodies: BCIP®/NBT solution, 
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premixed (Sigma-Aldrich, USA). 
Bovine serum albumin (BSA), molecular biology grade: 1 mg/mL (New England Biolabs, 
USA), stored at -20°C.  
Bradford reagent: 100 mg Coomassie Brilliant G-250 (Sigma-Aldrich, USA) dye was dissolved 
in 50 mL 95% (v/v) ethanol, then mixed with 100 mL 85% (v/v) phosphoric acid, and brought 
up to 1 L with dH2O. The solution was stored at 4°C, and filtered through a 0.20 μm filter 
before use.  
Bromophenol blue: 1% bromophenol blue (BDH Chemicals, USA) (w/v).  
Calcium chloride (CaCl2): 1 M CaCl2 (BDH Chemicals, USA) filter sterilised. 
Chloroform: 100% (v/v) chloroform (BDH Chemicals, USA).  
Chloroform: Isoamyl (CI): 96% (v/v) chloroform (BDH Chemicals, USA), 4% (v/v) isoamyl 
alcohol (BDH Chemicals, USA). 
Coating buffer (ELISA): 0.016 M Na2CO3 (BDH Chemicals, USA), 0.034 M NaHCO3 (BDH 
Chemicals, USA), pH 9.6.  
Coomassie blue staining: 
- Coomassie blue destain solution: 10% (v/v) ethanol (BDH Chemicals, USA) and 10% (v/v) 
glacial acetic acid (Fisher Scientific, USA).  
- Coomassie blue stain solution: 0.1% (w/v) Coomassie brilliant blue R-250 
(Sigma-Aldrich, USA), 50% (v/v) methanol (BDH Chemicals, USA), 10% (v/v) glacial acetic 
acid (Fisher Scientific, USA). 
DNA loading buffer 6X: 0.25% (w/v) bromophenol blue (BDH Chemicals, USA), 0.25% (w/v) 
xylene cyanol FF (Sigma-Aldrich, USA), 40% (w/v) sucrose (Sigma-Aldrich, USA), 10 mM 
Tris-HCl (pH 7.6). 
Deoxynucleotide (dNTP) solution mix: 10 mM each of dATP, dGTP, dTTP and dCTP (New 
England Biolabs, USA).  
Dextrose: 10% (w/v) in mH2O (BDH Chemicals, USA). Filter sterilised. 
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Ethanol: 70% (v/v), 95% (v/v), 100% (v/v) analytic ethanol (BDH Chemicals, USA). 
Ethidium bromide (EtBr): A stock solution of 10 mg/mL EtBr (Sigma-Aldrich, USA). 
Ethylenediaminetetra-aetate (EDTA) buffer: 0.25 M EDTA (Merck, Germany), pH 8.0. 
Formaldehyde: Formaldehyde (37% w/v) (Sigma-Aldrich, USA). 
Glucose: 20% in mH2O (BDH Chemicals, USA), filter sterilised. 
Glycerol: 100%, 50% (v/v) glycerol (BDH Chemicals, USA).  
Hydrochloric acid: 32% (w/v) (Ajax Chemicals Ltd., Australia).  
Hydrogen peroxide (H202): 30% (w/v) H2O2 (BDH Chemicals, USA).  
Immobilised ion metal affinity chromatography (IMAC) solutions:  
- Native Binding buffer: 50 mM NaH2PO4, 0.5 M NaCl, 10 mM imidazole. 
- Washing buffer: 50 mM NaH2PO4, 0.5 M NaCl, 20 mM imidazole. 
- Elution buffer: 50 mM NaH2PO4, 0.5 M NaCl, 250 mM imidazole. 
Imidazole: A 5 M Imidazole stock solution (Sigma-Aldrich, USA) was prepared and filtered 
through a 0.45 μm filter.  
Immunoblotting solutions: 
- Blocking buffer: 5% (w/v) skim milk in PBS 
- Antibody diluents: 1% (w/v) skim milk in PBS 
- Washing buffer: 1% (w/v) skim milk in PBST 
- TMB single solution: Life Technologies, USA 
Isopropanol: Propan-2-ol (BDH Chemicals, USA).  
Isopropyl-β-D-thiogalactopyranoside (IPTG) 1 M stock: 0.2 g/mL IPTG (Thermo Scientific, 
USA) sterilised and stored at -20°C. 
Magnesium chloride: BDH Chemicals, USA  
Methanol: 100% (v/v) (BDH Chemicals, USA).  
Nickel Sulphate (0.2 M): Nickel sulphate (2.6 g) (BDH Chemicals, USA) was dissolved in 50 mL 
of mH2O.  
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Phenol (saturated): Supplied by Astral Scientific, Australia.  
Phenol/chloroform-isoamyl: A ratio of 25:24:1 (BDH Chemicals, USA) of phenol, chloroform 
and isoamyl alcohol. 
Phosphate-buffered saline (PBS): 1 tablet Dulbecco’s A PBS (Oxoid, UK) in 100 mL H2O 
(sodium chloride 0.8%, potassium chloride 0.02%, disodium hydrogen phosphate 0.115% 
potassium dihydrogen phosphate 0.02%). Autoclaved if required. 
PBST: PBS and 0.05% (v/v) Tween 20 (polyoxyethylene sorbitan monolaurate) (Sigma-Aldrich, 
USA). 
Protease Inhibitor Cocktail (100X): mix of AEBSF, Aprotinin, Bestatin, E64, Leupeptin, and 
Pepstatin A (Cell Signaling Technology, USA) 
Saline: 0.85% sodium chloride (BDH Chemicals, USA).  
Sodium dodecyl sulfate: 10% (w/v) in mH2O. Filtered through 0.45 μm filter 
SDS-PAGE solutions: 
- Loading buffer (5x): 60 mM Tris (pH 6.8), 25% (v/v) glycerol (BDH Chemicals, USA), 2% 
(w/v) SDS (BDH Chemicals, USA), 14.4 mM β-mercaptoethanol (BioRad Laboratories, 
Australia), 0.1% (w/v) bromophenol blue (Sigma- Aldrich, USA).  
- Separating gel (12.5%): 375 mM Tris. HCl (pH 8.8), 0.1% w/v SDS , 12.5% v/v bis 
acrylamide with setting agents added prior to pouring: 0.06% w/v ammonium persulfate, 
0.03% v/v TEMED.  
- Stacking gel (4.5%): 125 mM Tris. HCl (pH 6.8), 0.1% (w/v) SDS and 4.5% bis acrylamide 
with setting agents added prior to overlaying of separating gel: 0.06% (w/v) ammonium 
persulfate and 0.03% (v/v) TEMED.  
- Running buffer stock (10x): 0.25 M Tris, 1.92 M glycine (BDH Chemicals, USA), 1% (w/v) 
SDS (BDH Chemicals, USA). The pH was adjusted to 8.3.  
Silver staining solutions:  
- Fixative solution: 40% (v/v) methanol (BDH Chemicals, USA), 10% (v/v) acetic acid (BDH 
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Chemicals, USA), 50% (v/v) mH2O. 
- Washing solution: 30% (v/v) absolute ethanol (BDH Chemicals, USA), 70% (v/v) mH2O. 
- Reductant: 0.02% (w/v) sodium thiosulfate (BDH Chemicals, USA) in mH2O. 
- Silver reagent: 0.2% (w/v) silver nitrate (Sigma-Aldrich, USA), 0.02% (v/v) formaldehyde 
(Sigma-Aldrich, USA) in mH2O. Stored in dark at 4
0C. 
- Developer: 3.2 % developer reagent (BioRad Laboratories, USA) in mH2O. Made for 
immediate use. 
- Stopping solution: 5% (v/v) acetic acid (Fisher Scientific, Australia) in mH2O. 
Skim milk: Bonlac Foods Limited, Australia. 
Sodium acetate: 3 M (BDH Chemicals, USA), pH 4.6.  
Sodium chloride: 5 M stock solution of sodium chloride. 
Sucrose gradient for virus purification:  
- TNE buffer: 50 mM Tris (BDH Chemicals, USA), 140 mM NaCl, 5mM EDTA (BDH Chemicals, 
USA), pH7.4. Sterilisation by autoclave. 
- Sucrose gradient: 15% and 60% high grade sucrose (BDH Chemicals, USA) in TNE buffer. 
Filtered through 0.2 μm filter and stored at 40C 
TCA: 100% (w/v) Trichloroacetic acid (Calbiochem, Germany) 
TE buffer x10: 100 mM Tris (BM Chemical, China), 10 mM EDTA (Amresco, USA), pH 8.0.  
TEMED (N,N,N.,N.-tetramethylethylenediamine): Electrophoresis purity (BioRad 
Laboratories, Australia).  
3, 3’, 5, 5’-tetramethylbenzidine (TMB): for ELISA, TMB substrate reagent A (BD Biosciences, 
USA) and TMB substrate reagent B (BD Biosciences, USA) were mixed in a ratio of 1:1 and 
used within 10 minutes.  
Tris (hydroxymethyl) aminomethane (Tris): 2 M stock solution (Merck, Germany).  
Tris-Acetate buffer (TAE) x 50: 2 M Tris (BDH Chemicals, USA), 1 M acetic acid, 0.1 M EDTA 
(BDH Chemicals, USA).  
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TRIzol® LB reagent: Invitrogen, USA 
Trypan Blue stain (0.4% (w/v)): Sigma-Aldrich, USA   
 
2.2.5.3 Enzymes 
All enzymes were used according to manufacturer’s instruction with their supplied buffer, 
and were stored at -200C.  
DNA polymerase, Taq DNA Polymerase with Standard Taq Buffer: 3U/μL (New England 
Biolabs, USA). 
DNA Ligase (T4): 10U/μL (New England Biolabs, USA). 
Trypsin-EDTA (1X): 0.05% with phenol red (Gibco®, USA). 
 
2.2.5.4 Antibodies 
Goat anti-chicken IgA-HRP: Abcam®, USA  
Goat anti-mouse IgG H&L AP: Abcam®, USA 
Goat anti-rabbit IgG H&L AP: Abcam®, USA 
Goat anti-rabbit IgG (whole molecule)-HRP: Sigma-Aldrich, USA. 
Mouse anti-6X His tag®: Abcam®, USA 
Mouse anti-His (C-Term)-HRP: Life Technologies, USA 
Rabbit influenza (A/Puerto Rico/8/34) antiserum: (provided by the WHO Collaborating 
Centre for Reference and Research on Influenza) 
Rabbit anti-chicken IgG-HRP: Merck Millipore, Germany  
Rabbit anti-mouse IgG (whole molecule)-HRP: Sigma-Aldrich, USA 
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2.3 Microbiological methods 
2.3.1 Bacterial strains and plasmids 
The description of all the bacterial strains used throughout this study is listed in Table 2.1, 
and destription of all plasmid vectors developed throughout the study is listed in Table 2.2. 
 
2.3.2 Bacterial storage  
E. coli and Salmonella strains were stored at -800C in 30% glycerol.  
 
2.3.3 Culture conditions 
All E. coli and Salmonella strains were cultured on solid microbiological media under aerobic 
conditions at 370C for 16-19 hours. When broth culutres were used, the strains were grown 
aerobically at 370C for 16-19 hours in a orbital shaking incubator (Edwards Instrument, 
Australia) set at 150 rotations per minute (rpm).  
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Table 2.1: Bacterial strains used in this study 
Bacterial strain Genotype/Description Source/Reference 
Escherichia coli DH5-α F’/endA1, hsdR17(r-km
+
k), subE44, 
thi-1, recA1, gyrA (NalR), relA1, 
Δ(lacZYA-argF)U169 (m80lacZΔM15) 
[321] 
Salmonella 
Typhimurium LT2-9121 
leu hsdL trpD2 rpsL120 ilv52 
metE551 metA22 hsdA hsdB 
Prof. P. Reeves, 
Department of 
Microbiology, The 
University of Sydney 
Salmonella 
Typhimurium STM1 
ΔaroA- Δsec- RMIT University [320] 
 
 
Table 2.2: Plasmid vectors used in this study. 
Plasmid Genotype/Description Source/Reference 
pCR2.1 3.9 kbp PCR cloning plasmid, AmpR, KmR, 
lacZ 
Invitrogen, USA 
pMOhly1  11.9 kbp protein expression plasmid 
containing the E. coli α-haemolysin 
secretion system. Gene of interest was 
ligated into a truncated hlyA’, immediately 
upstream of the C-terminus secretion signal 
and downstream of the initiation codon.  
Dr. I. Gentschev [322] 
pHES 4.9 kbp protein expression plasmid 
containing Salmonella Typhimurium LT-2 
ShdA autotransporter gene. Gene of 
interest was ligated into the N-terminus of 
the ORF immediately after the signal 
peptide.  
Dr. A. Fernandez [5] 
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2.4 Methods of RNA extraction and cDNA synthesis  
2.4.1 RNA extraction 
The protocol was adapted from the manufacturer’s instructions (Invitrogen, USA), with some 
modifications. All reagents and equipment were chilled to 40C prior to commencement, and 
all centrifugation steps were performed at 40C, unless otherwise stated. Equal volumes of 
purified PR-8 virus were mixed with TRIzol® reagent and incubated at room temperature for 
five minutes, followed by the addition of one tenth volume of chloroform.  
 
The reaction was vigorously mixed for 15 seconds and incubated for five minutes at room 
temperature. Following incubation, the samples were centrifuged at 12,000 x g for 15 
minutes, and the aqueous phase was collected for RNA precipitation. The RNA molecules 
were precipitated by the addition of an equal volume of isopropyl alcohol, and the samples 
were vigorously mixed and incubated at room temperature for five minutes. After incubation, 
the RNA molecules were pelleted by centrifugation at 12,000 x g for 10 minutes. The RNA 
pellet was washed twice with 75% ethanol and air dried before being resuspended in 
DNase/RNase-free water. The isolated RNA samples were subjected to immediate cDNA 
synthesis.  
 
2.4.2 cDNA synthesis  
The procedure was performed according to the manufacturer’s instructions (Bioline, 
Australia), with some modifications. All reagents and buffers were provided in the kit except 
the DNase/RNase-free water. Briefly, a RNA priming reaction was prepared (as shown in 
Table 2.3). The reaction was incubated at 650C for 10 minutes, followed by incubation on ice 
for two minutes. During the incubation steps, a Reverse transcription mix was prepared (as 
shown in Table 2.4). Following the RNA-priming incubation, 10 μL of the primed RNA solution 
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was combined with 10 μL of reverse transcription mix and incubated at 420C for one hour. 
The reaction was terminated by incubation at 700C for 15 minutes and then chilled on ice. 
The newly synthesised cDNA molecules were subjected to immediate PCR amplification.  
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Table 2.3: RNA priming solution  
Reagent  Amount 
RNA molecule   6.0 μg  
Oligo (dT)18  0.5 μL 
Random Hexamer  0.5 μL 
100 mM dNTP  1.0 μL 
DNase/RNase-free water  To a total volume of 10μL 
 
 
 
 
Table 2.4: Reverse transcription mix 
Reagent  Amount 
5X RT Buffer   4.0 μL 
RNase Inhibitor  1.0 μL 
Reverse Transcriptase (200U/μL)  0.25 μL 
DNase/RNase-free water  4.75 μL 
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2.5 Methods of DNA analysis 
2.5.1 Plasmid extraction 
Plasmids used in restriction digests and sequencing were purified using the QIAprep® spin 
miniprep kit as per the manufacturer’s instructions with modification, in which, the elution 
buffer was replaced with DNase/RNase-free water and eluted using a total of 30 μL in two 
steps (20 μL of DNase/RNase-free water was first added directly onto the spin column 
membrane, and incubated for five minutes at room temperature before centrifugation, 
thereafter, a 10 μL DNase/RNase-free water was added as described, and incubated for 10 
minutes prior centrifugation). 
 
2.5.2 Extraction of DNA from agarose gel 
DNA fragments were excised from the agarose gel and extracted using QIAquick gel 
extraction kit as per the manufacturer’s instructions with modification (as described in 
Section 2.5.1). This kit was also used for the purification of DNA ligation product as per the 
manufacturer’s instructions with modification (as described in Section 2.5.1). 
 
2.5.3 Agarose gel electrophoresis  
5 μL of PCR or extracted DNA fragment was mixed with 1 μL of 6X DNA loading buffer and 
separated on a 1-2% DNA grade agarose gel in a mini-gel or midi-gel unit filled with fresh 1X 
TAE buffer. A current of 90 V was applied to the gel, and DNA fragments separated for 1.5 
hours. The gel was then stained in a 3 μL/mg EtBr bath for 20 minutes, followed by a 40 
minutes destaining procedure in running tap water.  
 
The DNA products were visualised with an UV illuminator and photographed with the Gel 
Doc imaging system (BioRad Laboratories, USA). Sizes of DNA fragements were estimated by 
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the additions of the PstI/λ-DNA marker to the gel before electrophoresis. A diagram of the 
λ-DNA sizes is provided in Appendix 1.  
 
2.5.4 Spectrophotometric quantification of DNA  
The LUMIstar Omega Microplate luminometer was used to estimate the optical density (OD) 
of a solution of DNA at a wavelength of 260 nm, the optimal wavelength for nucleic acids. 
Protein contamination was detected by an OD reading at 280 nm. The OD ratio of 
DNA/protein was determined to estimate the quality of the DNA. Ratio of 1.8-2.0 indicated 
good quality DNA [323]. An OD of 1 corresponded to 50 μg/mL double stranded DNA and the 
amount of DNA present was determined using this standard.  
 
2.5.5 DNA quantification using DNA gel electrophoresis  
PstI/λ-DNA marker was separated on an agarose gel along with sample DNA fragmetns. The 
quantity of DNA within each digested fragment of λ-DNA is provided in Appendix 1 and was 
compared with intensities of unknown DNA samples.  
 
2.6 DNA manipulation  
2.6.1 Restriction enzymes  
The restriction enzymes (RE) used in the study are listed in Table 2.5. Approximately 1 μg of 
plasmid DNA was digested with 1 U of enzyme supplied with 1X buffer in a total volume of 20 
μL in a 370C water bath for three hours or overnight. When high purity DNA fragments were 
required for subsequent procedures (e.g. enzymatic ligation), enzymes were heat-inactivated 
to the manufacturer’s recommended temperature and duration. However, if the enzyme 
cannot be heat inactivated, QIAquick gel extraction kit was used to eliminate the enzymes as 
per manufacturer’s instruction. All enzymes were purchased from New England Biolabs, USA.  
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Table 2.5: List of restriction enzymes (RE) used in this study 
Restriction enzyme  Recognition sequence 
PvuI  
 
EcoRI  
 
SbfI  
 
NsiI  
 
PstI  
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2.6.2 DNA amplification 
2.6.2.1 Primers  
A list of primers used throughout the study is provided in Table 2.6. Primers were designed 
with the assistance of the software program Sci Ed Central compatible for Windows 7. In 
ideal situation, primers were designed to have guanine & cytosine (GC) content between 
40-60% with a melting temperature (Tm0C) between 55-750C. However, in the case of 
pMOhly1_SbfI_Rev, the GC content was compromised in the effort to incorporate a 6X 
His-tag for subsequent analysis. Primers were obtained as lyphilised samples from 
GeneWorks Pty. Ltd., Australia 
 
2.6.2.2 Polymerase chain reaction (PCR) using DNA templates 
General PCR was performed accoding to the polymerase manufacturer’s instructions (New 
England Biolabs, USA). The general reaction mix and programs was listed in Table 2.7 and 
Table 2.8. the annealing temperature is specified in the relavent chapters. Taq polymerase 
was used for all DNA amplification purposes.  
 
The reagents were prepared aspetically. Either G-strom or GeneAmp PCR machine was used 
to amplify the DNA. Approximately 10 ng of DNA template was used for the reactions, and 
reactions were prepared in a final volume of 50 μL.  
 
2.6.2.3 Colony PCR 
A protocol applied to fast screening for plasmid inserts directly from E. coli colonies.  
A small amount of colony was transferred into an eppendorf tube containing 50 μL of sterile 
PBS from freshly grown culture. The coloy was resuspended using vortex mixer and 
incubated at 1000C for three minutes on a dry heating block. Following incubation, the 
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sample was chilled on ice and 2 μL of the treated colony suspension was used as DNA 
template. The reaction composition and cycling conditions remained the same as described 
in Section 2.6.2.2. 
 
 72 
 
 
CHAPTER 2 
 
Table 2.6: List of primers used throughout this study 
Primer name  Sequence  Description Tm0C* 
pMOhly1_SbfI_For 5’-CGGCCTGCAGGCCTGAAGGCAAACCTACTGGTC-3’ Forward primer for amplification of influenza HA1 
for pMOhly plasmid, with sbfI RE site (underlined). 
71 
pMOhly1_SbfI_Rev 5’-CGGCCTGCAGGGTGATGGTGATGGTGATGCTTGGATT
GAATGGACGGATTG-3’ 
Reverse primer for amplification of influenza HA1 
for pMOhly plasmid, with sbfI RE site (underlined). 
74 
pHES_EcoRI_For 5’-CGCGAATTCATGAAGGCAAACCTACTGGT-3’ Forward primer for amplification of influenza HA1 
for pHES plasmid, with EcoI RE site (underlined). 
61 
pHES_PvuI_Rev 5’-CGCCGATCGTGGATTGAATGGACGGATTGT-3’ Reverse primer for amplification of influenza HA1 
for pHES plasmid, with PvuI RE site (underlined). 
64 
SEQF_pMOhly1 5’-GCCTGGACTTCAGGTGATCGTAAATG-3’ Forward sequencing primer of pMOhly1 plasmid  59 
SEQR_pMOhly1 5’-GCTGATGTGGTCAGGGTTATTGAG-3’ Reverse sequencing primer of pMOhly1 plasmid 57 
SEQF_pHES 5’-TTTCCCGACTGGAAAGCGGGCAGTGAG-3’ Forward sequencing primer of pHES plasmid  64 
SEQR_pHES 5’-CGGATTCCGCTTTACCCGCTTTG-3’ Reverse sequencing primer of pHES plasmid  59 
SEQF_PR8HA1 5’-CCCGGAAATAGCAGAAAGACCCAAAG-3’ Forward sequencing primer of PR-8 HA1 gene   59 
SEQR_PR8HA1 5’-AGCCCTCCTTCTCCGTCAGCCATAG-3’ Reverse sequencing primer of PR-8 HA1 gene 63 
* Calculated by company of synethesis  
Blue sequence indicating a sequence encoding for 6X-His tag 
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Table 2.7: Standard reaction conditions for amplification of DNA by PCR 
PCR reagent  Final concentration  
DNA template   10-100 ng  
dNTP  0.2 mM 
Primer A  0.2 mM 
Primer B  0.2 mM 
10X PCR buffer (with MgCl2)  1X 
Taq polymerase   1 U/50 μL 
 
 
 
 
Table 2.8: Standard amplification conditions of PCR with Taq polymerase 
Temperature (0C) Time (s) Cycle  
94 120 1X 
94 60  
Specific annealing 0C 60 35X 
72 60  
72 7 min  1X 
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2.6.3 Ligation 
Ligations were performed with purified digested DNA at a ratio of either 1:3 or 1:6 (vector 
molecule to insert molecules) with the addition of 2 U T4 ligase and buffer in a total volume 
of 10 μL. The reaction was incubated at 140C overnight. The ligated DNA product was then 
purified using QIAquick gel extraction kit prior to transformation via electroporation, which is 
crucial to prevent arcing during electrotransformation.  
 
2.6.4 Electrocompetent cell preparation 
Bacterial cells were prepared for electrotransformation by the method supplied with the 
Gene Pulser apparatus user’s mannual (BioRad Laboratories, USA) with minor adjustments. 
Briefly, 200 mL of Luria-Bertani (LB) borth was inoculated with 1 in 100 volume of an 
overnight bacterial culture. The cells were grown with vigorous shaking at 370C to an OD600 
of 0.5-0.7 (early to mid-log phase). The culture was cooled on ice for 30 minutes and the 
culture pelleted by 4,000 x g centrifugation for 10 minutes at 40C. The supernatant was 
discarded and the pellet resuspended in an equal volume of ice-cold sterile Milli Q water 
(mH2O). The cell suspension was centrifuged at 4,000 x g for eight minutes at 4
0C. The cells 
were pelleted as above and resuspended in 4 mL ice-cold 10% glycerol. The cells centrifuged 
once again at 3,500 x g for six minutes at 40C, and resuspended with 10% glycerol in a final 
volume of 200 μL. 50 μL aliquots were loaded for immediate use of electrotransformation.  
 
2.6.5 Electrotransformation 
The method supplied with Gene Pulser apparatus user’s manual (BioRad Laboratories, USA) 
was applied for the high efficiency electrotrnasformation of E. coli and S. Typhymurium. 
Freshly prepared electrocompletent cells were mixed with up to 2 μL of purified DNA and 
transferred to an ice-cold electroporation cuvette with a 0.2 cm gap. The pulse settings used 
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to deliver DNA into the cells were 2.4 kV, 25 μF and 200 Ω.  
 
After the pulser, S.O.C medium (pre-warm to 370C) was immediately added to the cells to a 
total volume of 1 mL and were incubated at 370C with 50 rpm shaking for one hour. 50 μL, 
100 μL and 200 μL of the transformed culture were plated out onto LB agar containing the 
appropriate selective agents. The remaining contents of transformed mixure were 
concentrated by centrifugation at 4,000 x g for five minutes and the cell pellet was plated 
onto LB agar containing the appropriate selective agents. 
 
2.6.6 DNA sequence analysis  
DNA sequence analysis was out-sourced from Australian Genome Research Facility, 
Melbourne. DNA samples were purified using QIAprep® spin miniprep kit and eluted in 
DNase/RNase-free water, the DNA quantity and quality were estimated using LUMIstar 
Omega Microplate luminometer. For double-stranded plasmid DNA, 600-1500 ng of purified 
DNA template was mixed with 9.6 pmol of primer in a total volume of 12 μL. The reaction 
mix was sealed in a 1.5 mL eppendorf tube, and sent to the facility via express post under 
ambient temperature. The sequencing result was analysed in Sci Ed Central software.  
 
2.7 Protein methods 
2.7.1 Preparation of whole cell lysates  
Samples of E. coli and S. Typhimurium from broth cultures were pelleted by centrifugation at 
16,000 x g for five minutes. The pellet was resuspended in one volume of 10mM Tris-HCl pH 
8.0 (supplemented with Protease Inhibitor Cocktail (Cell Signaling Technology, USA)), and 
sonicated using Branson Digital Sonifier®, with six cycles of 15 seconds ON, 45 seconds OFF 
at 18% amplitude. Cell debris was pelleted by centrifugation and the protein content of the 
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supernatant was determined using the Bradford protein assay.  
 
2.7.2 Bradford assay    
Protein content determination was performed using the Bradford assay [324, 325].  
Nine hundred microlitre of Bradford reagent was added to 100 μL of sample, or standards, 
mixed by vortexing and left to stand for two minutes. Samples and standards were diluted in 
filtered 0.15 M NaCl. Bovine serum albumin (BSA) was used as the standard protein solution. 
200 μL of processed sample was added to the well of a 96-well microtitre plate. The OD of 
samples was measured with iMarkTM microplate absorbance reader at 600 nm (OD600), and a 
standard curve constructed by plotting the concentrations of the bovine serum albumin 
standsrds (μg) versus absorbance was used to determine the protein concentration of 
unknowns.  
 
2.7.3 Polyacrylamide gel electrophoresis (SDS-PAGE)    
SDS-PAGE was performed using a discontinuous buffer system [324].  
The gels were prepared using SDS stacking gel buffer and SDS separating gel buffer. Proteins 
were mixed with 5X SDS loading buffer and heated to 1000C in a heating block for five 
minutes. The proteins were separated by eletrophoresis at 80 V for 30 minutes and then 180 
V for 50 minutes in an electrophoresis unit (BioRad Laboratories, USA) containing SDS 
running buffer. Three gels were run at the same time in this system. Two gels were 
transferred onto nitrocellulose membranes for immunoblotting, an the remaining gel was 
subjected to either silver or Coomassie blue staining. Protein markers were loaded together 
with other protein samples and used for the determination of relative protein mass.  
 
For silver stained gels, either a Protein Marker, Broad Range (New England Biolabs, USA) 
(Appendix 2) or a Precision Plus ProteinTM All Blue Standards (BioRad Laboratories, USA) 
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(Appendix 3) was used was loaded onto gels. For immunoblotting, either a ColorPlusTM 
Prestained Marker (New England Biolabs, USA) (Appendix 4) or a Precision Plus ProteinTM 
Dual Color Standards (BioRad Laboratories, USA) (Appendix 5) or a Precision Plus ProteinTM 
KaleidoscopeTM Standards (BioRad Laboratories, USA) (Appendix 6) was loaded onto gels 
(detail is specified in each relavent Figures). 
 
2.7.3.1 Coomassie staining  
SDS-PAGE gels were stained in Coomassie blue staining solution for 30 minutes. Gels were 
rinsed under dH2O and destained in the Coomassie detaining solution for one hour. A tissue 
was folded and placed into the destaining solution to assist with the stain removal. Gels were 
then soaked in dH2O and gently shaked overnight. 
 
2.7.3.2 Silver staining  
The SDS-PAGE gels were released into a flat-bottom glass tray and covered with Fixative 
solution for a minimum of 40 minutes or overnight. Direct contact with gel was definitely 
avoided. The gels were washed three times with the Washing solution, 20 minutes each. The 
gels were soaked in Reductant for one minute and rinsed with distilled water thoroughly 
(two minutes under running water), and soaked with Silver Reagent for 30 minutes. The gels 
were rinsed with distilled water again. The gel was then soaked in developer, and fresh 
developer was added when yellow precipitates appeared until protein bands reached the 
desired intensity. The gels were rinsed with running water for two minutes and soaked in 
Stop solution for at least 20 minutes. 
 
2.7.4 Immunoblotting    
Protein immunoblotting was performed after completion of SDS-PAGE (as described in 
Section 2.7.3) by the “iBlotTM Dry Blotting System” (Invitrogen, USA). The gel was placed 
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onto the (Anode) bottom stack with pre-placed nitrocellulose membrane, and a piece of 
filter paper was placed on top of the SDS-PAGE gel and the (Cathode) top stack was placed 
on top of the filter paper. A provided sponge was then loaded onto the lid of the iBlotTM 
machine, and the lid was closed and initiated the protein transfer. Proteins were transferred 
onto the nitrocellulose membrane using the default program for seven minutes.  
 
Following this the nitrocellulose membrane was removed and soaked in Blocking buffer for a 
minimum of one hour, then the membrane was soaked in primary antibody for minimum of 
two hours or overnight at 40C. The primary antibodies were diluted to 1:6000 in Diluent.  
 
The membrane was washed three times with Washing buffer, 20 minutes each, and then 
incubated with secondary antibody, which were diluted to 1:6000 in diluent for one hour in 
dark. The membrane was washed with Washing buffer three times, 20 minutes each. The 
membrane was developed with TMB (3, 3 ,´ 5, 5 -´tetramethylbenzidene) for HRP conjugated 
antibodies or BCIP/NBT solution for AP conjugated antibodies substrate until the desired 
signal intensity was reached. The membrane was gently rinsed with water to stop the 
development. 
 
2.7.5 Enzyme-linked immunosorbent assay    
Ninety-six well flat bottomed sterile plates (Greiner, Germany) were coated with 100 μL of 5 
μg/mL purified protein sample diluted in PBS and incubated for one hour at 370C or 40C 
overnight. Unbound protein was removed with three washes in PBST (PBS and 0.05% (v/v) 
Tween 20) and the plate coated with 200 μL of blocking buffer. After a further hour 
incubation at 37°C, plates were washed as above, patted dry on absorbent paper towelling, 
and 100 μL of primary antibody two-fold serially diluted in diluent (PBST/1% (w/v) skim milk) 
was added. Plates were incubated at 370C with 150 rpm shaking on an ELISA shaker platform 
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for two hours. The solution was discarded, wells washed four times in PBST and patted dry. 
Secondary antibody conjugated to HRP was diluted 1:5000 in diluent and 100 μL added to 
the wells of the ELISA plate. Following a one hour incubation at 370C on a shaking platform, 
the plates were washed four times in PBST followed by a wash in dH2O and then patted dry 
on absorbent paper. TMB substrate was prepared and 100 μL added to all wells. The 
development of the reaction was allowed to proceed for up 30 minutes and the reaction was 
stopped with 50 μL of 1 M sulphuric acid. The OD450 of the wells was determined in iMark
TM 
microplate absorbance reader. The endpoint was determined as the dilution at which the 
OD450 was three times the background level (OD≥0.2). All samples were tested in duplicate. 
 
2.8 Mammalian cells and tissue culture  
2.8.1 Cell type used in this study 
Madin-Darby canine kidney cells (MDCK) derived from the kidney of an adult cocker spaniel 
(The cell was purchased from Sigma-Aldrich, Australia as part of the Eruopean Collection of 
Cell Cultures operated by Public Health England). 
 
2.8.2 General maintainace 
All tissue culture procedures were performed under the protection of class II Biosafety 
cabinet (Aura 2000 M.A.C. BIOAIR Instrument, Italy). The cabinet and relevant equipment 
were ethanol disinfected and exposed under UV light for 20 minutes before commencing any 
work. Details of tissue culture procedures are described in [326]. 
 
Cell monolayers were generally maintained in 25 cm2 or 75 cm2 tissue culture flasks (Greiner, 
UK) in complete medium (Dulbecco’s modified Eagle’s medium (DMEM) with GlutaMAXTM 
supplement (Gibco®, USA), 10% (v/v) heat-inactivated FBS (Gibco®, USA), 1X 
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Penicillin-Streptomycin (Gibco®, USA) and incubated in a humidified incubator at 370C with 
5% CO2 supplement (New Brunswick, USA). Cells were trypsinised (Trypsin/EDTA Becton 
Dickinson Ltd., UK), and sub-cultured every four to seven days as necessary.  
 
2.8.3 Trypsinising and subculturing cells from a monolayer 
Medium was removed from the cell monolayer by decanting. Cell monolayer was gently 
washed twice with 370C 1X DPBS (Gibco®, USA) to remove any residual FBS that may inhibit 
the action of trypsin. Appropriate volume of 370C trypsin/EDTA solution (Gibco®, USA) was 
added to cover adhering cell layer, and incubated at 370C for up to 10 minutes. Monolayer 
was checked every two to three minutes for detachment by tilt against light, and gently 
tapped to facilitate the process. Up to 5 mL of complete medium was added to stop 
trypsinising process, and Pasteur pipette was used to rinse the bottom of the flask with cell 
suspension to help dislodge any remaining adherent cells. The cell suspension was 
centrifuged at 700 x g for three minutes, and cell pellet was resuspended with an equal 
volume of complete medium. Appropriate volume of complete medium was added into a 
fresh flask, and inoculated with the cell suspension, and the flask was incubated in a 
humidified 370C, 5% CO2 incubator. Sub-confluent culture was fed after three to four days if 
necessary, by removing old medium and replacing with fresh 370C complete medium. 
Passage of secondary culture when cell line became confluent by repeating steps outlined 
above, and continue to passage as necessary.  
 
2.8.4 Cell stock freezing and resuscitation 
Adherent cells were trypsinised, resuspended in the DMEM, and pelleted at 700 x g for three 
minutes. Cells were then resuspended in “freezing medium” (DMEM supplemented with 20% 
FBS and 10% DMSO (Santa Cruz Biotechnology, Inc., USA)), aliquoted into cryovials (Nalgene 
Company, USA), and frozen at -200C for two hours, then -700C for three days before 
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long-term storage in liquid N2. For resuscitation of cells, cryovials were rapidly thawed at 
370C before centrifugation at 700 x g. Cells were then resuspended in complete medium and 
inoculated into tissue culture flask with appropriate volume of medium, then incubated at 
370C with 5% CO2 overnight. Medium was replaced after 24 hours in order to remove traces 
of DMSO. 
 
2.9 Virus propagation  
2.9.1 Virus strain used in this study 
Influenza virus strain A/Puerto Rico/8/34 (H1N1) (PR-8) (stock provided by RMIT University). 
 
2.9.2 Virus cultivation in cell monolayer 
The virus propagation protocol was adapted from the published protocol [327]. 
A confluent monolayer of MDCK cells were infected with virus diluted in DMEM at an 
appropriate multiplicity of infection. Prior to infection, the monolayer was washed twice with 
370C 1X DPBS to remove all traces of serum, and incubated with 1:1000 diluted virus stock 
(HA titre = 400). Following incubation at 370C for one hour, the medium was discarded and 
washed once with DMEM (generally, 7 mL for 25 cm2 flask and 13 mL for 75 cm2 flaks). 
DMEM (supplemented with 0.2% Bovine serum albumin fraction V solution (Gibco®, USA)), 
was added and the cells were incubated at 370C for up to four days, with regular observation 
for cytopathic effect (cell death). Incubation was stopped when 50% of the monolayer cells 
were detached from the bottom. The flasks were frozen at -800C until purification. 
 
2.9.3 Virus purification and storage 
Virus infected cell monolayer was subjected to two cycles of freeze and thaw, and 
centrifuged at 5,000 x g for 10 mintues to removed cell debris. The supernatant was filtered 
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through 0.2 μm filter and the processed supernatant was gently loaded onto a two-layer 
sucrose gradient (15-60%). Sucrose gradient was prepared by loading 2 mL of 60% sucrose 
solution and overlaid with 2 mL of 15% sucrose solution in a Ultra-ClearTM thinwall tube 
(Beckman Coulter, Australia). The tubes were loaded into a Beckman Coulter SW 41 Ti rotor 
and centrifuged at 152,000 x g in a Beckman Coulter Optima L-80 XP Ultracentrifuge 
(Beckman Coulter, Australia) for 1.5 hours. After centrifugation, the gradient interphase was 
carefully removed and diluted to a final volume of 8 mL in TNE buffer, and loaded into a new 
Ultra-ClearTM thinwall tube for centrifugation as previously described. The virus pellet was 
resuspended in 50 μL TNE buffer and aliquoted into 10 μL fractions for storage at -800C until 
required.  
 
2.10 Mouse studies  
Four to six week old female BALB/c mice were purchased from the Animal Resource Centre, 
Canningvale, Western Australia. Mice were acclimatised for a minimum of one week prior to 
the start of any experimentation. 
 
Mice were bled from the retro-orbital vein using a capillary tube. Blood samples were 
separated by centrifugation at 5,450 x g for 10 minutes and the sera was collected and stored 
at -20°C until required for assays. More detailed methods will be described in the relavent 
chapter. More detailed methods are described in Chapter 3. This mouse study was approved 
by the RMIT Animal Ethics Committee under AEC# 0911. 
 
2.11 Chicken studies 
Newly broiler chickens were acquired from Inghams Farms, Pakenham, Victoria. The chicks 
were allowed to acclimatise for one week prior to the start of any procedure.  
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Chicken were wing-tagged at seven days of age for identification. Chicken sera was collected 
at the end point of the trial after decapitation. Blood samples were separated by 
centrifugation at 5,450 x g for 10 minutes and the sera was collected and stored at -20°C 
until required for assays. More detailed methods are described in Chapter 5. The chicken 
study was approved by the RMIT Animal Ethics Committee under AEC# 1310. 
  
 
 
Chapter 3 
Vaccination Study Using  
P. pastoris Expressed rHA1 
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3.1 Introduction 
The influenza virus can cause seasonal epidemics and has been implicated in four 
well-documented human pandemics in the past [163, 198]. Furthermore, the emergence of 
the HPAIV H5N1 and recent outbreak of H7N9 in China highlights the potential threat of an 
imminent pandemic. The HPAIV (i.e. H5 and H7 subtype) has been known to cause recurrent 
outbreaks in the poultry industry, which have resulted in occasional spill-over infections into 
the human population. Molecular studies have revealed the co-existence of human and avian 
influenza preferential-tropism receptors in many animals including swine, chicken and 
humans [216].  
 
The potential of virus hybridisation in such situation is high, and a virus reassortment may 
lead to the emergence of a pandemic novel influenza strain [328]. To date, the best 
prevention method for influenza infections is through immunisation with egg-based vaccines. 
However, such a vaccine production method is unable to rapidly respond to pandemic 
outbreaks from antigenically novel strains due to its time-consuming production, and 
possibility of an egg-shortage during an avian influenza strikes [253].  
 
Alternative approaches for influenza vaccine production have been intensively investigated in 
recent years. Many approaches have been tested and evaluated, one such example is the use 
of in vitro expressed influenza antigen HA protein as an immunogen [170]. The employment 
of recombinant influenza HA as a vaccine antigen can potentially overcome the 
disadvantages of the currently used egg-based vaccine manufacture [272, 289], as the 
antigen can be recombinantly produced in cultures instead of eggs, and the HA gene can be 
isolated soon after the outbreak of a newly circulating strain [329]. The influenza (HA) 
surface-glycoprotein is known to play an important role in the initial viral attachment and 
host cell endocytosis, and a significant population of HA-specific antibodies are responsible 
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for the inhibition of HA binding and/or fusion [241, 243]. HA1 is known to possess the major 
antigenic targets for these neutralising antibodies that inhibit viral attachment to target cells, 
and most of these antigenic sites are more liable to antigenic variation than the rest of the 
protein due to immune selection pressure [228, 330]. Therefore, the HA1 protein makes a 
promising candidate in vaccine developments for the prevention of influenza infection.  
 
Pichia pastoris (P. pastoris) is a well-established eukaryotic expression system that has a 
number of advantages over the prokaryotic expression system in regards to the production 
of recombinant vaccine antigens [331], including: 1) rapid production; 2) well characterised 
expression-vectors and easy genetic manipulation steps; 3) diverse post-translational 
modifications including glycosylation, peptide-folding, and targeting secretion; 4) simple 
purification steps from engineered secretion proteins [290, 291, 332]. Among these 
advantages, post-translational protein glycoslation is considered the most important, 
because it facilitates the correct peptide folding and virus-host receptor recognition 
[333-335].  
 
In my previous study, a codon-optimised gene sequence encoding for HA1 derived from 
influenza (A/Puerto Rico/8/34(H1N1)) was synthesised by GenScript USA Inc. (Figure 3.1), 
and inserted into the yeast vector pPICZα-A (Figure 3.2 and Figure 3.3), a vector equipped 
with a methanol inducible promoter.  
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     1  GAATTCGACACAATATGTATAGGCTACCATGCGAACAATTCAACCGACACTGTTGACACA 
    61  GTACTCGAGAAGAATGTGACAGTGACACACTCTGTTAACCTGCTCGAAGACAGCCACAAC 
   121  GGAAAACTATGTAGATTAAAAGGAATAGCCCCACTACAATTGGGGAAATGTAACATCGCC 
   181  GGATGGCTCTTGGGAAACCCAGAATGCGACCCACTGCTTCCAGTGAGATCATGGTCCTAC 
   241  ATTGTAGAAACACCAAACTCTGAGAATGGAATATGTTATCCAGGAGATTTCATCGACTAT 
   301  GAGGAGCTGAGGGAGCAATTGAGCTCAGTGTCATCATTCGAAAGATTCGAAATATTTCCC 
   361  AAAGAAAGCTCATGGCCCAACCACAACACAAACGGAGTAACGGCAGCATGCTCCCATGAG 
   421  GGGAAAAGCAGTTTTTACAGAAATTTGCTATGGCTGACGGAGAAGGAGGGCTCATACCCA 
   481  AAGCTGAAAAATTCTTATGTGAACAAAAAAGGGAAAGAAGTCCTTGTACTGTGGGGTATT 
   541  CATCACCCGCCTAACAGTAAGGAACAACAGAATCTCTATCAGAATGAAAATGCTTATGTC 
   601  TCTGTAGTGACTTCAAATTATAACAGGAGATTTACCCCGGAAATAGCAGAAAGACCCAAA 
   661  GTAAGAGATCAAGCTGGGAGGATGAACTATTACTGGACCTTGCTAAAACCCGGAGACACA 
   721  ATAATATTTGAGGCAAATGGAAATCTAATAGCACCAATGTATGCTTTCGCACTGAGTAGA 
   781  GGCTTTGGGTCCGGCATCATCACCTCAAACGCATCAATGCATGAGTGTAACACGAAGTGT 
   841  CAAACACCCCTGGGAGCTATAAACAGCAGTCTCCCTTACCAGAATATACACCCAGTCACA 
   901  ATAGGAGAGTGCCCAAAATACGTCAGGAGTGCCAAATTGAGGATGGTTACAGGACTAAGG 
   961  AACAATCCGTCCATTCAATCCAGACCTCTAGA 
Figure 3.1: The HA1 gene sequence synthesised by GenScript USA Inc.,  
The gene has two restriction site inserts EcoRI & XbaI (in Blue), and two additional 
cytosine bases (in Red ) were added to ensure that the protein is “in-frame”. The total 
length of this HA1 sequence was 992bp. 
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Figure 3.2: The in silico construct developed in SECentalTM Clone Manager. 
 
   1  mrfpsiftav lfaassalaa pvntttedet aqipaeavig ysdlegdfdv 
  51  avlpfsnstn ngllfintti asiaakeegv slekreaeae fdticigyha 
 101  nnstdtvdtv leknvtvths vnlledshng klcrlkgiap lqlgkcniag 
 151  wllgnpecdp llpvrswsyi vetpnsengi cypgdfidye elreqlssvs 
 201  sferfeifpk esswpnhntn gvtaacsheg kssfyrnllw ltekegsypk 
 251  lknsyvnkkg kevlvlwgih hppnskeqqn lyqnenayvs vvtsnynrrf 
 301  tpeiaerpkv rdqagrmnyy wtllkpgdti ifeangnlia pmyafalsrg 
 351  fgsgiitsna smhecntkcq tplgainssl pyqnihpvti gecpkyvrsa 
 401  klrmvtglrn npsiqsrple qkliseedln savdhhhhhh 
 
Figure 3.3: The protein sequence expressed from the pPICZα-A construct containing HA1 
gene.  
The protein sequence in Blue was the α-factor signal that is incorporated in the pPICZα-A 
vector and is responsible for protein secretion. The sequence in Purple is the rHA1 protein 
sequence, and the 6X-His tag is coloured Red. 
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The pPICZα-A construct was then incorporated into the P. pastoris GS115 genome via 
homologous recombination between the transforming DNA and regions of homology (AOX1 
gene) within the genome [336, 337]. Successful transformation was confirmed using PCR 
(Figure 3.4), and recombinant influenza HA1 was detected as a secretory protein in a pilot 
expression study in a methanol induced culture (Figure 3.5). 
 
In this study, the expression of rHA1 was optimised and rHA1 was expressed and purified by 
IMAC. An animal trial was then carried out to examine the immunogenicity of the rHA1 
protein.  
 
The work described in this chapter was as follows: 
- To optimise the expression of rHA1 protein in P. pastoris by using different media and 
expression time.  
- To purify rHA1 using IMAC and to analyse the protein using techniques including 
SDS-PAGE, immunoblotting with 6x-His antibody and PR-8 antiserum, and 
deglycosylation. 
- To evaluate the immune responses to the purified rHA1 in a mouse trial. 
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Figure 3.4: The PCR amplification analysis on the DNA construct that has been transformed 
into the P. pastoris chromosomal DNA.  
Lane M: PstI/λ-DNA marker, Lane 1: chromosomal DNA of non-transformed P. pastoris GS115, 
Lane 2: PCR product of chromosomal DNA of non-transformed P. pastoris GS115, Lane 3: 
chromosomal DNA of putative clone, Lane 4, PCR product of chromosomal DNA of the 
putative clone. The information of primer sequences and PCR conditions were provided in 
EasySelectTM Pichia Expression Kit (Life Technologies, USA), designed to amplify the AOX1 
gene. In the case of successful chromosomal insertion of the HA1 gene, a PCR product of 
approximately 1.5 kbp should be amplified, indicating the insertion of HA1 gene. As shown, 
the PCR confirmed the chromosomal insertion.  
 
 
1.5 kbp 
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Figure 3.5: The silver stained SDS-PAGE gel of protein expression samples from BMMY 
medium.  
Lane M: Protein Marker, Broad Range, Lanes 1 to 3: non-transformed P. pastoris GS115 at 0, 
48 and 96 hours after expression, respectively, Lanes 4 to 6: transformed P. pastoris clone at 
0, 48 and 96 hours after expression, respectively. The SDS-PAGE result showed that the rHA1 
was expressed; as the expression medium of the clone appeared to have an additional 
protein-smear at approximately 80 kDa in molecular weight with an increasing intensity 
along the time-course of protein expression, which was not observed from the 
non-transformed P. pastoris. Furthermore, the rHA1 appeared as smears on the SDS-PAGE, 
indicating that the protein was hetero-glycosylated. 
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3.2 Materials and methods 
3.2.1 General solution and media 
3.2.1.1 Buffer solution for media 
1 M potassium phosphate buffer, pH 6.0: prepared by combining 132 mL of 1 M K2HPO4 
(BDH Chemicals, USA), 868 mL of 1 M KH2PO4 (BDH Chemicals, USA) and pH was adjusted 
using phosphoric (Sigma-Aldrich, USA) acid or potassium hydroxide (Sigma-Aldrich, USA). 
 
3.2.1.2 Growth and expression media for P. pastoris 
Minimal dextrose medium + histidine (MDH): 1.34% (w/v) Yeast Nitrogen Base (YNB) 
(Invitrogen, USA), 4 x 10-5% (w/v) biotin (Sigma-Aldrich, USA), 2% (w/v) dextrose (BDH 
Chemicals, USA). All stock solutions were made separately and filter sterilised. mH2O was 
autoclaved and cooled before addition of stocks. In the case of protein induction, 0.5% (v/v) 
methanol was added prior to inoculation of pre-expressed Pichia culture, and supplemented 
with 0.25% (v/v) methanol every 12 hours during expression. 
 
Minimal methanol medium + histidine (MMH): 1.34% (w/v) YNB (Invitrogen, USA), 4 x 10-5% 
(w/v) biotin (Sigma-Aldrich, USA), 0.5% (v/v) methanol (BDH Chemicals, USA). All stock 
solutions were made separately and filter sterilised. mH2O was autoclaved and cooled before 
addition of stocks. 0.5% (v/v) methanol was added prior to inoculation of pre-expressed 
Pichia culture, and supplemented with 0.25% (v/v) methanol every 12 hours during 
expression. 
 
Buffered minimal glycerol medium (BMMH): 1.34% (w/v) YNB, 4 x 10-5% (w/v) biotin, 1% 
(v/v) glycerol (Sigma-Aldrich, USA), 0.5% (v/v) methanol (BDH Chemicals, USA), 100 mM 
potassium phosphate buffer pH 6.0. The medium was prepared by autoclaving mH2O and 
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cooled before the addition of other supplements. 0.5% (v/v) methanol was added prior to 
inoculation of pre-expressed Pichia culture, and supplemented with 0.25% (v/v) methanol 
every 12 hours during expression. 
 
Buffered methanol-complex medium (BMMY): 1% (w/v) yeast extract (Oxoid, UK), 2% (w/v) 
peptone (Oxoid, UK), 1.34% (w/v) YNB, 4 x 10-5% (w/v) biotin, 1% (v/v) glycerol 
(Sigma-Aldrich, USA), 0.5% (v/v) methanol (BDH Chemicals, USA), 100 mM potassium 
phosphate buffer pH 6.0. The medium was prepared by autoclaving mH2O containing 1% 
yeast extract and 2% peptone, and cooled before the addition of other supplements. 0.5% 
(v/v) methanol was added prior to inoculation of pre-expressed Pichia culture, and 
supplemented with 0.25% (v/v) methanol every 12 hours during expression.  
 
3.2.2 rHA1 expression in P. pastoris 
The clone was incubated for 40 hours in the MDH prior to expression, and protein-expression 
was induced by changing the carbon source from dextrose to methanol to up-regulate the 
AOXI methanol-utilisation gene, and thus express the recombinant protein. 
 
3.2.2.1 Optimisation of rHA1 expression 
MMH, BMMH and BMMY expression medium were prepared in fresh and 100 mL of each of 
these expression medium was inoculated with 10 mL of the 40 hours-old cell culture. Four 
clones and one non-transformed P. pastoris GS115 were included in the pilot expression. All 
cultures were incubated at 300C with 300 rpm shaking, 100% methanol (filter sterilised) was 
used to make up the final concentration of 0.5% (v/v) methanol every 12 hours, and 1 mL of 
expression medium were collected at 12 hours time intervals. All samples were snap-frozen 
with liquid N2, and stored at -80
0C for analysis. 
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3.2.2.2 Large-scale protein expression 
Twenty milliliters of 40 hours-old P. pastoris clone culture was centrifuged at 2,500 x g for 
five minutes, and the cell pellet was inoculated into 200 mL of BMMY expression medium in 
a 2 Litre baffled flask. The culture was incubated at 300C and 300 rpm. Filter sterilised 100% 
methanol was added to the culture to the final concentration of 0.5% (v/v) every 12 hours for 
84 hours. After expression, the culture was centrifuged at 4,500 x g for five minutes to 
remove yeast cells, and supernatant was snap-frozen with liquid nitrogen and stored at -800C 
until protein purification.  
 
3.2.3 Purification of rHA1 using IMAC 
Five milliliters of chelating Sepharose fast flow® resin was loaded into a 10 mL propylene 
column (QIAGEN, Australia). The column was washed with 5 column volumes (CV) of sterile 
mH2O, and loaded with 0.5 CV of 0.2 M NiSO4. The column was then washed with 5 CV of 
sterile mH2O to remove unbound Nickel ions and then equilibrated with at least 5 CV of 
Native Binding Buffer.  
 
Protein sample (expression medium) was filtered with 0.45 μm filter, and 8 mL of sample was 
loaded into the column and continuously rotated for 20 minutes to allow the His-tagged 
protein to bind to the Nickel ion. The column was placed in an upright position to allow resin 
to settle, and the sample was subsequently allowed to flow through. The same amount of 
sample was loaded and the process above was repeated for up to four times. The column 
was then washed with 15 CV of Native Wash Buffer, and loaded with 5 CV of Native Elution 
Buffer. The first 1 mL flow through was discarded since this is considered as the “dead 
volume” in the column, and the remaining flow through was collected for either immediate 
buffer exchange or stored at -800C until use.  
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3.2.3.1 Cleaning and regeneration of column  
IMAC columns were re-used up to five times and cleaned between each use to remove 
hydrophobic and ionic bound contaminants. Column cleaning involves the application of 10 
CV of 2 M NaCl, followed by 10 CV of 1 M NaOH, and finished with 10 CV of 70% ethanol 
(v/v). Columns were washed with dH2O between each solution and Ni2+ was stripped with 2 
CV 0.05 M EDTA, 0.5 M NaCl, pH 7.0. A 20% ethanol solution was added to the sepharose 
when stored for later use. 
 
3.2.4 Buffer exchange and protein concentration  
Eluted proteins were concentrated using Centricon® centrifugal device (Milipore, Australia) 
with a cut-off pore size of 30 kDa according to the manufacturer’s instructions. Briefly, 4 mL 
of DNase/RNase-free water was added to the Centricon® centrifugal device and centrifuged 
at 4,500 x g for 15 minutes, and the flow-through discarded. 20 mL of protein sample was 
loaded into the device, and the tubes were centrifuged at 4,500 x g until the sample has 
been reduced to 1/100 of its original volume. Thereafter, sterilised PBS was added to top-up 
the sample volume to 20 mL and centrifuged again as described above, and the process was 
repeated three more times. The sample volume was reduced to a minimum and stored at 
-800C until use. Salts and metals were removed by continual concentration and dilution of 
the protein sample in the new buffer. 
 
3.2.5 Quantification of expressed rHA1 
Quantification of purified protein was done using the Bradford assay (Section 2.7.2) and a 
spectrophotometric measurement at 600 nm on an iMarkTM microplate absorbance reader. 
After quantification, the integrity of the protein was confirmed via SDS-PAGE gel.  
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3.2.6 Deglycosylation analysis 
Glycoslation of rHA1 was evaluated by using Protein Deglycosylation Mix (New England 
Biolabs, USA), and examined using SDS-PAGE with silver staining and immunoblotting. The 
protocol used was derived from the Protein Deglycosylation Mix user guide (2009) (New 
England Biolabs, USA). The reaction composition were varied to examine the deglycosyation 
efficacy; 1 U enzyme equals to 5 μL of the deglycosylation enzyme mix in the total of 50 μL 
reaction; whereas 2 U equal to 10 μL of the enzyme mix in total of 50 μL reaction with 
reduced amount of H2O added accordingly. Both native and denaturing conditions were 
available for the reaction. However, the deglycosylation enzymes were less effective to 
remove the additional oligosaccharide chains under native reaction conditions. 
 
3.2.7 SDS-PAGE and Immunoblotting  
SDS-PAGE gels subjected to silver staining and immunoblotting was used to examine the 
rHA1 protein integrity. SDS-PAGE gels were loaded with purified rHA1 and samples were 
separated together in the same electrophoresis system. After electrophoresis, gels were 
silver stained (as described in Section 2.7.3.2), or transferred onto nitrocellulose membrane 
for immunobloting using “mouse anti-His (C-term) antibody (Life Technologies, USA)” and 
“rabbit influenza (A/Puerto Rico/8/34 antiserum) (WHO)” (PR-8 antiserum). The 
immunoblotting procedure is as described in Section 2.7.4 with some modifications.  
 
For immunoblotting with anti-His (C-term) antibody, the primary antibody was diluted 
1:5000 in diluents and then incubated with the nitrocellulose membrane at room 
temperature for two hours in dark on a roller mixer (Ratek, Australia). The secondary 
antibody used was rabbit anti-mouse IgG-HRP (Sigma-Aldrich, USA) diluted 1:5000 in diluents, 
and the assay was developed using TMB single solution (Life Technologies, USA).  
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For the immunoblot assay with PR-8 antiserum, the primary antibody was diluted 1:3000 in 
diluents, and secondary antibody was goat anti-rabbit IgG-HRP (Sigma-Aldrich, USA) diluted 
1:6000, and the assay was developed using TMB single solution (Life Technologies, USA). 
 
3.2.8 Mouse vaccine trial using rHA1 vaccine candidate 
The animal experimentation and relevant protocol were approved by the RMIT Animal Ethics 
Committee (AEC#0911). BALB/c mice was chosen to be the study model for this trial because 
there are predicted MHC class I and MHC class II epitopes for T-lymphocytes in BALB/c mice 
for HA1. The predictions were carried out using epitope prediction servers including  
- “SYFPEITHI: Epitope prediction 
(http://www.syfpeithi.de/bin/MHCServer.dll/EpitopePrediction.htm). 
- MHC-I binding predictions – IEDB Analysis Resource 
(http://tools.immuneepitope.org/analyze/html/mhc_binding.html).  
 
Two groups of five mice (five to seven week old female BALB/c mice) were immunised three 
times subcutaneously at days 7, 21 and 35 (around the flank region skin fold of dorsal area) 
using a 1 mL syringe and 23 or 25 gauge needle (depending on the viscosity of the mixture) 
with 100 μL of protein:adjuvant emulsion, which consists of 25 μg of protein. FCA (Frenud’s 
Complete Adjuvant) was used for the first injection, and FIC (Frenud’s Incomplete Adjuvant) 
was used for the subsequent two booster injections. The groups consisted of rHA1:Freund’s 
adjuvant and PBS:Freund’s adjuvant. The group administered with PBS:Freund’s adjuvant 
served as the control. Serum samples were collected three weeks after the final vaccination 
for the evaluation of humoral responses. The mice were killed by cervical dislocation and 
spleens were collected for immediate analysis of cell-mediated immune responses. In 
instances where organs were not required for further analysis, mice were killed by 
intraperitoneal (i.p.) administration of an overdose of Lethabarb (Euthanasia injection, 325 
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mg/mL Pentobarbitone Sodium) (Virbac-Animal Health, Australia).  
 
3.2.8.1 Vaccine preparation 
Prior to vaccinations, the rHA1 was prepared in an equal volume of FCA (Merck Millipore, 
Australia) for the initial injection, and FIA for the subsequent two booster injections. Briefly, 
an emulsion was prepared by drawing up and expelling equivalent volumes of protein and 
adjuvant through a 21 gauge needle in a 3 mL glass syringe until the fluidic suspension 
increased markedly in viscosity and was no longer able to disperse when a drop was placed 
in a glass beaker of cold water. Vaccine prepared in adjuvant was used within three hours of 
preparation.  
 
3.2.9 Immunological assays for the mouse trial  
3.2.9.1 ELISA protocols  
Antibody responses of vaccinated mice were measured using the ELISA outlined in Section 
2.7.5 with some modifications. Wells were coated with 10 μg/mL of purified rHA1 in ELISA 
coating buffer. Four-fold dilutions (starting at 1/50 dilution and serial diluted 11 times) of 
serum samples acquired from vaccinated mice were used as the primary antibody, and 
horseradish peroxidase-conjugated goat anti-mouse IgG (Sigma-Aldrich, USA) (diluted 
1:5000 in PBST/1% (w/v) skim milk) was used as the secondary conjugated antibody. The 
assay was developed using the substrate TMB (Life Technologies, USA), plates were 
incubated for 15 minutes before the addition of 50 μL of a 1 M sulphuric acid solution. The 
endpoint was determined as the dilution at which the optical density (OD) at a wavelength of 
450 nm (OD450) was three times the background level.  
 
 
CHAPTER 3 
99 
 
3.2.9.2 ELISpot assay 
3.2.9.2.1 Media 
RPMI/NCS: RPMI 1640 (Gibco®, USA) with 5% (v/v) heat-inactivated Newborn Calf Serum 
(NCS) (Gibco®, USA). 
RPMI/NCS/Abs: RPMI/NCS with 0.1% (v/v) Penicillin-Streptomycin (Gibco®, USA). 
 
3.2.9.2.2 Buffers and solutions  
ACK lysing buffer: 0.15 M NH4Cl (BDH Chemicals, USA), 10 mM KHCO3 (Sigma-Aldrich, USA), 
0.1 mM Na2EDTA (Sigma-Aldrich, USA) dissolved in mH2O and adjust pH to 7.3 using HCl (Ajax 
Chemicals Ltd., Australia). Filter sterilised.  
Antibody diluents: PBS with 1% (v/v) NCS. 
ELISpot blocking buffer: 5% (v/v) NCS in PBS. 
ELISpot coating buffer: 35 mM NaHCO3 (BDH Chemicals, USA), 11 mM Na2CO3 (BDH 
Chemicals, USA), pH 9.6. 
Concanavalin A: 100 μg/mL in RPMI/NCS/Abs (Sigma-Aldrich, USA).  
 
3.2.9.2.3 Antibodies  
Interferon-gamma (IFN-γ) (capture antibody): BD Pharmingen, USA. 
Interleukin-4 (IL-4) (capture antibody): BD Pharmingen, USA. 
Biotinylated detection antibody: BD Pharmingen, USA. 
Alkaline phosphatase-labeled streptavidin: Sigma-Aldrich, USA. 
 
3.2.9.2.4 Equipment 
Cell strainer: BD FalconTM cell strainer (100 μm) (BD Biosciences, USA). 
ELISpot plate: purchased from Millipore, USA.  
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3.2.9.2.5 ELISpot protocol 
After cervical dislocation, mouse spleen cells were isolated for ELISpot assay. The protocol 
was adapted from a published method [4]. Briefly, spleens collected were crushed and 
resuspended in 5 mL of RPMI/NCS/Abs and filtered through a cell strainer. The cells were 
recovered by centrifugation at 750 x g for five minutes, and resuspended in 5 mL of ACK 
lysing buffer for depletion of red blood cells. After five minutes of incubation, 5 mL of 
RPMI/NCS/Abs was added and the cells recovered by centrifugation as described above. The 
splenocytes were washed three times with RPMI/NCS, and resuspended in RPMI/NCS. The 
number of viable cells was estimated using the Countess® Automated Cell Counter 
(Invitrogen, USA), by mixing a small volume of cells suspension with equal volume of Trypan 
Blue 0.4% staining solution (Sigma-Aldrich, USA), and loaded into a Countess® Cell Counting 
Chamber Slide (Invitrogen, USA) for viable cell estimation.  
 
Before the day of the assay, the ELISpot plate was prepared by wetting the membrane with 
100% methanol for five minutes, followed by three washes in sterile PBS. Capture antibodies 
were diluted in ELISpot coating buffer and added to the wells with the amount of 100 μL/well 
(IL-4 was diluted to 0.5 μg/mL and IFN-γ was diluted to 1.0 μg/mL). The plates were 
incubated overnight at 40C. On the following day, the capture antibodies were discarded, and 
wells were washed three times with PBST. The wells were incubated with ELISpot blocking 
buffer for three hours. Prior to the addition of splenocytes, the wells were washed three 
times with 200 μL of PBST.  
 
Prepared splenocytes were seeded in five wells at 1 x 106 cells in 90 μL of media per well. 10 
μL of rHA1 protein was added at a concentration of 250 μg/mL in triplicate. 10 μL of 
RPMI/NCS/Abs was added in one well as an internal negative control, and 10 μL of 
Concanavalin A (100 μg/mL) solution was used as a positive control.  
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The plates were incubated for 20 hours at 370C supplemented with 5% CO2. After incubation, 
the splenocytes were discarded and the wells were washed seven times with 300 μL of PBST 
and twice with sterile mH2O. The biotinylated detection antibody was diluted in antibody 
diluents to a final concentration of 0.5 μL/mL (v/v) and wells were incubated with 100 μL of 
the diluted antibody for two hours at room temperature. The plates were then washed six 
times using PBST and 100 μL of 1:1000 diluted alkaline phosphatase-labeled streptavidin was 
added to the wells. The plates were incubated for two hours at room temperature in the dark. 
After incubation, the antibody solution was discarded, and wells washed seven times with 
PBST and three times with PBS. The assay was developed by adding alkaline phosphatase 
substrate BCIP/NBT solution (Sigma-Aldrich, USA) (50 μL in each well), and incubation at 
room temperature in the dark until blue spots developed (30 minutes). The reaction was 
then stopped by three washes of dH2O, and the plates air-dried before analysis. The spots 
were enumerated by visualisation under a dissecting microscope. 
 
3.2.9.3 Hemagglutination Inhibition assay  
3.2.9.3.1 Hemagglutination assay 
A hemagglutination (HA) assay was carried out to estimate the virus titre of the stock, which 
is a prerequisite step for performing hemagglutination inhibition (HI) assay [338, 339].  
 
One hundred microlitres of PBS diluted virus sample was added into the first well of a 
V-bottom-shaped 96-well plate, and a two-fold serial dilution was performed throughout the 
same row, resulting in 50 μL of serial diluted virus samples across the row.  
 
Human erythrocytes (purchased from CSL Limited, Australia) were washed twice with sterile 
PBS and diluted to 0.75% (v/v). An equal volume of 0.75% human erythrocytes was then 
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added to all wells and incubated for one hour at room temperature. The ability of influenza 
HA to bind to the sialic acid receptors on the erythrocytes prevents these cells from settling 
to the V-shaped bottom. The HA unit was expressed as the highest virus dilution at which no 
hemagglutination was observed (Figure 3.6).  
 
3.2.9.3.2 Hemagglutination Inhibition assay  
The HI assay was used to evaluate viral-neutralising antibody responses elicited in immunised 
mice using PR-8 virus and human erythrocytes (CSL Limited, Australia) according to the WHO, 
2011. Briefly, 50 μL of PBS diluted mouse serum was added into the first well of a 
v-bottom-shaped 96-well plate, and a two-fold serial dilution in PBS was performed, resulted 
in 25 μL of diluted serum across all wells. 4 HA units of PR-8 virus was added to each well and 
incubated at room temperature for 30 minutes. An equal volume of 0.75% human 
erythrocytes in PBS was then added to all wells and incubated for another hour. The HI titers 
were expressed as the logarithm of the reciprocal of the highest serum dilution at which no 
hemagglutination was observed, expressed as log2 value (Figure 3.7).  
 
3.2.10 Statistical analysis  
All statistical analysis was calculated using the Microsoft Excel 2007 with the Data Analysis 
add-in. The results displaying a normal distribution and equal variances were analysed using 
Student’s T-test.  
 
 
 
 
 
 
 
 
 
CHAPTER 3 
103 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: An example of hemagglutination assay.  
Well 1: 1:100 PBS diluted PR-8 virus, wells 2-12: two-fold serially diluted virus sample. The 
HA unit was the dilution factor of the last well exhibiting complete hemagglutination, which 
was the forth well (1:400). Therefore, 1 HA unit was expressed as 400. 
 
 
 
 
 
 
Figure 3.7: An example of hemagglutination inhibition assay. 
Well 1: 1:50 PBS diluted mouse serum, well 2-12: serial diluted mouse serum sample. 
The HI titre was the highest serum dilution at which no hemagglutination was observed, 
expressed as log2 value. As such, the last well showing no hemagglutination was the third 
well (1:200 dilution), which is equivalent to 7.64 log2. 
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3.3 Results 
3.3.1 Optimisation of rHA1 expression   
In comparison of the silver staining and immunoblotting on the expressed protein samples of 
different expression medium, BMMY was the medium which gave the best protein 
expression level; whereas the MMH expression medium was not optimal for the 
recombinant-protein expression (as shown in Figure 3.8). An estimation of rHA1 
concentrations present in each growth medium was carried out using samples collected after 
96 hours post-induction. Bradford assay revealed an estimated 1.57 mg/L, 2.02 mg/L and 
2.15 mg/L in MMH, BMMH and BMMY media, respectively.  
 
3.3.2 Time-course study on rHA1 expression   
The BMMY appeared to be the optimal medium for the expression of rHA1, and thus a 
time-course study of the protein expression level in BMMY was carried out. As shown with 
the SDS-PAGE gel and immunoblot depicted in Figure 3.9, the concentration of the rHA1 
gradually increased throughout the course of the protein expression, and the highest rHA1 
concentration was reached between 72 hours and 96 hours after expression. Therefore, 84 
hours of protein expression was used for the scale-up protein expression and further studies. 
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Figure 3.8: Silver-stained SDS-PAGE and immunoblotting results from P. pastoris expressing 
rHA1 using different media. 
Three different yeast expression media were used to optimise protein expression, which 
includes MMH, BMMH and BMMY, each sample was harvested from expression medium 
after 96 hours of the initial induction. Lane M: ColorPlus™ Prestained Protein Marker, Lanes 1, 
3, 6 and 7 were silver stained SDS-PAGE gels, and 2, 4, 6 and 8 were immunoblots against 
PR-8 antiserum. Lane 1 and 2 were the non-transformed yeast culture grown in BMMY for 96 
hours as negative control. The results indicated that the maximum rHA1 yield was achieved 
in BMMY expression medium. 
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Figure 3.9: Time-course protein expression using BMMY medium.  
A) Silver stained SDS-PAGE gel, and B) Immunoblot assay with PR-8 antiserum. Lane M: 
Protein Marker, Broad Range for A) and ColorPlus™ Prestained Protein Marker for B), Lanes 1 
to 9: expression medium collected at 12 hour intervals (0, 12, 24, 36, 48, 60, 72, 84 and 96 
hours after expression). Highest rHA1 expression reached after 72 hours of expression. 
A) 
B) 
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3.3.3 Protein purification and analysis  
Large-scale protein expression was performed to generate large quantities of rHA1 for 
protein analysis and vaccine purposes. Immobilised Metal Affinity Chromatography (IMAC) 
with Nickel ions was used for protein purification, and successful purification of rHA1 was 
achieved (as shown in Figure 3.10) using the method described in Section 3.2.3. The purified 
rHA1 was deglycosylated with Protein Deglycosylation Mix (New England Biolabs, USA) to 
cleave off the oligosaccharide chains, and thus resulted as a clear protein band on the 
SDS-PAGE gel and immunoblot for estimation of the actual molecular weight of the rHA1 (as 
shown in Figure 3.11). Bradford assay estimated that the total rHA1 yield in the optimised 
protein expression was approximately 2.9 mg/L, and the Centricon ® Filter Device with 30 
kDa cut-off was used to remove Imidazole and also concentrate the protein samples. 
Following buffer exchange, another Bradford assay was carried out to estimate the rHA1 
content in solution, and the result estimated that the protein concentration of buffer 
exchanged products was approximately 6.2 x 103 mg/L. 
 
Deglycosylation of the purified rHA1 was carried out to examine the true molecular weight of 
the protein. Both native and denaturing deglycosylation-reactions conditions were examined, 
and different amount of deglycosylation enzymes were included to examine the effcacy of 
deglycosylation reactions. As shown in Figure 3.11, the protein smear became a sharp band 
with corresponding molecular weight approximately 45 kDa. The molecular weight was 
approximately 3 kDa lower than what was predicted from ExPASy Proteomics Server. 
However, this small variation could be caused by inaccurate protein migration along the 
SDS-PAGE. 
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Figure 3.10: SDS-PAGE and immunoblotting results of IMAC purified rHA1 protein. 
A) Silver stained SDS-PAGE gel, B) The immunoblot using Mouse anti-His (C-Term) antibody, C) 
The immunoblot using PR-8 antiserum; Lane M: ColorPlus™ Prestained Protein Marker, Lanes 
1 to 3: 1st to 3rd elutions from IMAC column (the elutions were 1 mL fraction). Results 
showed the successful purification of rHA1 using IMAC purification. Minor degradation of the 
rHA1 was observed in silver stained SDS-PAGE gel, however, the majority of the rHA1 
retained its glycosylated state.   
C) 
A) B) 
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Figure 3.11: SDS-PAGE and immunoblotting results of deglycoslated rHA1 protein. 
A) Silver stained SDS-PAGE gel, B) The immunoblot using Mouse anti-His (C-Term) antibody; 
Lane M: ColorPlus™ Prestained Protein Marker; Lane 1: untreated rHA1 protein sample, Lane 
2: rHA1 protein underwent native-condition deglycosylation, Lanes 3 to 6: rHA1 protein 
underwent denaturing-condition deglycosylation with 0.5, 1.0, 1.5 and 2 U of enzyme, 
respectively. The reaction successfully removed the oligosaccharide chains and resulted in 
clear protein bands at approximately 45 kDa.  
B) 
A) 
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3.3.4 Humoral IgG response in rHA1 vaccinated mice 
Mice injected with the vaccine formulations developed no signs of abnormality or change in 
behavior. Serum samples collected three weeks after the final vaccination were subjected to 
ELISA for the analysis of HA1-specific IgG responses, and the mice vaccinated with 
PBS:adjuvant served as negative controls for this assay. The result indicated that mice 
vaccinated with the rHA1 elicited strong IgG responses (the endpoint titre was 51200, shown 
in Figure 3.12). 
 
3.3.5 Cell-mediated immune responses in rHA1 vaccinated mice 
The T-lymphocyte IL-4 and IFN-γ responses against P. pastoris expressed rHA1 were 
evaluated using splenocytes obtained from immunised mice. In this animal study, only the 
secretion of IL-4 and IFN-γ were evaluated, which was because the production of other 
cytokines such as IL-2, IL-6, and IL-10 is not stringently restricted to a single T-lymphocyte 
sub-population [340]. In the past, the expression of Th1 and Th2 cytokines was considered to 
be mutually exclusive, however, some T-lymphocytes expressing both Th1 and Th2 cytokines 
have been observed during differentiation and also in terminally differentiated cells 
[341-343]. Furthermore, the uniqueness of IL-4 and IFN-γ compare to other Th1 and Th2 
cytokines are their positive feedback ability to sustain and proliferate their own T helper 
lymphocyte sub-population, hence only these two cytokine secretions were evaluated. 
 
Results of the ELISpot assay were expressed as the number of spot-forming T-lymphocytes 
per 1 x 106 splenocytes with cells from each mouse assayed in duplicate. In contrast to the 
control group (PBS), rHA1 immunised mice exhibited significantly elevated IL-4 secretion 
(P<0.05) (Figure 3.13), but no significant stimulation of IFN-γ secretion was observed (Figure 
3.14). The Column labeled Con A represents the stimulation with Concanavalin A, a 
plant-based mitogen known to stimulate T-lymphocyte proliferation and this served as an 
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internal positive control. In both instances of IL-4 and IFN-γ stimulation, Con A stimulated 
splenocytes were able to elicit statistically significant T-lymphocyte proliferations from both 
PBS and rHA1 immunised mice (P<0.05). Results were reported as spot count with standard 
deviation (S.D.). 
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Figure 3.12: Total IgG responses of immunised mice against P. pastoris expressed rHA1. 
The endpoint was determined as the dilution at which the optical density (OD) at a 
wavelength of 450 nm (OD450) was three times higher than the background level, which was 
51200. This is an aggregated data collected from five mice. The individual IgG response is 
provided in Appendix 7.  
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 Figure 3.13: ELISpot assay of IL-4 secreting T-lymphocytes from rHA1 vaccinated mice.  
Compared to the control group, splenocytes obtained from rHA1 immunised mice exhibited 
significant elevation of IL-4 secretion after being stimulated with rHA1. (* P<0.05). This is an 
aggregated data obtained from three mice in the trial. The data of each individual mouse is 
provided in Appendix 8. 
 
 
 
 
 
 
 
 
 
* 
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Figure 3.14: ELISpot assay of IFN-γ secreting T-lymphocytes from rHA1 vaccinated mice.  
rHA1 stimulated splenocytes were unable to elicit any significant elevation of IFN-γ secretion. 
However, the internal positive control validated the experiment outcome. This is an 
aggregated data obtained from three mice in the trial. The data of each individual mouse is 
provided in Appendix 8. 
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3.3.6 Virus-neutralising humoral response in rHA1 vaccinated mice 
Mice serum samples were subjected to the virus-neutralising hemagglutination inhibition (HI) 
assay. The HI assay specifically examined the virus-neutralising ability of serum antibodies 
obtained from rHA1 immunised mice. In contrast to the control group, the serum samples 
collected from rHA1 immunised mice displayed a significant level of virus-neutralising 
antibody response (P<0.05) (Figure 3.15). The HI titer of serum samples collected from rHA1 
immunised mice was determined as 7.4log2 ± 5.5log2. In contrast, serum samples collected 
from PBS control group demonstrated no virus-neutralising ability.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 3 
116 
 
 
 
 
 
Figure 3.15: Hemagglutination inhibition assay using serum samples collected from rHA1 
immunised mice.  
Compared to the control group, mice immunised with rHA1 exhibited significant 
virus-neutralising antibody responses, at a HI titer of 7.4 in logarithmic base-2 scale. (P<0.05) 
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3.4 Discussion  
In this study, the rHA1 derived from the influenza model strain PR-8 was successfully 
expressed from P. pastoris GS115 via chromosomal integration of recombinant pPICZα-A 
vector. The rHA1 was collected as a soluble secretory protein in BMMY expression medium 
after 84 hours of methanol induction, and the rHA1 was subjected to purification, analysis 
and buffer exchange for later vaccine use.  
 
In a comparison of the silver staining and immunoblotting profiles of the expressed protein 
samples in different expression medium, BMMY was the medium which gave the best 
protein expression level; whereas the MMH expression medium was not suitable for rHA1 
expression. MMH is minimal methanol medium which contains minimal nutrients without 
buffering ability, as a result the acidity was increased by accumulation of metabolic 
byproducts of P. pastoris. Hence even the protein expression was induced by the presence of 
methanol, but the high acidity of the expression medium could inhibit the protein expression 
or secretion, or even denature the recombinant protein. On the other hand, the BMMH 
contains the same levels of nutrient as MMH, but the medium was buffered at approximately 
pH 6.0, and the resulting protein expression was significantly higher than observed in MMH, 
which indicated the importance of pH buffering in recombinant-protein expression. 
Moreover, the protein expression was observed highest in the BMMY by estimating the 
protein concentration on both silver stained SDS-PAGE gel and immunoblotting with PR8 
antiserum, and Bradford assay. Therefore, BMMY was selected for further investigations. It is 
possible that the addition of yeast extract and peptone not only provide extra nutrients for 
protein expression, but also helps to stabilise secreted protein and prevent or reduce 
proteolytic activity of secreted proteins [344]. 
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The α-factor secretion signal located on the N-terminus of the rHA1 was able to direct the 
secretion of recombinant protein across the membrane, and the 6X-His tag located on the 
C-terminus of the protein was present for purification using Nickel-charged IMAC. After IMAC 
purification and buffer exchange, the rHA1 appeared to be intact and retains the HA 
antigenicity with minor protein degradation.  
 
In addition, the rHA1 expressed by P. pastoris was glycoslated via the means of 
post-translational modification. P. pastoris has the tendency to glycoslate recombinant 
glycoprotein by the addition of an average of 8-14 mannose glycol-motif per side-chain [345, 
346]. The result of deglycosylation analysis revealed that the highest deglycosylation 
efficiency was observed with 1 U of the protein deglycosylation enzyme mix for four hours 
reaction time, as the protein smear was reduced to a minimum; whereas some smearing still 
appeared right above the protein band and the most was observed in the reaction which 
underwent non-denaturing deglycosylation. The monoclonal anti-His (C-term) antibody was 
used for immunoblotting the deglycosylated rHA1 protein, and the resulting bands were 
clear and with a corresponding molecular weight of approximately 45 kDa. 
 
Glycosylation is a crucial post-translational modification in regards to expression of 
glycoproteins for recombinant vaccine purposes [347]. The correct glycosylation on synthetic 
glycoproteins enables the protein to fold and assemble into the native structure, and 
enhancement of protein stability and secretion processes was also documented [347]. Two 
forms of glycosylation have been found in P. pastoris, the O- and N-linkage carbohydrates 
moieties. In lower eukaryotes such as P. pastoris, the O-linkage glycoslation exists solely with 
mannose residues; however the function and specificities of these additional O-linkage 
mannose moieties have not yet been fully understood, whereas, the N-linked glycosylation in 
P. pastoris is found to be important in human pharmaceutical products. The N-linkage 
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glycosylation in P. pastoris involves transferring the lipid-containing oligosaccharide unit 
“Glc3Man9GlcNAc2” to the recognition protein sequence “Asn-X-Ser/Thr” [292]. In contrast 
with secretory proteins in S. cerevisiae, hyper-glycosylation is often observed as the 
oligosaccharide chain is elongated in the Golgi via the addition of mannose groups along the 
outer chain (typically 50 ~ 150 mannose-residues) [345]. These hyper-glycosylated proteins 
with extended mannose residues raise significant concerns in the application of 
pharmaceutical products, because the long mannose chains could be hyper-antigenic when 
administrated intravenously into mammals and these hyper-antigenic proteins will be 
cleared rapidly via liver [291]. Furthermore, hyper-glycosylation may hinder the antigenic 
properties or function on the protein of interest by masking important epitopes or functional 
sites. S. cerevisiae glycosylation has terminal α-1,3 linked mannose residues added to 
expressed proteins, which is known to have hyper-antigenic nature, hence making them 
unsuitable for therapeutic use [332, 348, 349]. In comparison, the N-linkage oligosaccharide 
chains expressed from P. pastoris are more similar to those from higher eukaryotes than in S. 
cerevisiae due to the absence of elongated mannose-residues and terminal α-1,3 linked 
mannose residues [345, 350, 351]. Therefore, P. pastoris is a more preferable host for the 
expression of recombinant vaccine antigens. 
 
In comparison to the native influenza HA1, Ward et al., 1981 [352] has revealed the 
composition of the N-linked oligosaccharide of influenza HA1 is strain variable. In influenza 
A/Memphis/102/72 (H3N2) and A/Aichi/2/68 (H3N2), the N-linked oligosaccharide 
compositions are “Fuc0.6Gal2.5Man5.4GlcNac4” and “Fuc0.3Gal0.6Man6GlcNac2”, respectively. 
The authors’ result indicated that the oligosaccharide “Glc3Man9GlcNAc2” expressed in P. 
pastoris has similar composition to the native influenza HA1 oligosaccharide at the terminal 
“-GlcNacx” sugar motif. However, the number of mannose-residues in P. pastoris expressed 
N-linked oligosaccharide is higher than the native HA1. The influenza HA 
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glycan-oligosaccharides have been proposed to shield antigenic sites on HA, and promote 
virus survival. However, addition of glycan-oligosaccharides can also interfere with the 
receptor binding properties of HA [353]. Therefore, a fine balance must be met regarding the 
optimal pattern of rHA1 glycosylation to induce protective immunity against the target virus.  
 
In terms of the potential of producing influenza antigens in P. pastoris, this study has 
suggested that such an expression system may be used as an alternative for a more 
cost-effective and rapid production platform for the development of influenza vaccine. The 
rHA1 produced in P. pastoris can be easily purified from the media facilitated by the presence 
of 6X-His tag under the native conditions of the protein, and it does not require a costly 
cell-lysis procedure for protein extraction. In the future, a high protein yield could be 
accomplished in a large-scale fermentation bioreactor with the help of potent inducible 
promoters. Safety wise, the recombinant protein expression in P. pastoris could be 
performed in almost serum-free media, which minimises the potential of harbouring harmful 
pathogens, hence surpassing the safety profile of conventional egg-based influenza vaccines.  
 
The immunogenic potential of P. pastoris expressed rHA1 evaluated in the mouse model 
demonstrated its ability to elicit potent humoral and Th2-biased cell-mediated immune 
responses. Serum samples collected from rHA1 immunised mice exhibited potent 
rHA1-specific IgG responses with an endpoint titer of 51200. Furthermore, the HI assay, a 
“gold-standard” procedure used to evaluate virus-neutralising antibody responses was 
carried out, and a HI titer of 7.4 log2 was obtained from serum samples collected from rHA1 
immunised mice. This indicates that the rHA1 expressed in P. pastoris was able to stimulate 
the production of HI-specific reactive serum. The elicitation of T-lymphocyte immune 
responses by rHA1 immunisation was evaluated using the ELISpot assay. The results show 
that the splenocytes obtained from rHA1 immunised mice had a significant elevation of IL-4 
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secretion after rHA1 stimulation but no significant IFN-γ secretion, implying that the elicited 
T-lymphocyte response was biased towards the CD4+ Th2 proliferation pathway [354, 355].  
 
In Figure 3.13, a large error bar was observed in the rHA1 stimulated splenocytes. As shown 
in Appendix 8, the amount of IL-4 secretion was different between mice. Such variation 
might be from a number of factors, including variation in immune responses in different mice, 
variation in seeding the isolated splenocytes for the assay, and variation of splenocytes in 
response to stimuli. However, it is not unusual to observe such immunogenic variations in 
vaccine trials.  Furthermore, it has been observed that the amount of IL-4 production in 
rHA1 stimulated splenocytes was slightly higher than what was observed in Con A stimulated 
splenocytes. It is possible that the rHA1 stimulated not only Th2 immune responses, but also 
elicited a strong B cell response. As demonstrated in the animal study, the rHA1-immunised 
mice exhibited a significant increase of IL-4 and antibody production; hence, it is possible 
that strong B cell activation was involved in the vaccines immunogenicity. Activated B cells 
upregulate MHC class II expression, proliferating more B cells and secrete IL-4 [356, 357]. 
Moller et al., 1986 [358] reported that Con A is not sufficient to induce strong B cell 
responses through its non-specific mitogenic ability. Therefore, the enhanced B cell activity 
may have played a role in the slightly higher IL-4 production compare to non-specifically 
stimulated splenocytes. 
 
Moreover, a small and unique sub-population of T-lymphocytes known as Tc2 might also 
being involved in this study. In the past, CD8+ T-lymphocytes have been considered as a 
homogenous population of cytotoxic cells expressing a limited number of cytokines, however, 
recent studies have revealed that CD8+ T-lymphocytes are similar to their CD4+ counterparts 
in diversity [359-364]. Similar to the Th1/Th2 terminology, the CD8
+ sub-populations were 
named Tc1 and Tc2. CD8
+ T-lymphocytes are differentiated in a similar manner to CD4+ 
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T-lymphocytes, in which, IL-4 and IFN-γ induce the differentiation of naïve CD8+ 
T-lymphocytes into Tc2 and Tc1, respectively, and IL-12 promotes the proliferation of Tc1 cells 
[359, 365, 366]. It has been documented that after differentiation, these effector 
T-lymphocytes show a stable cytokine production pattern, in which, Tc1 cells produce IFN-γ 
and a range of other cytokines but no IL-4; whereas, Tc2 cells produce IL-4 but no IFN-γ [340]. 
In conclusion, although Th2 activation was most likely the main immunological pathway 
leading to the experiment outcome, however, the possibility of B regulatory cells and Tc2 cells 
being involved in the Pichia-expressed rHA1 immunogenicity should not be neglected 
 
The Th2 proliferation is indicated from the production of cytokines such as IL-4 and IL-5, 
whereas, Th1 proliferation is mainly indicated from the production of IFN-γ, IL-2 and TNF-α 
[354, 355, 367]. In the instances of viral infections such as influenza, CD4+ Th1 and Th2 
proliferations are crucial in sustaining CD8+ T-lymphocyte and humoral responses, 
respectively [368, 369]. It has been known that subunit vaccines are generally less 
immunogenic and often require the help from potent adjuvant and repeated vaccinations to 
elicit long-lasting protective immune responses [41, 57, 60]. As might be expected, the 
recombinant HA1 vaccine elicited Th2 responses due to the nature of a subunit vaccine. 
Furthermore, the prevention of influenza infection mainly relies on a robust Th2 response to 
induce the production of neutralising antibodies, which was achieved as shown by the HI 
assay.  
 
Collectively, the high level production of protective antibody and secretion of IL-4 could be 
an indication of strong stimulation of B regulatory cells. B cells are the key regulators in both 
humoral and adaptive immunity. The presence of IL-4 not only induces B cell activation, but 
also upregulate MHC class II production, and decreases the activation of Th1 T-lymphocytes 
[356, 357]. Therefore, the results suggest that the Pichia-expressed rHA1 vaccine favours the 
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activation of Th2 responses, resulting in strong activation of B cells. These activated B cells 
produce protective antibodies and IL-4, leading to the upregulation of MHC class II molecule 
and inhibiting Th1 responses.  
 
Freund’s adjuvants (FA) were used in the trial to assist rHA1 immunogenicity, where the 
primary vaccination was adjuvanted with FCA, and two subsequent booster vaccinations 
were adjuvanted with FIA. The primary vaccination used FCA to stimulate priming immunity, 
and the subsequent FIA-prepared vaccinations were aimed to boost and maintain a lasting 
immunity. 
 
FA has been documented to enhance vaccine immunogenicity including rapid uptake of the 
FA component by dendritic cells, improve phagocytosis, stimulate cytokine production by 
mononuclear phagocytes, and transient proliferation of CD4+ T-lymphocyte responses [370]. 
FCA contains mycobacterial components which primarily induces CD4+ Th1 response, hence 
the proliferation of CD8+ cell-mediated immune response [371]. FIA on the other hand, 
contains no PAMP stimuli such as mycobacterial components, hence primarily proliferates 
CD4+ Th2 responses, and the overall immune responses are more restricted to humoral 
immunity and the secretion of IL-4 and IL-5 [370, 372].  
 
According to some model studies, the microbial constitutes such as mycobacterial 
components used in FCA are responsible for the recognition as “non-self” or “danger” via 
PAMP receptors, resulting in the activation of professional APCs. The activated APCs are 
promoted to acquire co-stimulatory properties, the “antigen”, and lead to the release of 
mediators that biases Th1-type immune responses [372-374]. Nevertheless, under certain 
conditions, immunisation with FIA could result in the reduction of cell-mediated immune 
responses. This phenomenon is characterised as the suppression of Th1 cell-mediated 
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response by the regulatory function of proliferated Th2 cells [375-377]. The original 
interpretation of this phenomenon was a form of immune tolerance. However, further 
investigations suggested that the failure to stimulate APCs by FIA resulted in a Th2-directed 
skewing of the immune response, which favors the development of a strong Th2-type 
response [370, 372, 373]. 
 
A similar study conducted by Saelens et al., 1999 [235] has examined the immune responses 
in mice after being vaccinated with the recombinant HA protein of A/Victoria/3/75 (H3N2 
subtype) expressed in P. pastoris. Saelens and colleagues expressed HA as soluble secreted 
molecule in induced culture medium, and the HA protein was purified under native condition 
by means of an FPLC apparatus equipped with an LCC-501 plus controller and an UV-MII 
optical unit. Immunised mice exhibited a significant elevation of virus-specific IgG response 
and complete survival rate in a 10 LD50 challenge using homologous viral strain.  
 
Murugan et al., 2013 [378] reported that the HA protein derived from highly pathogenic 
(A/Hatay/2004/H5N1) was expressed in the membrane of Pichia. The HA protein was 
purified under denaturing condition and then refolded prior administered in mice, and 
HA-specific immune responses were observed in both HI and ELISA assays.  
 
This investigation has demonstrated the immunogenic potential of P. pastoris expressed 
H1N1 rHA1 for vaccine purposes. The successful IMAC purification under native conditions 
implied a potential platform for rapid and cost-effective production of vaccine antigen with 
minimum downstream processes. Furthermore, the antigenicity and immunogenicity of the 
rHA1 were not compromised due to the purification procedures as the purified rHA1 was 
able to elicit potent virus-specific antibody and significant T-lymphocyte responses. 
Therefore, this system may act as an attractive and effective platform for the production of 
CHAPTER 3 
125 
 
recombinant HA for the prevention of influenza infections.  
 
A further investigation was carried out by the collaborating institute - Institute of 
Biotechnology (IBT), Vietnam Academy of Science and Technology. Their study has 
successfully expressed rHA1 of (A/Hatay/2004/H5N1) as soluble secreted protein, and the 
rHA1 was purified and the immunogenicity of this protein was evaluated in chickens 
(personal communication).  
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4.1 Introduction  
As previously described and demonstrated, immunisation with rHA1 is capable of eliciting 
potent virus-specific humoral and CD4+ Th2 cell-mediated immune responses. However, such 
recombinant vaccine systems require parenteral injection, and the high costs associated with 
vaccine administration has lead to sub-optimal coverage in the poultry industry [260].  
 
A promising alternative has been discerned from successful demonstrations of in vivo 
expression of an influenza vaccine antigen delivered by live-attenuated Salmonella vaccine 
carriers [311, 312]. Salmonella vaccine carriers can be delivered simply via oral delivery 
through drinking water or aerosol spray. The vaccine is easily produced and able to elicit both 
humoral immunity, including serum and secretory IgA antibody, and strong cell-mediated 
immune responses that include cytotoxic and memory T-lymphocytes. Furthermore, 
recombinant Salmonella not only elicits immune responses against the heterologous antigen 
upon vaccination, but also to the Salmonella homologous antigens, providing protective 
immunity against both Salmonella and the heterologous pathogen [98, 379, 380].  
 
In this study, Salmonella Typhimurium strain STM1 (developed at RMIT), harbouring a 
mutation in the aroA gene region that renders it attenuated, is used as a delivery vector for 
PR-8 HA1. Different strategies were used to present the antigen from various destinations to 
optimise immunogenicity. These include one to display the HA1 antigen on the outer 
membrane of Salmonella (utilising plasmid pHES, encoding the N-terminal signal peptide and 
the essential C-terminal translocation unit of the ShdA autotransporter derived from S. 
Typhimurium strain LT-2 [5]), and another to secrete it into the media (pMOhly1, encoding 
the necessary components of the E. coli α-haemolysin secretion system [6]). 
 
Autotransporters (ATs) are among the largest group of proteins secreted by some pathogenic 
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Gram-negative bacteria, and consist of an N-terminal signal peptide (SP) followed by a 
passenger domain, which typically harbours bacterial virulence genes/factors such as 
cytotoxins, adhesins and proteases [381]. The C-terminal region of ATs fold into a β-barrel 
that forms a hydrophilic pore and anchors to the outer membrane, which is responsible for 
the translocation of the passenger domain into the extracellular space [5] (Figure 4.1). The AT 
vector used in this study, pHES (Figure 4.2), encodes a modified ShdA gene derived from S. 
Typhimurium. The ShdA is a large outer membrane protein which belongs to the AT family, 
and has the usual AT β-barrel anchorage domain, and a SP-coupled passenger domain (Figure 
4.3). The function of Salmonella ShdA passenger domain is known to be responsible for the 
attachments to extracellular matrix proteins (i.e. Fibronectin and collagen I) [382, 383].  
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Figure 4.1: Schematic representation of a native autotransporter. 
The native autotransporter consists the signal peptide, passenger domain, and C-terminal 
domain consisting of an α-helix and β-barrel which anchors to the bacterial outer membrane 
(Image adapted from [5]). 
 
 
 
 
Figure 4.2: Map of pHES plasmid.  
The ShdA ORF consists of the signal peptide (SP), the passenger domain, followed by the 
C-terminal anchoring domain α-helix and β-barrel.  
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Figure 4.3: Tertiary-structure prediction of the ShdA C-terminal domain.  
The α-helix is represented in red, and the transmembrane amphipathic β-barrel is 
represented in yellow (Image adapted from [5]). 
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Another expression vector used in this study was the pMOhly1 (Figure 4.4), which encodes 
the necessary components of the E. coli α-haemolysin secretion system. This vector encodes 
the E. coli α-haemolysin hly operon which consists of four genes, hlyA’, hlyB, hlyC, hlyD, 
responsible for transporting proteins directly out of the cell [384]. The pMOhly1 vector has 
the full sequence of the structural genes hlyC, hlyB and hlyD and a truncated version of the 
hlyA gene, hlyA’ (Figure 4.5). The full hlyA gene is not required for secretion, as only the 
N-terminus 34 amino acids and the C-terminus 61 amino acids are the regions that are 
directly transported through the cytoplasm to the extracellular space [322]. pMOhly1 does 
not require induction for protein expression as it is a constitutive expression vector [322].  
 
Upon protein expression, the first 34 N-terminal amino acids of hlyA’ are responsible for 
assisting the activation of haemolysin system, and the last 61 C-terminal amino acids encode 
the secretion signal of hlyA’ that is responsible for transmembrane exportation of the protein 
[322]. HlyC assists in the synthesis of the constructs and is an acetylase required for 
post-translational activation of the haemolysin system. Furthermore, the hlyB gene is a 
translocase protein that is located at the C-terminus of the construct and works in 
conjunction with the hlyD protein. HlyD is a transmembrane protein which interacts directly 
with outer membrane (OM) proteins and TLRs, as well as hlyB translocase, to form a 
haemolysin complex which conduits through the cytosol to the extracellular space [384-386] 
(Figure 4.6). 
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Figure 4.4: Map of pMOhly1 plasmid.  
 
 
 
 
 
 
Figure 4.5: The pMOhly1 hly operon 
 
 
 
hlyC    hlyA’            hlyB             hlyD 
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Figure 4.6: Illustration of the formation of E. coli α-haemolysin complex.  
The hlyD interacts with hlyB and Tol-C (TLR) to form a transmembrane complex and allows 
the recombinant hlyA construct to be exported through cytosol to the extracellular space 
(image adapted from [387]). 
 
 
 
Extracellular 
space  
Intracellular 
space  
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The problem of toxicity of over-expressed recombinant protein or the formation of inclusion 
bodies may be overcame by the use of the plasmid vectors described above. Cytoplasmic 
accumulation of recombinant protein often results in inactive and insoluble products [388]. 
The signal peptide encoded in pHES plasmid prevents cytoplasmic accumulation of the fusion 
rHA1 in STM1 by translocating the protein through the periplamic space to bacterial outer 
membrane. pMOhly1 plasmid encodes the necessary components of the E. coli α-haemolysin 
secretion system, which secrete the fusion rHA1 out of the cell.  
 
The aim of work described this chapter was as follows: 
- To obtain the HA1 DNA sequence from viable PR-8 virus using RNA extraction, reverse 
transcription and PCR amplification.  
- To clone the amplified HA1 DNA sequence into pHES and pMOhly1 plasmids, and 
transform these plasmid constructs into Salmonella STM1. 
- To optimise the rHA1 protein expression from these vaccine constructs.  
- To evaluate and characterise the ability of pHES surface-display and pMOhly1 
extracellular secretion. 
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4.2 Materials and methods 
4.2.1 Overview 
The PR-8 virus HA1 gene used in this study was directly obtained from viable PR-8 virus. The 
PR-8 virus was cultivated in a mammalian cell-line, and the DNA sequence encoding the HA1 
gene was firstly obtained by total RNA isolation, followed by reverse transcription into cDNA. 
The gene of interest was then amplified by PCR, using designated primer pairs listed in Table 
2.6.  
 
For the construction of HA1 fused pHES vector (pHES/HA1), the PR-8 HA1 gene was inserted 
in the passenger domain of the encoded ShdA sequence, and the construct was transferred 
into Salmonella STM1 for surface display of the antigen (Figure 4.7). In addition, the pHES 
vector consists a 6x-His tag located close to the SP of the passenger domain and a lacIq-Plac 
promoter. This promoter not only has the normal function of IPTG inducible protein 
expression, but the expression also can be inhibited via the presence of glucose.  
 
For the construction of HA1 fused pMOhly1 vector (pMOhly/HA1), the amplified PR-8 HA1 
gene was inserted in the middle of the truncated hlyA’ gene sequence (Figure 4.8). The signal 
peptide encoded in the hlyA’ directs the fusion rHA1 out of the cell through E. coli 
α-haemolysin complex (as shown in Figure 4.6) 
 
 
 
 
 
 
 
CHAPTER 4 
136 
 
 
 
 
 
 
 
 
Figure 4.7: Development of pHES/HA1 plasmid construct. 
A) Schematic representation of the ShdA operon encoded in pHES plasmid with the inserted 
influenza HA1 (Image modified from [5]). B) Map of the complete pHES/HA1 construct. The 
HA1 gene was inserted in the passenger domain (PD) for surface display. 
 
PD  Influenza HA1 insert    PDs A) 
B) 
HA1 insert    
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Figure 4.8: Development of pMOhly1/HA1 plasmid construct. 
A) Schematic representation of the hly operon encoded in pMOhly1 plasmid with the 
inserted influenza HA1. B) Map of the complete pMOhly1/HA1 construct. 
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4.2.2 Preparation of HA1 gene from PR-8 virus  
4.2.2.1 Virus cultivation and purification  
MDCK cell monolayers were prepared as described in Section 2.8, and the method for PR-8 
virus propagation and purification is described in Section 2.9.  
 
4.2.2.2 RNA extraction and cDNA synthesis   
Purified PR-8 virus was subjected to RNA extraction and cDNA synthesis as described in 
Section 2.4. 
 
4.2.2.3 PCR amplification using cDNA template   
The primer pairs used for these amplifications are listed in Table 2.6. For the amplification of 
pMOhly1 insert, the primer pairs were pMOhly1_SbfI_For and pMOhly1_SbfI_Rev. For the 
pHES insert, the pairs were pHES_EcoRI_For and pHES_PvuI_Rev.  
 
The general PCR procedure is described in Section 2.6.2.2. However, optimisation of the PCR 
reactions was required. Briefly, the cDNA concentration was estimated using a Microplate 
luminometer (BMG LABTECH GmBH, Germany), and the PCR reactions were performed using 
different amount of cDNA template (between 10-100 ng), for each primer pair. Furthermore, 
the annealing temperatures for these reactions were lowered to 480C for both primer pairs.  
 
4.2.2.4 TA cloning strategy   
Having successfully amplified both HA1 DNA inserts, the PCR products were cloned directly 
into the TA cloning vector pCR2.1 according to the manufacturer’s instructions (Invitrogen, 
USA). The ligation products were cleaned using the QIAquick gel extraction kit (Section 2.5.2). 
The purified ligation products were used for electroporation (Section 2.6.5), into 
electrocompetent E. coli DH5α (Section 2.6.4). 
CHAPTER 4 
139 
 
Following transformation, the cells were cultured on LB agar (containing 40 μg/mL X-Gal, 1 
mM IPTG and 100 μg/mL Ampicillin), for Blue/White screening. These putative clones were 
then grown in LB broth containing 100 μg/mL Ampicillin. Clones were screened by restriction 
enzyme digestion. Positive clones were grown overnight and stored at -800C until use.  
 
4.2.3 Sub-cloning 
4.2.3.1 Background development of constructs 
The primer pairs used for cloning in this study (Table 2.6) were designed based on the HA 
gene sequence of influenza PR-8 virus obtained from GenBank (access number: EF467821).  
 
For the construction of pHES/HA1, the HA1 gene sequence was designed to be inserted into 
the multiple cloning site of the pHES vector immediately downstream of the 6x-His tag 
sequence. The forward and reverse primers for pHES/HA1 cloning were incorporated with 
EcoRI and PvuI (New England Biolabs, USA), enzyme sites respectively, and a T nucleotide 
was placed immediate upstream of the PvuI enzyme site for in-frame protein expression. 
These restriction sites were used as they did not appear within the PR-8 HA1 gene.  
 
For the construction of pMOhly1/HA1, the presence of an NsiI site in the PR-8 HA1 sequence 
precluded its use in the primers designed for cloning into pMOhly1. The SbfI enzyme site was 
not present in the PR-8 HA1 sequence, and the recognition sites of NsiI (ATGCA↓T) and SbfI 
(GG↑ACGTCC) have complementary overhangs of ACGT for ligation, therefore the pMOhly1 
forward and reverse primers were incorporated with SbfI sites for subsequent cloning. A 
sequence of “GTGATGGTGATGGTGATG” encoding 6x-His was placed immediately upstream of 
the reverse primer SbfI site for the incorporation of a 6x-His tag into the pMOhly1/HA1 
protein. Additional CT nucleotide bases were placed in front of the 6x-His sequence for 
in-frame expression of the 6x-His tag.  
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4.2.3.2 Preparation of pHES and pMOhly1 vectors 
For pMOhly1-bearing E. coli, the cells were grown overnight in LB broth containing 100 
μg/mL Ampicillin, whilst pHES-bearing E. coli was grown overnight in LB broth containing 40 
μg/mL Chloramphenicol and 2% (w/v) glucose. Following incubation, pHES and pMOhly1 
plasmids were isolated from overnight cultures using the QIAprep® spin miniprep kit 
(described in Section 2.5.1).  
 
The pHES vector was digested with PvuI and EcoRI for four hours in a 370C water bath; 
whereas the pMOhly1 vector was digested with NsiI for two hours under the same 
conditions.  
 
Following digestion, the digested vectors were run on a 0.5% agarose gel and the appropriate 
fragments were excised from the gel and purified using the QIAquick gel extraction kit (as 
described in Section 2.5.2). The purified DNA fragments were used immediately for ligation. 
 
4.2.3.3 Sub-cloning HA1 insert into pHES vector 
The pCR2.1 clone harbouring HA1 insert for pHES/HA1 was grown and the plasmid isolated 
via QIAprep® spin miniprep kit. The PCR fragment was then digested from pCR2.1 using EcoRI 
and PvuI, and run on a 0.5% agarose gel. The appropriate fragment was excised from the gel 
and purified using the QIAquick gel extraction kit. The fragment was then directly ligated into 
the previously digested pHES vector (Section 4.2.3.2). Following ligation, the ligation product 
was purified (as described in Section 2.5.2), and 4 μL of ligation product was used for 
electroporation into electrocompetent E. coli DH5-α. The cells were then grown on LB agar 
(containing 40 μg/mL chloramphenicol and 2% (w/v) glucose), and incubated for 16 hours at 
37°C. Putative clones were sub-cultured onto fresh LB agar for screening. 
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4.2.3.4 Sub-cloning HA1 insert into pMOhly1 vector 
Similar to procedures used in Section 4.2.3.3. The restriction enzyme was replaced with SbfI, 
and cells grown on LB agar (containing 100 μg/mL Ampicillin).  
 
4.2.4 Screening of clones 
The putative clones were grown in LB broth (containing appropriate supplements), overnight 
at 370C with 200 rpm shaking, and plasmid were isolated using the QIAprep® spin miniprep 
kit. 
 
For pHES clones, the clone was confirmed using restriction enzyme digestion (EcoRI and PvuI), 
and PCR amplification using combinations of primers listed in Table 4.1. The annealing 
temperature was set to 480C, and the remaining parameters were as described in Section 
2.6.2.2.  
 
Screening for pMOhly1 clones was solely based on PCR amplification, as the NsiI and SbfI 
enzyme sites are not recleavable following ligation. Colony PCR amplification (Section 2.6.2.3) 
using the following combinations of primers (Table 4.2) was used for the confirmation of HA1 
insertion and appropriate orientation.  
 
 
 
 
 
 
 
 
CHAPTER 4 
142 
 
 
Table 4.1: Screening PCR primer combinations for pHES/HA1 clone.  
Primer combination   Expected fragment sizes 
being amplified (bp) 
SEQF_pHES + SEQR_pHES  1620 
SEQF_pHES + SEQR_PR8HA1  867 
SEQR_pHES + SEQF_PR8HA1  589 
 
 
 
Table 4.2: Screening PCR primer combinations for pMOhly1/HA1 clone, and for confirmation 
of insert orientation.  
Primer combination   Expected fragment sizes being 
amplified (bp) 
Correct insert orientation   
SEQF_pMOhly1 + SEQR_pMOhly1  1618 
SEQF_pMOhly1 + SEQR_PR8HA1  903 
SEQR_pMOhly1 + SEQF_PR8HA1  551 
Incorrect insert orientation   
SEQF_pMOhly1 + SEQR_pMOhly1  1618 
SEQF_pMOhly1 + SEQR_PR8HA1  No product  
SEQR_pMOhly1 + SEQF_PR8HA1  No product  
 
 
 
 
CHAPTER 4 
143 
 
4.2.5 DNA sequence analysis for confirmation of clones 
The putative clones selected as previously described were subjected to DNA sequence 
analysis (Section 2.6.6). The construct plasmids were isolated using QIAprep® spin miniprep 
kit, and the DNA concentration was estimated using Microplate luminometer (BMG LABTECH 
GmBH, Germany). Each isolated plasmid was prepared with four primers (as listed in Table 
2.6), and the individual DNA sequences were amplified and analysed.  
 
4.2.6 Passage of plasmids 
Having successfully cloned PR-8 HA1 into each expression vector, and confirmed by sequence 
analysis, the plasmid constructs were isolated from E. coli DH5-α using the QIAprep® spin 
miniprep kit. Electrotransformation (Section 2.6.5) was used to transform the plasmid into 
the intermediate vector strain, S. Typhimurium LT2-9121. The plasmid constructs were then 
isolated a second time using the same method described above from the S. Typhimurium 
LT2-9121 and electrotransformation  was used again to incorporate these passaged 
plasmids into the S. Typhimurium STM1 vaccine strain. The STM1 harbouring pHES/HA1 and 
pMOhly1/HA1 will be referred as pHES/HA1/STM1 and pMOhly1/HA1/STM1 hereafter. 
Negative control clones were also generated by passage of blank pHES and pMOhly1 vectors 
into STM1, which will be referred as pHES/STM1 and pMOhly1/STM1, respectively.  
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4.3 Materials and methods for protein expression, and 
characterisation 
4.3.1 pHES/HA1/STM1 protein expression 
4.3.1.1 Pilot expression of rHA1 protein   
The pHES/HA1/STM1 clone was grown in 10 mL LB broth containing 40 μg/mL 
chloramphenicol and 2% (w/v) glucose overnight at 300C with 100 rpm orbital shaking. The 
next day, overnight cultures were diluted to a final optical density at 600 nm (OD600nm) of 0.5 
in fresh LB broth containing 0.5 mM IPTG and 40 μg/mL chloramphenicol, in a total volume 
of 200 mL, and the culture was incubated for five hours at 370C with 200 rpm orbital shaking. 
Ten milliliter samples were collect prior to induction with IPTG and every hour thereafter. 
Samples were washed twice with ice-cold 10 mM Tris-HCl pH 8.0, and resuspended using the 
same buffer (supplemented with Protease Inhibitor Cocktail (Cell Signalling Technology, USA)), 
followed by cell lysis using sonication (Section 2.7.1). Protein concentration of the 
supernatant was measured using the Bradford assay (Section 2.7.2), and up to 30 μL of lysed 
cell supernatant was analysed using SDS-PAGE and immunoblotting (Section 2.7.3 and 
Section 2.7.4). 
 
4.3.1.2 Optimisation of rHA1 expression  
Based on the same parameters used in Section 4.3.1.1, different IPTG concentrations (0.1 
mM, 0.5 mM and 1.0 mM), were used in the expression media for optimising protein 
expression levels. Different expression media were also used for optimising protein 
expression levels, such as BHI, LB, MH, and NB (as listed in Section 2.2.5.1). An additional 
step was included to ensure the promoter-inhibitory agent – glucose was removed from the 
expression media, in which, the overnight grown pHES/HA1/STM1 was washed three times 
with sterile PBS prior to inoculation into expression media. Different temperature conditions 
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were used to optimise the rHA1 protein yield; including 300C for overnight expression and 
340C for 10 hours expression. Samples were collected, processed and analysed as described 
in Section 4.3.1.1. 
 
4.3.1.3 Cell membrane fractionation 
Having optimised the protein expression conditions, the rHA1 protein was analysed using cell 
fractionation, protocol adapted from [5]. A sample of the expressed culture was harvested at 
the time-point where the highest rHA1 protein concentration was observed. The 
pHES/HA1/STM1 cells were washed twice with 10 mM Tris-HCl pH 8.0, and resuspended in 
the same buffer supplemented with Protease Inhibitor Cocktail (PIC), and then sonicated as 
described in Section 2.7.1. Following sonication, the supernatant was passed through a 0.2 
μm filter, and 8 mL of protein extract was subjected to centrifugation at 100,000 x g for one 
hour at 40C. After ultracentrifugation, the supernatant was collected and stored at -200C, and 
the pellet was resuspended in 10 mM Tris-HCl pH 8.0 with supplements of PIC and 5% (v/v) 
Triton X-100 (Sigma-Aldrich). The sample was incubated on ice for 30 minutes and 
centrifuged again at 100,000 x g for one hour at 40C. The supernatant was collected and 
stored at -200C, and the pellet was resuspended in 10 mM Tris-HCl pH 8.0 with supplements 
of PIC and 4 M Urea (Sigma-Aldrich, USA). The sample was subjected to another cycle of ice 
incubation and ultracentrifugation, and the supernatant was collect and stored at -200C. The 
remaining pellet was resuspended in 10 mM Tris-HCl pH 8.0 with PIC and stored at -200C. The 
protein concentrations of the collected protein fractions were measured using the Bradford 
assay, and 30 μg of fraction samples were evaluated using SDS-PAGE and immunoblotting.  
 
4.3.1.4 SDS-PAGE and immunoblotting 
For pilot and optimisation studies of pHES/HA1/STM1 protein expression, the SDS-PAGE was 
stained using EzStain AQUA (ATTO, Co., USA) as per the manufacturer’s instructions.  
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As for immunoblotting (Section 2.7.4), the membranes were probed with either primary 
6x-His antibody or PR-8 antiserum, and coupled with conjugate secondary antibodies, 
anti-mouse IgG AP and anti-rabbit IgG AP, respectively (Section 2.2.5.4). To develop 
AP-conjugated antibodies, BCIP/NBT solution (Sigma-Aldrich, USA) was added for incubation 
with gentle agitation. The reaction was stopped by washing with dH2O. 
 
4.3.2 pMOhly1/HA1/STM1 protein expression 
4.3.2.1 Expression of extracellular rHA1 from pMOhly1/HA1/STM1 
pMOhly1/HA1/STM1 was cultured in 10 mL of BHI supplemented with 100 μg/mL ampicillin 
for 18 hours at 370C with 150 rpm orbital shaking. Following incubation, the culture was 
centrifuged at 5,450 x g for 10 minutes at 40C, and the supernatant was collected and passed 
through a 0.45 μm filter. The supernatant was then subjected to Nickel-charged IMAC 
purification. 
 
4.3.2.2 IMAC purification for detection of extracellular fusion rHA1 
The same protocol was used as described in Section 3.2.3. Briefly, 10 mL of supernatant 
prepared from overnight culture was added to 3 mL of chelating Sepharose fast flow® resin, 
which was previously charged with Nickel ions and equilibrated with Native Binding Buffer. 
The column was incubated for one hour at 40C on a roller mixer (Ratek, Australia). The 
column was placed upright, and the sample allowed flow through. Fifteen CV of Native Wash 
Buffer was loaded, followed by the addition of 5 CV of Native Elution Buffer. The elution 
fractions were collected in 1 mL aliquots and stored at -200C until analysis.   
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4.3.2.3 SDS-PAGE and Immunoblotting 
The elution fractions collected from IMAC purification were examined using silver stained 
SDS-PAGE (described in Section 2.7.3.2) and Immunoblotting with PR-8 antiserum (described 
in Section 2.7.4).  
 
4.4 Results 
4.4.1 Tissue culture, virus propagation and gene amplification 
Healthy MDCK cells were cultivated and successfully maintained as an adherent cell-line. 
Upon introduction of PR-8 virus, the cytopathic effect of cell death could be observed 
between two to four days post-infection (Figure 4.9). 
 
4.4.2 Virus purification and HA titre 
PR-8 virus was successfully extracted and purified, and an HA test (Section 3.2.9.3.1) was 
carried out to determine the HA titre of the purified samples. The results indicated an 
average between 400-800 HA units can be obtained from the procedure described in Section 
2.9, using two flasks (75 cm2) of 100% confluent MCDK monolayer, which was infected with 
1:1000 diluted virus stock (originally 400 HA units), and harvested when more than 50% of 
MDCK cells detached from the bottom of the flask.  
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Figure 4.9: Photographic images of healthy and PR-8 virus infected MDCK cells under 40X 
magnification.  
A) healthy MDCK cell-line about 50% confluency; B) 4 days post-infection of a 100% 
confluent monolayer; C) negative control flask of image B), where no virus was introduced, 
but media replaced with virus propagation media (Section 2.9.2).  
A) 
B) 
C) 
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4.4.3 RNA extraction and cDNA synthesis  
Two hundred microlitres of freshly purified PR-8 virus was subjected to RNA extraction using 
TRIzol® LB reagent (Section 2.4.1). The resulting RNA pellet was resuspended in 20 μL of 
chilled DNase/RNase-free water, and immediately used for cDNA synthesis. The 
concentration of extracted viral RNA was estimated using a spectrophotometer at 260 nm, 
and the results indicated the sample contained approximately 3.0 μg/μL of RNA. An 
equivalent to 6 μg of extracted RNA molecule was used as a template for cDNA synthesis, 
and approximately 1.5 μg/μL cDNA was generated from the reaction. A 1% agarose gel was 
prepared to visualise the RNA and cDNA samples (Figure 4.10).  
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Figure 4.10: RNA extraction and cDNA synthesis.  
Lane M: PstI/λ-DNA marker, Lane 1: extracted PR-8 RNA (3.0 μg), Lane 3: complementary 
cDNA reverse transcribed from PR-8 RNA extract (3.0 μg). No clear bands were observed. 
These smearings are considered normal for separating RNA or single-strand DNA molecules 
on standard gel electrophoresis.  
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4.4.4 Amplification of the influenza HA1 gene  
The initial PCR amplification of the HA1 gene used 0.5 μg, 1.0 μg and 5.0 μg of cDNA 
molecules as a template, and annealing temperature at 550C did not result in any PCR 
products (data not shown). The PCR annealing temperature was lowered to 500C and a DNA 
fragment at the expected size of 0.98 kbp was amplified using pHES_EcoRI_For and 
pHES_PvuI_Rev primer pair with 1.0 μg of cDNA template, but no DNA product was amplified 
using pMOhly1_SbfI_For and pMOhly1_SbfI_Rev primer pair (Figure 4.11).  
 
The PCR reaction was repeated again using a 480C annealing temperature, resulting in DNA 
fragments at the expected size of 0.98 kbp using pHES_EcoRI_For and pHES_PvuI_Rev primer 
pair with 0.5 μg, 1.0 μg and 5.0 μg of cDNA molecules as template. On the other hand, PCR 
reactions with pMOhly1_SbfI_For and pMOhly1_SbfI_Rev primer pair only resulted in one 
expected DNA fragment at the expected size of 0.98 kbp in the reaction which was supplied 
with 1.0 μg of cDNA template (Figure 4.12).  
 
The freshly amplified HA1 gene was immediately subjected to TA cloning.  
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Figure 4.11: PCR amplification of influenza HA1 gene at annealing temperature of 500C. 
Lane M: PstI/λ-DNA marker, Lane 1, 2 and 3: PCR reactions using pHES primer pair with 0.5 
μg, 1.0 μg and 5.0 μg of cDNA template, respectively. Lane 4, 5, and 6: PCR reactions using 
pMOhly1 primer pair with 0.5 μg, 1.0 μg and 5.0 μg of cDNA template, respectively. The PCR 
reactions used 550C as annealing temperature did not result in any PCR product; whereas, by 
lowering down the annealing temperature to 500C, an expected DNA fragment of 
approximately 0.98 kbp was amplified in the reaction with pHES primer pair with 1.0 μg 
cDNA template.  
 
0.98 kbp 
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Figure 4.12: PCR amplification of influenza HA1 gene at annealing temperature of 480C. 
Lane M: PstI/λ-DNA marker, Lane 1: 1.0 μg of freshly synthesised influenza cDNA, Land 2, 3 
and 4: PCR reactions using pHES primer pair with 0.5 μg, 1.0 μg and 5.0 μg of cDNA template, 
respectively. Lane 5, 6, and 7: PCR reactions using pMOhly1 primer pair with 0.5 μg, 1.0 μg 
and 5.0 μg of cDNA template, respectively. All three reactions using pHES primer pair 
generated expected DNA fragments at a size of approximately 0.98 kbp, and similar fragment 
was amplified in the reaction supplied with pMOhly1 primer pair and 1.0 μg of cDNA 
template. 
 
0.98 kbp 
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4.4.5 TA cloning strategy 
Both pHES and pMOhly1 inserts were ligated into the pCR2.1 vector, and transformed into 
electrocompetent E. coli DH5-α cells via electroporation, and then inoculated onto agar 
containing X-gal for Blue/White screening (described in Section 4.2.2.4).  
 
Following overnight incubation at 370C, three white colonies were collected from each pHES 
and pMOhly1 insert group for screening. For suspected clones harbouring pHES insert, the 
plasmids were digested with EcoRI and PvuI; whereas, for suspected clones harbouring 
pMOhly1 insert, the plasmid were digested with SbfI alone. The digested plasmids were run 
on a 1% agarose gel for examination (Figure 4.13).  
 
The result indicated that pHES insert was successfully ligated into clone No. 1 and No. 3 from 
the pHES group, and pMOhly1 insert was successfully ligated into clone No. 3 of the 
pMOhly1 group. Clone No. 1 of the pHES group and clone No. 3 of the pMOhly1 group were 
chosen for subsequent use. 
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Figure 4.13: Screening for pCR2.1 vectors harbouring pHES or pMOhly1 insert. 
Lane M: PstI/λ-DNA marker, Lane 1: digested pHES insert, Lane 2, 3 and 4: enzymatic 
digested pCR2.1 clones harbouring pHES insert, Lane 5: digested pMOhly1 insert, Lane 6, 7 
and 8: enzymatic digested pCR2.1 clones harbouring pMOhly1 insert. Partial digestion was 
evident in Lanes 6, 7 and 8. pHES clone from Lane 2 and pMOhly1 clone from Lane 8 were 
chosen for subsequent use.  
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4.4.6 Cloning and construction of pHES/HA1 and pMOhly1/HA1 in  
E. coli DH5-α 
The inserts were digested from pCR2.1 using the corresponding restriction enzymes (pHES 
insert: PvuI/EcoRI, pMOhly1 insert: SbfI). The pHES insert was excised from an agarose gel 
and ligated into the PvuI/EcoRI digested pHES vector using T4 DNA ligase. The pMOhly1 
insert was extracted and ligated into the NsiI digested pMOhly1 vector using the same ligase. 
The resulting plasmids were named pHES/HA1 and pMOhly1/HA1, respectively. Resulting 
clones were screened for successful insertion of the influenza HA1 gene, and directionality of 
the insert for pMOhly1/HA1. 
 
4.4.6.1 Screening and confirmation for pHES/HA1 clone 
Plasmids were extracted from suspected pHES clones, and digested using PvuI and EcoRI for 
screening (Figure 4.14). The result indicated the ligation frequency was quite low and many 
of the colonies screened contained the empty vector only. One clone (No. 36), was shown to 
have a digested DNA fragment of an expected size of 0.98 kbp matching to the size of 
digested pHES insert, but the fragment matching to digested pHES vector was very faint, 
hence the clone was cultured and plasmid extracted for re-examination. The digested pHES 
clone produced two DNA fragments at the expected sizes of 4.5 and 0.98 kbp matching the 
sizes of digested pHES vector and insert, respectively (Figure 4.15).  
 
A PCR reaction using an annealing temperature of 480C coupled with three combinations of 
primers (listed in Table 4.1), was used to confirm the clone. Three strong bands at the 
expected sizes of 1.620, 0.867 and 0.589 kbp (Figure 4.16), were observed, which indicated 
the successful insertion of pHES insert into the vector.  
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Figure 4.14: Screening for pHES/HA1 clones.  
Lane M: PstI/λ-DNA marker, Lane 1: digested pHES vector, Lane 2: digested pHES insert, Lane 
3 to 18: clones subjected to screening. Clone No. 36 (Lane 15) appeared to have the 
expected DNA fragments, hence it was subjected to confirmation.  
 
 
 
 
 
 
 
 
0.98 kbp 
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Figure 4.15: Confirmation of pHES/HA1 clone. 
Enzymatic digestion of pHES/HA1 using EcoRI and PvuI. Lane M: PstI/λ-DNA marker, Lane 1: 
digested pHES vector, Lane 2: digested pHES insert, Lane 3: digested pHES construct. 
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Figure 4.16: PCR confirmation of pHES/HA1 construct using three combinations of primers 
(refer to Table 4.1 for each reaction). 
Lane M: PstI/λ-DNA marker, Lane 1: primer combination (SEQF_pHES + SEQR_pHES), Lane 2: 
primer combination (SEQF_pHES + SEQR_PR8HA1), Lane 3: primer combination (SEQR_pHES 
+ SEQF_PR8HA1). The PCR reactions confirmed the successful ligation of influenza HA1 gene 
into pHES vector in the correct orientation.  
 
 
 
 
 
 
1.62 kbp 
0.87 kbp 
0.58 kbp 
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4.4.6.2 Screening and confirmation for pMOhly1/HA1 clone 
Colony PCR using an annealing temperature of 480C, and coupled with SEQF_pMOhly1 + 
SEQR_pMOhly1 primer pair (listed in Table 4.2), was used for screening pMOhly1 clones. The 
ligation frequency was relatively low compared to the construction of pHES clone, as 
hundreds of colonies contained only the empty pMOhly1 vector. Two pMOhly1 clones (clone 
No. 290 and No. 495), were shown to have PCR product at the expected size of 
approximately 1.62 kbp (Figure 4.17). The putative clones were screened for directionality 
using the primer combinations listed in Table 4.2. For Clone No. 290, three products at the 
expected sizes of 1.62, 0.90 and 0.55 kbp were amplified, which indicated the successful 
ligation of influenza HA1 gene into pMOhly1 hlyA in the correct orientation (Figure 4.18). The 
PCR results of Clone No. 495 indicated that influenza HA1 gene was ligated into pMOhly1 
vector in the incorrect orientation.  
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Figure 4.17: PCR screening for putative pMOhly1/HA1 clones using primer combination 
SEQF_pMOhly1 + SEQR_pMOhly1. 
Lane M: PstI/λ-DNA marker, Lane 1 to 9: putative pMOhly1/HA1 clones. The PCR result 
shows a strong band at an expected size of 1.62 kbp from Clone No. 290 (lane 9). This PCR 
product indicted an extra 0.98 kbp was inserted in the middle of pMOhly1 hlyA Open 
Reading Frame, which suggested the successful insertion of the influenza HA1 gene. Other 
putative clones have only shown the amplification of the hlyA gene alone, or no PCR product 
at all. Clone No. 290 was then screened using the combinations of primer listed in Table 4.2 
for directionality of the insert.  
 
 
 
1.62 kbp 
0.64 kbp 
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Figure 4.18: Directional screening of putative pMOhly1/HA1 clones (primer combinations 
refer to Table 4.2).  
Three PCR reactions were set up for each clone according to the primer combinations listed 
in Table 4.4. Ticks indicate a PCR product is expected if the insert is in the correct orientation, 
crosses indicate a PCR product is not generated as the insert is in the incorrect orientation. 
From the results, Clone No. 290 appeared to have the influenza HA1 gene inserted into 
pMOhly1 hylA ORF in the correct orientation.  
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4.4.6.3 Sequencing analysis for the confirmation of pHES/HA1 and pMOhly1/HA1 
clone 
Sequencing of these clones revealed that the PCR-confirmed pHES/HA1 clone and 
pMOhly1/HA1 clone had the correct insert in the correct orientation. In comparison with the 
sequence information of influenza A PR-8 HA gene, two point substitutions were observed in 
the HA1 inserts in both clones at the same position. The result suggests that the mutations 
could not have being introduced during the cloning procedure, but had always existed in the 
virus stock (Figure 4.19). In silico analysis confirmed that one of the base substitutions will 
result in an amino acid substitution (Figure 4.20A & Figure 4.20B). BLAST analysis shows that 
the substituted amino acid (Serine) at this position does occur in other strains of influenza 
virus. 
 
4.4.7 Transformation of the plasmid constructs into vaccine strain 
STM1  
The plasmids of pHES/HA1 and pMOhly1/HA1 were passed through the intermediate strain 
of S. Typhimurium LT2-9121 in STM1 so that transformation would occur at a higher 
frequency between the two related bacterial strains. These vaccine strains will be referred to 
as pHES/HA1/STM1 and pMOhly1/HA1/STM1. The STM1 transformants were confirmed 
using colony PCR reactions coupled with combinations of primers listed in Table 4.1 and 
Table 4.2 (Figure 4.21). Original pHES and pMOhly1 plasmids were also transformed into 
STM1 as negative control strains for subsequent analysis. 
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Figure 4.19: Illustration of two base-substitutions found in the virus stock. 
The HA1 DNA sequence of influenza PR-8 virus. The base-substitutions were coloured in red. 
These two DNA bases were Cytosine (C), and they were substituted with Thymine (T). 
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Figure 4.20: Amino acid substitution of the rHA1 based on the base substitutions. 
A) Alignment of the reference pHES/rHA1 protein sequence and the amino acid substituted 
pHES/rHA1 protein. B) Alignment of the reference pMOhly1/rHA1 protein and the amino 
acid substituted pMOhly1/rHA1 protein. These alignments have indicated that the DNA 
base-substitutions found in the sequence analysis will result in an amino acid substitution in 
both pHES/rHA1 and pMOhly1/rHA1 fusion proteins, in which, a Proline (P) will be 
substituted with Serine (S) in the rHA1 proteins. 
 
 
 
A) 
B) 
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Figure 4.21: PCR confirmation of STM1 transformants.  
A) pHES/HA1 transformants amplified using primer combinations listed in Table 4.1.  
B) pMOhly1/HA1 transformants amplified using primer combinations listed in Table 4.2. The 
plasmid constructs were successfully transformed into vaccine strain STM1. 
A) 
B) 
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4.4.8 pHES/HA1/STM1 protein expression, optimisation and 
characterisation  
The pilot expression described in Section 4.3.1.1 did not result in any detectible rHA1 from 
cell lysates. Several detailed steps were carefully considered to increase the rHA1 protein 
yield and enhance the assay sensitivity. An extra step was included to ensure glucose – the 
promoter-inhibitory agent was reduced to a negligible level by washing the overnight cells 
three times with sterile ice-cold PBS, and resuspending the cell pellet with expression 
medium to an OD600nm of 0.5, in a total volume of 200 mL. The amount of protein loaded 
onto SDS-PAGE gel for subsequent immunoblotting was increased to approximately 100 μg 
per well. These changes enabled the detection of a protein at approximately 80 kDa, which is 
similar to the predicted MW of rHA1 expressed in pHES plasmid at 79.26 kDa (prediction was 
performed using the ExPASy Compute pl/Mw tool) (Figure 4.22).  
 
The expression was then optimised by varying the amount of inducing agent, IPTG. The 
clones were expressed in LB broth supplemented with 0.1 mM, 0.5 mM and 1.0 mM of IPTG. 
The result indicated that the addition of 1.0 mM of IPTG allowed optimal yield of rHA1 
protein expression at approximately three hours post-induction (Figure 4.23). A time-course 
study of the protein expression was performed to determine the optimal time for harvesting 
rHA1. Results indicated that the highest rHA1 protein yield was reached three hours 
post-induction, and the yield gradually decreased thereafter (Figure 4.24). Different culture 
media were also tested for the optimal rHA1 yield, which included BHI, MH, LB and NB broth. 
The results showed that LB broth enabled the optimal rHA1 yield, followed by MH broth 
(Figure 4.25). BHI and NB broth were unable to support the expression of rHA1 from 
pHES/HA1/STM1.  
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Figure 4.22: Pilot expression of rHA1 from pHES/HA1/STM1. 
Pilot expression: Western blot probed using 6x-His antibody, M: Precision Plus Protein TM 
Dual Color Standards, Number (1-5) above blot indicate the number of hours post-induction. 
Three faint protein bands with MW at approximately 80 kDa were observed in lane 3 to 5, 
indicating the expression of pHES/HA1 fusion protein. Three additional protein bands were 
also observed at approximately 30 kDa, which remained detectible in Western blot probed 
with 6x-His antibody, but not reactive with PR-8 antiserum (in the subsequent Western blot 
images). This indicated that these 30 kDa protein could not have being the breakdown 
product of pHES/HA1 fusion protein. It is possible that these proteins are the stress related 
proteins, which have been expressed due to the expression of the pHES/HA1 fusion protein 
[389]. 
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Figure 4.23: Optimisation of pHES/HA1/STM1 expression by media supplemented with 
different concentrations of IPTG.  
A) The immunoblot using 6x-His antibody, B) The immunoblot using PR-8 antiserum; Lane M: 
Precision Plus Protein TM Dual Color Standards, Lane 1: pHES/HA1/STM1 at 0 hour, Lane 2 
and 3: pHES/HA1/STM1 induced with 0.1 mM IPTG for 3 and 6 hours, Lane 4 and 5: 
pHES/HA1/STM1 induced with 0.5 mM IPTG for 3 and 6 hours, Lane 6 and 7: 
pHES/HA1/STM1 induced with 1.0 mM IPTG for 3 and 6 hours. Optimal rHA1 protein yield 
was achieved in the media induced with 1.0 mM IPTG for three hours.  
 
B) 
A) 
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Figure 4.24: Time-course study of rHA1 protein expression using media supplemented with 
1.0 mM IPTG.  
A) The immunoblot using 6x-His antibody, B) The immunoblot using PR-8 antiserum; Lane 1: 
pHES/STM1 clone 5 hours post-induction, Lane M: Precision Plus Protein TM Dual Color 
Standards, Lane 2 to 7: pHES/HA1/STM1 clone 0 to 5 hours post-induction. Results indicate 
that rHA1 protein yield increases gradually after induction and reached the maximum yield 
at approximately three hours post-induction, and yield decreases thereafter.  
 
B) 
A) 
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Figure 4.25: Optimisation of pHES/HA1/STM1 expression using different media.  
A) The immunoblot using 6X-His antibody, B) The immunoblot using PR-8 antiserum; Lane M: 
Precision Plus Protein TM Dual Color Standards, Lane 1: pHES/STM1 clone at 5 hours 
post-induction, Lane 2 to 5: pHES/HA1/STM1 clone expressed in BHI, LB, MH and NB broth, 
respectively. Results indicate that BHI and NB broth were unable to support the expression of 
rHA1, and LB broth appears to provide the optimal expression conditions for the clone.  
 
 
B) 
A) 
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Based on the optimised parameters obtained, expression of rHA1 at a lower temperature 
was also investigated. However, the results indicated that 370C was still the optimal 
temperature for the expression of rHA1. Overnight expression of rHA1 at 300C did not result 
in any detectable rHA1 using immunoblotting, and 340C expression resulted in a similar 
pattern of rHA1 expression to the profile observed from 370C expression (data not shown). In 
conclusion, the rHA1 was successfully expressed from pHES/HA1/STM1. The optimal 
expression condition was determined to be 370C in LB broth induced with 1.0 mM IPTG, and 
the maximum yield was reached at three hours post-induction.  
 
The pHES plasmid encoded with the essential AT components derived from S. Typhimurium 
LT-2, hence, to determine the location of the fusion rHA1 expressed from pHES/HA1/STM1 
clone, a cell membrane fractionation was performed. As described in Section 4.4.8. The 
pHES/HA1/STM1 clone was induced and harvested at three hours post-induction. The cells 
were sonicated and supernatant was subjected to several ultra-centrifugations using 
different buffers.  
 
The procedure of membrane fractionation allowed the separation of total cell-lysate into 
soluble protein fraction, envelope protein fraction, non-integral outer membrane (OM) 
proteins and integral outer membrane proteins. The results showed that the pHES/rHA1 
fusion protein was expressed as a part of STM1 integral outer membrane protein (Figure 
4.26).  
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Figure 4.26: Membrane fractionation of induced pHES/HA1/STM1 and pHES/STM1 clones. 
A) The immunoblot using 6x-His antibody, C) The immunoblot using PR-8 antiserum; Lane 1 
to 4 and Lane 5 to 8 are samples from pHES/STM1 (negative control) and pHES/HA1/STM1, 
respectively. Lane M: Precision Plus Protein TM KaleidoscopeTM Standards, Lane 1 and 5: 
soluble protein fractions, Lane 2 to 4 and Lane 5 to 8, envelope protein fractions: inner 
membrane proteins, non-integral outer membrane proteins and integral outer membrane 
proteins respectively. B) and D) are the immunoblot of whole cell protein extracts from 
pHES/HA1/STM1 using 6x-His antibody and PR-8 antiserum, respectively. The results 
indicated that the rHA1 was expressed as a part of STM1 integral outer membrane protein.  
C) 
A) B) 
D) 
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4.4.9 pMOhly1/HA1/STM1 protein expression and characterisation  
The detection of the pMOhly1/HA1 fusion protein from the pMOhly1 vector was difficult, as 
the level of expression from the haemolysin vector has been reported to be as little as 25 to 
100 μg/L [390]. The STM1 harbouring the pMOhly1/HA1 and empty pMOhly1 were grown in 
BHI culture and the supernatant was tested for the expressed constructs.  
 
Initially, trichloroacetic acid (TCA) precipitation was used to concentrate the fusion rHA1 
from culture supernatants, but no protein of interest was detected from neither the 
SDS-PAGE nor immunoblot (data not shown).  
 
Nickel-charged IMAC purification was then carried out (as described in Section 3.2.3). These 
samples were taken from both mid-log phase and overnight cultures. This method used the 
fused 6x-His tag to purify and concentrate the fusion protein in its native form. Fusion rHA1 
was recovered using competitive elution with 250 mM of imidazole, and the samples were 
collected in 1 mL fractions. The samples were examined using SDS-PAGE coupled with silver 
staining and immunoblotting with PR-8 antiserum.  
 
For the mid-log phase cultures, no fusion rHA1 was observed from the clone (data not 
shown). However, for the overnight cultures, a protein band at approximately 50 kDa was 
detected from the pMOhly1/HA1/STM1 clone, and the band was not seen in the 
pMOhly1/STM1 clone (Figure 4.27). In silico analysis predicted that the pMOhly1/HA1 fusion 
rHA1 has a MW of 49.04 kDa (prediction was performed using the ExPASy Compute pl/Mw 
tool) (Figure 4.28).  
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Figure 4.27: IMAC concentrated fractions of pMOhly1/HA1 fusion protein.  
A) Silver stained SDS-PAGE gel, B) The immunoblot using PR-8 antiserum; Lane M: Precision 
Plus Protein TM All Blue Standards for A), Precision Plus Protein TM KaleidoscopeTM Standards 
for B), Lane 1 to 3: IMAC elution fractions (2nd to 4th mL) from pMOhly1/STM1 clone, Lane 4 
to 6: IMAC elution fractions (2nd to 4th mL) from pMOhly1/HA1/STM1 clone. An unexpected 
protein band was also observed at approximately 45 kDa, which was purified by IMAC, but 
not reactive with PR-8 anti-serum. This suggested that this 45 kDa protein was not a 
breakdown product of the pMOhly1/HA1 fusion protein. It is possible that this protein is a 
stress-induced product, which has been expressed due to the expression of the 
pMOhly1/HA1 fusion protein. The yield of pMOhly1/HA1 was approximately 230 μg/L in 
overnight BHI broth. 
 
 
 
B) A) 
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Figure 4.28: The protein sequence of fusion rHA1 expressed in pMOhly1/HA1/STM1.  
The fusion HA1 has an estimated MW of 49.04 kDa. Red coloured letters are the sequence 
encoding for influenza HA1 and the purple coloured letters are the 6x-His tag introduced to 
assist purification and detection.  
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4.5 Discussion 
The MDCK cell-line was resuscitated from liquid nitrogen stocks and used to infect confluent 
MDCK cell-lines. The propagation of PR-8 virus in infected cell-lines was confirmed by the 
signs of cellular destruction and increased cell death using light inverted microscope.  
 
The purification of PR-8 virus was straightforward and the purified virus samples were 
immediately stored at -800C to prevent the degradation of influenza viral envelope, which is 
made up of host cell lipid-bilayer. 
 
The extraction of influenza total RNA using TRIzol® LB reagent and subsequent cDNA 
synthesis were relatively simple and no obvious difficulties encountered during the 
procedure. However, great care was taken to prepare the workstation before commencing 
any procedure, and all procedures were conducted at low temperature to prevent cross 
contamination and degradation. Furthermore, the entire procedure from RNA extraction to 
PCR amplification using cDNA templates was performed within a day to minimise 
degradation.  
 
Difficulties were encountered in the PCR amplification using insert primers. The initial 
attempt of setting the annealing temperature at 550C did not result in any DNA products, and 
lowering the annealing temperature to 500C resulted in an expected PCR product using pHES 
primer pair. The predicted Tm0C of thesis primers was above 600C, therefore, it was 
surprising that a temperature lower than 550C was required. 
 
The insert primers for pMOhly1 were unable to generate any PCR product until the annealing 
temperature was lowered to 480C. The excessive length of pMOhly1_SbfI_Rev primer may 
have contributed to the difficulty of generating PCR product using higher annealing 
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temperatures. The excessive length of the primer was required to introduce 6x-His tag into 
the pMOhly1 recombinant hlyA’ gene for protein detection and purification.  
 
The sub-cloning of HA1 gene into pHES vector was achieved. The pHES/HA1 clone was 
confirmed using both enzymatic digestion to check for expected patterns, and also PCR to 
confirm. The plasmid construct was also amplified for sequence analysis, and the result 
indicated that the HA1 gene was inserted into pHES vector as expected. Two 
base-substitutions were observed in the inserted HA1 gene, and it was determined later that 
the mutations had always been in the virus stock and were not introduced during cloning 
procedure. One mutation was synonymous, and the other non-synonymous. The 
synonymous mutation resulted in an amino acid substitution from Proline to Serine in the 
PR-8 rHA1 protein sequence. However, the Serine substitution at the position does occur in 
other influenza strains such as (A/Cameron/JY2/1946(H1N1)). 
 
In order to use the hly operon in its most efficient form, the NsiI site is the ideal place to 
insert a coding region to be expressed. PCR amplification proved useful in determining 
orientation of the insert. PCR determination of the orientation was achieved using different 
primer combinations by mixing pMOhly1 sequencing primers and the primers designed to 
elongate from the middle of the PR-8 HA1 gene. In theory, if the insert was present in the 
correct orientation there should be DNA products produced as listed with expected sizes. In 
the pMOhly1 screening, Clone No. 290 produced three bands and two of them were 
indicative of the correct orientation of the HA1 insert. In the screening of Clone No. 495, 
there was a product with a size of 1618 bp, indicating successful insertion of the gene. 
However, the absence of a PCR product when using primer combination SEQF_pMOhly1 + 
SEQR_PR8HA1, indicated incorrect orientation of the insert. Multiple bands were observed 
using primer combination SEQR_pMOhly1 + SEQF_PR8HA1 which can be attributed to 
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non-specific binding of the primers on the pMOhly1 plasmid. Though the PCR screening was 
at times unpredictable, it proved successful in identifying the correct pMOhly1/HA1 
construct. Sequence analysis was also used to confirm the correct insertion of the influenza 
HA1 gene, and the same base-substitutions that appeared in the pHES/HA1 clone were also 
observed. The base-substitutions can be attributed to a single amino acid substitution, 
where the original Proline is substituted with Serine. 
 
The passage of pHES/HA1 and pMOhly1/HA1 plasmid into vaccine strain STM1 was 
successful using PCR reactions. Using the primer combinations to confirm the correct 
insertion of the HA1 gene, the plasmid constructs isolated from bacterial vectors E. coli 
DH5-α, S. Typhimurium LT-2 and S. Typhimurium STM1 were shown to be the same for both 
pHES/HA1 and pMOhly1/HA1 plasmid constructs. 
 
The purpose of using the pHES plasmid was to construct a vaccine carrier that displays the 
heterologous vaccine antigen on the bacterial surface. The pHES plasmid encodes a modified 
ShdA derived from S. Typhimurium LT-2, which is a known autotransporter gene.  
 
The expression of recombinant ShdA is controlled by lacIq-Plac promoter. This promoter can 
be induced using IPTG and inhibited by glucose. Difficulties were encountered during pilot 
expression of the pHES/HA1 fusion protein, because even the presence of trace amount of 
glucose can still inhibit protein expression. However, an unexpected phenomenon was 
observed during the initial attempts of protein expression. It was found that if glucose was 
not added into the pre-expression overnight cultures, the expression became “leaky” (trace 
amount of expression), which resulted in inefficient induction of expression. Therefore, an 
extra wash step was included to remove glucose form the overnight pre-expression culture 
prier to induction.  
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Several parameters were considered in the optimisation of fusion pHES/HA1 expression, 
which included amount of inducing agent, expression temperature, expression media and a 
time-course study of the protein expression was performed to determine the optimal time to 
harvest clones for analysis. According to the results, the optimal expression condition was 
achieved in LB broth induced with 1.0 mM IPTG at 370C. The amount of pHES rHA1 increased 
along the expression time-course, and reached its maximum at three hours post-induction. 
Among media tested for rHA1 expression, LB broth provided optimal conditions for 
expression followed by MH broth. BHI and NA failed to support the expression of pHES rHA1, 
which might be explained by the fact that these two media contain a substantial amount of 
glucose which would have inhibited rHA1 expression.  
 
The location of pHES fusion rHA1 was determined using cell membrane fractionation. The 
procedure separates the total cell lysate into soluble and insoluble fractions, as the insoluble 
fraction mostly contained envelope proteins. The insoluble fraction was then treated with 
Triton X-100 and urea to dissolve some of the envelope proteins, and the remaining insoluble 
fraction was composed predominantly the outer membrane-bound proteins. As shown in 
Figure 4.26, a protein at the expected size of approximately 80 kDa was detected in the 
integral outer membrane fraction, which indicated that the pHES rHA1 was successfully 
expressed and translocated to the outer membrane of the vaccine strain STM1. The 
translocation of the recombinant passenger domain to the STM1 surface was as expected. 
This was similar to a previous report where it was demonstrated that the pHES plasmid 
encoding ShdA was able to express and translocate the passenger domain onto the E. coli 
surface [5].  
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Other than the use of the Salmonella ShdA gene for the purpose of surface displaying 
heterologous antigens, there are a number of other autotransporter genes which have been 
explored. Rizos et al., [391] examined the potential of using AIDA-I (E. coli adhesion involved 
in diffuse adherence) autotransporter domain to display antigenic fragments of the urease A 
subunit of H. pylori in an attenuated S. Typhimurium vaccine strain. Similar to the Salmonella 
ShdA autotransporter, AIDA-I consists of a 49 aa signal peptide, a 797 aa adhesion (passenger 
domain) and a 440 aa β-barrel domain anchored in the bacterial wall [392]. In this study, the 
fusion urease A subunit was successfully expressed and translocated on the Salmonella 
surface, and orally immunised mice exhibited reduced colonisation of H. pylori. In contrast to 
the strategy described in this chapter, Rizos and colleague incorporated a constitutive 
promoter for transcriptional control of the recombinant AIDA-I gene, and the resulting 
protein expression level appeared to be higher. However, the expression level of any 
recombinant protein is a multi-factor challenge in the development of such live vaccine 
carrier. 
 
Charbit et al., 1987 [393] described a different strategy to display antigenic peptide at the 
surface of E. coli by using the outer membrane LamB protein as carrier. Although the 
experiment successfully elicited epitope-specific antibodies in an immunised animal model, 
there is a limitation in using such outer-membrane proteins as carrier. The use of 
outer-membrane proteins such as Omps, flagella and fimbriae for the purpose of surface 
display may be limited by the insert sizes, and the expression of globular-folded protein 
could inevitably disrupt normal functions of the Omp [394]. Autotransporters on the other 
hand, often have passenger domains over 100 kDa, an indication of that they are more 
feasible for expressing large inserts [395, 396].  
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The expression of fusion rHA1 was successful from the pMOhly1 plasmid in the vaccine strain 
STM1, but the level of expression was very low. The detection of rHA1 can only be achieved 
by concentrating the 6x-His tagged rHA1 using IMAC from 10 mL overnight culture. The 
concentrated sample could then be detected using SDS-PAGE stained with silver reagent and 
immunoblotting probed with PR-8 antiserum. Although pMOhly1 is a useful recombinant 
expression system, as it secretes protein from cells, it has been observed that expression 
levels can vary from 25 to 100 μg/L of culture supernatant [390].  
 
Hahn and von Specht, 2003 [390] reported that culture size can significantly affected the 
protein expression rate in the haemolysin expression system due to the reduction in oxygen 
saturation levels in small culture volumes. This activation of the haemolysin system under 
reduced oxygen levels might be beneficial under in vivo conditions as the gastrointestinal 
tract is a low oxygen environment. It could result in a higher level of expression of the fusion 
products which could potentially increase the potency of the immune responses.  
 
In general, extracellular expression of recombinant proteins has  advantages in the 
development of live vaccine carriers. Currently, a large majority of recombinant proteins are 
expressed and secreted using the SecB-dependent type-II pathway. In this secretion pathway, 
prior secretion takes place; the pre-protein is first translocated across the inner membrane 
and folded in the periplasm, and then secreted into the culture medium through the means 
of non-specific periplasmic leakage [397]. This passive two-step secretion process can 
sometimes result in decreased extracellular yields due to partial secretion [398]. In contrast 
in the type I secretion system used in this study (E. coli α-haemolysin), the passenger protein 
is actively exported into the culture medium without accumulation in the periplamic space 
[399, 400]. It is known that the expression level using α-haemolysin is low, however, some 
studies reported an increased translocation efficiency by introducing mutagenesis in HlyAs, 
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HlyB and HlyD [401-403]. Sugamata and Toshikazu, 2005 [401] reported that some mutants 
created by random mutagenesis of HlyB exhibited increased secretion levels of a single-chain 
antibody-HlyA fusion protein for up to 27-fold compare to the wild-type α-haemolysin. Such 
techniques may be used in future studies to increase the protein expression and secretion 
level. 
 
Currently, there are only a small number of studies that have successfully expressed 
recombinant proteins using the E. coli α-haemolysin in attenuated Salmonella. Orr et al., 
1999 [404] reported that low level expression and secretion of a mutant Diphitheria toxin 
molecule (CRM197) was achieved in S. Typhi CVD908-htrA carrying pMOhly plasmid. Similar to 
what has been described in this Chapter, the gene encoding for the mutant Diphitheria toxin 
molecule was inserted into the NsiI site within the truncated hlyA gene. Another similar 
study conducted by Gentschev et al., 1995 [405] also demonstrated the successful 
expression and secretion of Lysteriolysin in S. dublin aroAΔ by the same cloning strategy 
described in Orr et al., 1999. Collectively, although extracellular secretion of recombinant 
protein could be achieved by using E. coli α-haemolysin, it is apparent that low level 
expression of the recombinant protein is the major obstacle needed to be overcome for the 
broad application as a Salmonella-based live vaccine carrier. 
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4.6 Conclusion  
The construction of both pHES/HA1 and pMOhly1/HA1 was successful, and the plasmid 
constructs were successfully transformed into the vaccine strain STM1.  
 
The expression of pHES fusion rHA1 was achieved and the expression level was optimised for 
analysis and subsequent vaccine study. Furthermore, membrane fractionation confirmed the 
pHES fusion rHA1 was expressed and translocated to the outer membrane of the STM1. The 
expression of pMOhly1 fusion rHA1 was also successful, and the protein was detected in the 
supernatant of an overnight culture. Most importantly, both fusion proteins were detectable 
by PR-8 antiserum, indicating the presence of antigenic epitopes of the influenza HA. The 
immunogenicity of these clones was assessed in chickens, which is presented in Chapter 5.
  
 
 
Chapter 5 
Vaccination of Chickens Using 
STM1 Expressing rHA1 
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5.1 Introduction 
Avian influenza viruses are the cause of some of the most important diseases in the poultry 
industry which can also lead to spill-over infections into the human population. The rapid 
and continuous antigenic variation of the influenza virus has caused many episodes of 
widespread poultry epidemics in the past, and resulted in tremendous socioeconomic impact 
[172, 174, 406]. The currently utilised vaccines for the prevention of avian influenza in 
poultry are suboptimal [171, 257]. The conventional egg-based vaccines and in vitro 
expressed recombinant vaccine antigens require parenteral administration, and limited use 
has been reported due to high labour costs [260]. In vivo expression of influenza vaccine 
antigen using various viral and bacterial vectors has shown some success. However, 
pre-existing immunity to the vaccine carrier can significantly decrease the vaccine efficacy 
[162, 306].  
 
Salmonella vaccine carriers may be used for large-scale immunisation in the poultry industry 
for the prevention of influenza infections via in vivo expression of influenza antigens. The 
intrinsic ability of Salmonella invasiveness allows it to provoke both B- and T-lymphocyte 
memory responses, hence inducing long-lasting mucosal, humoral and cell-mediated 
immunity [107]. After oral immunisation, Salmonella infiltrate through Microfold cells in the 
gut to gain entrance to the intestinal lining, and are taken-up by professional phagocytic cells, 
such as, macrophages and DCs, that disseminate to systemic compartments such as the liver 
and the spleen [379, 407].  
 
After phagocytosis, Salmonella is found in vacuoles or phagosomes, and antigen presentation 
is predominantly restricted to the MHC class II pathway, eliciting primarily CD4+ Th1 and Th2 
immune responses [408, 409] (Figure 5.1). In the case of viral infection, stimulated CD4+ Th1 
cells are responsible for cytokine production including IFN-γ, IL-2 and TNF-α, which are 
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crucial for sustaining CD8+ T-lymphocyte responses; whilst CD4+ Th2 cells secrete IL-4 and IL-5 
are important for the stimulation of humoral immune responses, all of which are essential in 
combating viral infections [354, 367, 410].  
 
Several commercialised live-attenuated Salmonella vaccines exist, including STM1, which 
when used in chickens cause no signs of illness and can confer heterologous protection [320, 
411-413]. Modification of these attenuated vaccines into vaccine carrier has been widely 
investigated using a varied assortment of heterologous pathogen antigens [3, 159, 160, 281, 
309, 319, 414]. There have been various degrees of success using Salmonella as a vaccine 
carrier depending on the host animal and disease, including targeting avian influenza in 
chickens using hemagglutinin as a protective antigen [309, 310, 312].  
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Figure 5.1: Diagramatic representation of the induction of T-lymphocyte response.  
In the endogenous pathway, antigens from intracellular pathogens, such as viruses are 
degraded by the proteasome and the resulting peptides are loaded onto MHC class I 
molecules via the endoplasmic reticulum. The MHC class I complex is transported to the cell 
surface, where it stimulates CTLs. On the other hand, extracellular pathogens (such as 
Salmonella) are engulfed by phagosomes through the exogenous pathway. After phagosomic 
processing, the pathogen-derived peptides are loaded onto MHC class II, and after being 
transported for presentation, it stimulates CD4+ Th1 and Th2 immune responses, leading to 
the production of cytokines and antibodies, which are essential for sustaining CD8+ 
T-lymphocyte and humoral immune responses. Furthermore, other than the classical 
pathways described above, dendritic cells can present exogenously processed antigens on 
MHC class I molecules via a process known as “cross-presentation”. Image modified from 
[415]. 
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Several factors may influence the efficacy and type of immune response induced against 
heterologous passenger antigen. For instance, the translocation of heterologous antigen 
after expression may vary the immunogenicity of such an in vivo expressed antigen for 
induction of humoral immunity. It is important that the heterologous antigen can translocate 
into the periplasmic membrane or outer membrane surface, or even be secreted into the 
extracellular space. Another factor that can play a vital role is the type of mutation 
engineered to attenuate the vector vaccine. Some mutations that lead to the disruption of 
genes encoding for essential metabolic enzymes for the survival of a microbe in vivo result in 
the generation of mutants which are safe and have minimal survival in the host. However, 
such mutations may have an impact on the course of infection, hence changing the quality of 
the induced immune response [129]. Furthermore, the expression of heterologous antigen 
may result in unnecessary metabolic burden to the vaccine vector, and lead to 
over-attenuation of the organism [129].  
 
One potential impediment for the use of Salmonella vaccine carrier is pre-existing immunity 
as a result of pre-exposure to either a heterologous or homologous strain. For chickens, 
Salmonella exposure can occur via both horizontal and vertical transmission and many 
different strategies have been used to reduce transmission including feed and drinking water 
acidification, immune strategies based on passive and active immunity, nutrient composition 
to reduced susceptibility to Salmonella and improve hygiene practices [416].  
 
Currently, there is speculation over the effect of pre-existing immunity on heterologous 
delivered antigens. There have been various reports that conclude that pre-existing 
immunity leads to up-regulation of the immune response to the delivered antigen [2, 4, 
417-422]. However, there have been some contradictory reports that pre-existing immunity 
reduces heterologous antigen-specific immune responses and that this effect is a restrictive 
CHAPTER 5 
190 
 
limitation of this delivery system as exposure to Salmonella is common [423-426].  
 
In the previous chapter, work leading to the generation of a set of recombinant STM1 vaccine 
strains was described. The aim of the work described in this chapter is to evaluate the ability 
of the Salmonella STM1 vaccine to deliver heterologous antigen in vivo and elicit both 
cellular and humoral immune responses. Influenza hemagglutinin domain 1 was used as the 
heterologous antigen, in which, the pHES/HA1/STM1 strains were engineered to translocate 
and display the rHA1 on STM1 outer membrane, and pMOhly1/HA1/STM1 strains were 
equipped with the ability to secrete rHA1 into extracellular space.  
 
The aim of work described in this chapter was as follows:  
- To evaluate the plasmid stability of STM1 harbouring influenza HA1 in vivo after being 
orally administered in chickens. 
- To evaluate the immune responses of the STM1 vaccine strains harbouring influenza HA1 
in a chicken trial. 
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5.2 Materials and methods  
5.2.1 Chickens and bacterial strains 
Newly hatched mix-gender Broiler chicks were obtained from Inghams Farms, Pakenham, 
Victoria. The recombinant STM1 clones used in the immunisation study were described in 
Chapter 4. These included pHES/HA1/STM1 and pMOhly1/HA1/STM1 carrying influenza HA1 
gene in the pHES and pMOhly1 vector, respectively, and the negative controls pHES/STM1 
and pMOhly1/STM1 carrying the expression vector only.  
 
5.2.2 Vaccine preparation 
Prior to preparation, all clones were confirmed using PCR amplification with primer 
combinations as listed in Table 4.1 and Table 4.2. 
 
For pHES/HA1/STM1 and pHES/STM1 vaccines, the clones were expressed in LB broth 
induced with 1.0 mM IPTG at 370C for three hours with 180 rpm orbital shaking. The cells 
were washed three times with sterile ice-cold PBS, and diluted to 1 x 109 CFU/mL for 
administration. For pMOhly1/HA1/STM1 and pMOhly1/STM1 vaccines, the clones were 
cultured in BHI broth at 370C for 16 to 18 hours with 180 rpm orbital shaking. Cells were 
washed as described above for pHES clones. 
 
5.2.3 Immunisation of chickens via oral route 
The immunogenicity of the vaccine strains pHES/HA1/STM1 and pMOhly1/HA1/STM1, and 
negative control strains pHES/STM1 and pMOhly1/STM1 was determined in a chicken. A 
total of 20 newly-hatched mix-gender chicks were divided into four groups (Table 5.1), 
where each chicken was vaccinated twice at 7 and 22 days of age with STM1 expressing 
influenza HA1 either from pHES or pMOhly1 plasmid, and STM1 vector carrying empty pHES 
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or pMOhly1 plasmids as a negative control. Vaccines were given via oral gavaging at 1 x 109 
CFU vaccine STM1 per chicken. Chicken faecal samples were collected one day prior the first 
immunisation and every other day thereafter throughout the study for assessing vector 
retention and IgA extraction. Chickens were decapitated two weeks after the second 
immunisation, and serum samples and spleens were collected for immunological assays. 
Prior to decapitation, the chickens had undergone anaesthesia via an intramuscular injection 
into the pectoral muscle using a cocktail mix of 1.0 mg Ketamine (Parnell, Australia) and 2.0 
mg Xylazine (Troy Laboratories, Australia) per 1 Kg chicken. 
 
5.2.4 Detection of STM1 vaccine strains from faecal samples 
Eight fresh faecal samples were collected from each experimental group one day prior to the 
first vaccination and every second day thereafter. Each faecal sample was collected and 
stored at 40C until processed. For the pre-vaccination samples, the samples were streaked 
onto selective media XLD agar (Oxoid, UK), to determine whether the chicks had been 
exposed to Salmonella. Vaccine constructs were isolated on Ampicillin (100 μg/mL) 
supplemented LB media for pMOhly1 clones, and Chloramphenicol (40 μg/mL) and glucose 
(2% w/v) supplemented LB media for pHES clones. The isolated clones were confirmed by 
colony PCR.  
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Table 5.1: Vaccine trial configuration. 
Groups Vaccination Number of chicks 
Group 1 pHES/STM1: 
STM1 harbouring empty pHES plasmid  
5 
Group 2 pHES/HA1/STM1: 
STM1 expressing HA1 using pHES plasmid 
vector  
5 
Group 3 pMOhly1/STM1: 
STM1 harbouring empty pMOhly1 plasmid 
  4** 
Group 4 pMOhly1/HA1/STM1: 
STM1 expressing HA1 using pMOhly1 
plasmid vector 
5 
Group 1 and 3 were negative controls, group 1 chickens were vaccinated with STM1 
harbouring empty pHES plasmid and group 3 chickens were vaccinated with STM1 
harbouring empty pMOhly1 plasmid. The evaluation of humoral and cell-mediated immune 
responses from group 2 and 4 were compared with these negative controls accordingly.  
** One chick was found unhealthy and subsequently euthanised on welfare grounds. 
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5.2.5 Preparation of faecal samples for secretory IgA analysis 
Faecal samples were collected within minutes of defecation over a period of an hour. 
Samples were weighed and processed immediately. Standard faecal preparations of 1:10 
dilution (w/v) were made in sterile PBS, and the samples were vortexed vigorously for 5 
minutes and allowed to stand at room temperature for one hour [427]. After centrifugation 
at 15,000 x g for 15 minutes, the supernatant was collected and stored at -200C until analysis.  
 
Prior to analysis, the samples were thawed at room temperature and added to the ELISA 
plate in triplicate. Wells were coated with either 10 μg/mL of purified rHA1 expressed from 
Pichia or 5 μg/mL heat-inactivated influenza PR-8 virus [428]. Two- or four-fold dilution of 
faecal extract obtained from vaccinated chickens were used as primary antibody, and goat 
anti-chicken IgA-HRP (Abcam®, USA) diluted 1:5000 in diluent (PBST/1% (w/v) skim milk), was 
used as secondary conjugated antibody. 
 
5.2.6 ELISA protocols for chicken IgG 
Serum antibody responses of vaccinated chickens were measured using the ELISA as outlined 
in Section 2.7.5 with a few modifications. Wells were coated with either Pichia-expressed 
rHA1 or heat-inactivated influenza PR-8 virus as described above. Two- or four-fold dilutions 
of sera obtained from vaccinated chickens were used as primary antibody, and Goat 
anti-rabbit IgG (whole molecule)-HRP (Sigma-Aldrich, USA) diluted 1:5000 in diluent, was 
used as secondary conjugated antibody. Following the addition of the substrate TMB, plates 
were incubated for 15 to 30 minutes before the addition of 50 μL of a 1 M solution of 
sulphuric acid. The endpoint was determined as the dilution at which the optical density (OD) 
at a wavelength of 450 nm (OD450) was three times the background level. 
 
CHAPTER 5 
195 
 
5.2.7 Hemagglutination Inhibition assay  
HI titre of vaccinated chickens was measured using the protocol outlined in Section 3.2.9.3.2, 
and both serum IgG and secretory IgA samples were examined for specific virus-neutralising 
antibody responses from immunised chickens.  
 
5.2.8 ELISpot assay 
5.2.8.1 Media, buffers and solutions  
5.2.8.1.1 Media 
Blocking medium: RPMI1640 (Gibco®, USA) supplemented with 2% (v/v) Fetal Calf Serum 
(FCS) (Gibco®, USA) and 100 U/mL Pen/Strep (Gibco®, USA). 
Collection medium: Same as blocking medium 
Culture medium: RPMI1640 supplemented with 10% (v/v) FCS, 100 U/mL Pen/Strep, and 50 
μM β-mercaptoethanol (Gibco®, USA). 
 
5.2.8.1.2 Buffers and solutions  
Assay buffer: PBST added with 1% (w/v) BSA. 
Carbonate buffer 1: 1 M NaHCO3 in Milli Q water. Filter sterilised and stored at 4
0C. 
Carbonate buffer 2: 1 M Na2CO3 in Milli Q water. Filter sterilised and stored at 4
0C. 
ELISpot coating buffer: combine 3.4 mL Carbonate buffer 1 and 1.5 mL Carbonate buffer 2 in 
100 mL sterile Milli Q water. Adjust to pH9.6 using either Carbonate buffer 1, or Carbonate 
buffer 2. Made for immediate use.  
1X Dulbecco’s Phosphate Buffer Saline: 10-fold dilution of 10X DPBS (Gibco®, USA) in sterile 
Milli Q water.  
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5.2.8.1.3 IFN-γ chicken antibody pair 
Chicken IFN-γ levels were determined using the IFN-γ Chicken Antibody Pair Kit (CAC1233, 
Life Technologies, USA). This kit includes Anti-Chicken IFN-γ, Anti-Chicken IFN-γ Biotin and 
Streptavidin-HRP. 
 
5.2.8.2 Preparation of ELISpot plates 
MultiscreenTM-IP 96-well ELISpot plates (Merck, USA) were prepared by wetting the 
membranes with sterile 35% ethanol, followed by three washes with sterile 1X DPBS. Plates 
were coated for 24 hours at 40C with 100 μL anti-chicken IFN-γ antibody (5.0 μL/mL) in 
ELISpot coating buffer; the wells were washed twice with Blocking medium and patted dry 
with autoclaved paper towelling. Plates were blocked with 200 μL of Blocking medium for 
one hour at 370C supplemented with 5% CO2. A volume of 100 μL of Culture medium was 
added to each well whilst the splenocyte samples were prepared.  
 
5.2.8.3 Collection and preparation of chicken splenocytes  
Upon necropsy, chicken spleens were removed aseptically and placed in Collection buffer 
and stored on ice until process. The chicken splenocytes were homogenised by squashing the 
spleen using the back of a 3 mL syringe. The homogenised cells were resuspended in 5 mL of 
Collection medium and filtered through a cell strainer (70 μm) (BD Biosciences, USA). 
Splenocytes were isolated by density-gradient centrifugation at 850 x g for 20 minutes in 
Histopaque®-1077 (Sigma-Aldrich, USA), and cells were washed once in 1X DPBS and twice in 
Culture medium, and resuspended in Culture medium. Cell viability was calculated using 
Trypan Blue exclusion. Ten microlitres of cell suspension, 10 μL of Trypan Blue (Sigma-Aldrich, 
Australia) and 80 μL of 1X DPBS were mixed and viable cells counted in a Countess 
Automated Cell Counter (Life Technologies, USA). Cell concentration was adjusted to 1 x 106 
cells in 180 μL Culture medium. The splenocyte suspension was used to determine chicken 
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IFN-γ levels.  
 
5.2.8.4 Determination of chicken IFN-γ levels 
Upon seeding prepared splenocytes, the Culture medium was discarded, plates were patted 
dry and 180 μL of splenocytes assed to each well (containing 1 x 106 cells/180 μL). All 
standard and sample wells were seeded in triplicate, as well as three wells per control. The 
addition of 20 μL of a stock (10 μg/mL) of Concanavalin A (Sigma-Aldrich, Germany), a 
mitogen that would serve as a positive control, 50 μg per well BSA would serve as a negative 
unrelated protein control and 20 μL of Culture medium to confirm that there was no 
contamination of the tissue culture media. Two sets of stimuli were prepared in Culture 
medium, which includes the purified Pichia-expressed rHA1 protein at a concentration of 250 
μg/mL and 20 μL added to each sample well, and heat-inactivated influenza PR-8 virus [428] 
at a concentration of 50 μg/mL and 20 μL added to each sample well. The plates were 
incubated in a humidified incubator at 410C supplemented with 5% CO2 for 48 hours. 
 
Subsequently, the plates were washed six times with PBST and once with PBS, 50 μL of 
Detection Biotinylated anti-chicken IFN-γ in Assay buffer at a concentration of 0.5 μg/mL was 
added to each well and the plate incubated at room temperature for two hours with 100 rpm 
shaking. The plates were washed five times with PBST and once with PBS. To each well 100 
μL of 2 μg/mL Streptavidin-alkaline phosphatase (Life Technologies, USA) was added and the 
plates were incubated at room temperature for one hour in dark at room temperature. The 
plates were washed five times with PBST and once with PBS and patted dry with autoclaved 
paper towelling. To develop the assay, 50 μL of BCIP®/NBT (Sigma-Aldrich, USA) was added to 
each well and incubated at room temperature with gentle continual shaking for 30 minutes 
in dark. The assay was stopped by washing the plates with plenty of water and allowed the 
plates to dry before analysis. The spots were counted under a dissecting microscope. 
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5.2.9 Statistical analysis  
All statistical analysis was calculated using the Microsoft Excel 2007 using the Data Analysis 
add-lin. The results displaying a normal distribution and equal variances were analysed using 
Student’s T-test.  
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5.3 Results   
5.3.1 Immunisation of chickens 
Prior to the first immunisation, one chick was found unhealthy and subsequently euthanised 
on welfare grounds by the RMIT Animal Ethics Committee – Animal Welfare Officer. A 
necropsy was carried out and the result indicated inappetence. Professional advice 
suggested that it is not unusual in young chick flocks, as supplementary food is already 
provided and no further investigation was taken. A group of four chicks was used for 
immunisation with STM1 carrying pMOhly1 empty plasmid. 
 
5.3.2 Recovery of STM1 vaccine plasmids from faecal samples 
Pre-immunisation samples were streaked onto XLD agar to check for 
pre-exposure/colonisation of Salmonella serovar strains [429, 430]. No typical S. 
Typhimurium strains were found in the faecal samples collected prior to immunisation. 
 
In order to determine how successfully the constructs are retained after immunisation, the 
percentages of STM1 vaccine constructs were determined from freshly defecated faecal 
samples. The result is presented as percentages of positive detection of vaccine constructs 
using antibiotic-containing LB agar and PCR confirmation along the course of the trial.  
 
For pHES/STM1 and pHES/HA1/STM1 vaccines, results indicated that neither pHES vaccine 
constructs can retain plasmid stability immediately after immunisation (data not shown) as 
neither the antibiotic-containing agar plates nor the PCR reactions detected pHES plasmids. 
However, pMOhly1/STM1 and pMOhly1/HA1/STM1 vaccine plasmids were detectible for up 
to seven days after the first immunisation and up to six days after the second immunisation 
in collected faecal samples (Figure 5.2). An overall decreased positive detection rate of 
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pMOhly1 vaccine constructs after the second immunisation was also observed. The highest 
detection rate of pMOhly1/STM1 and pMOhly1/HA1/STM1 after the first immunisation was 
88% (7/8) and 75% (6/8) respectively, and after the second immunisation was 75% (6/8) and 
38% (3/8) respectively. 
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Figure 5.2: Detection of pMOhly1/STM1 and pMOhly1/HA1/STM1 vaccine constructs from 
faecal samples along the course of the trial.  
According to the results collected, the pMOhly1 vaccine constructs were able to persist in 
vivo for up to seven days after immunisation, and the overall positive detection rate of the 
vaccine constructs were higher after the first immunisation than the second immunisation.  
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5.3.3 Humoral immune responses 
In order to determine the immunogenicity of the STM1 vaccine strains, HA1-specific and 
virus-specific humoral responses were measured using ELISA.  
 
Sera collected upon decapitation was analysed for the presence of IgG humoral responses 
specific to both the Pichia-expressed rHA1 and inactivated virion of influenza PR-8. Neither 
pHES/HA1/STM1 (Figure 5.3A & Figure 5.3B) nor pMOhly1/HA1/STM1 (Figure 5.4A & Figure 
5.4B) vaccinated groups showed elevated immune responses against rHA1 or inactivated 
PR-8 virion over the control groups. 
 
Similarly faecal IgA collected prior to decapitation did not show any specific immune 
response against pHES/HA1/STM1 (Figure 5.5A & Figure 5.5B) or pMOhly1/HA1/STM1 
(Figure 5.6A & Figure 5.6B). Furthermore no statistically significant differences were found 
between samples collected prior to the first immunisation and prior to decapitation (data not 
shown).  
 
Specific virus-neutralising humoral responses of the collected serum IgG and faecal IgA were 
determined using HI assay. However, no inhibition of hemagglutination between PR-8 virus 
and human red blood cells was observed (data not shown).  
 
In conclusion, neither the pHES/HA1/STM1 and pMOhly1/HA1/STM1 vaccine strains were 
able to elicit specific humoral responses against Pichia-expressed rHA1 or the influenza PR-8 
virion.  
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Figure 5.3: IgG response of pHES/HA1/STM1 vaccinated groups.  
A) specific IgG response against PR-8 virion; B) specific IgG response against Pichia-expressed 
rHA1. The results showed no significant difference between the pHES/HA1/STM1 vaccinated 
group over the control group at any given dilution factor (P>0.1).  
A) 
B) 
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Figure 5.4: IgG response of pMOhly1/HA1/STM1 vaccinated groups.  
A) specific IgG response against PR-8 virion; B) specific IgG response against Pichia-expressed 
rHA1. The results showed no significant difference between the pMOhly1/HA1/STM1 
vaccinated group over the control group at any given dilution factor (P>0.1).  
A) 
B) 
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Figure 5.5: IgA response of pHES/HA1/STM1 vaccinated groups.  
A) specific IgA response against PR-8 virion; B) specific IgA response against Pichia-expressed 
rHA1. The results showed no statistically significant differences between the 
pHES/HA1/STM1 vaccinated group over the pHES/STM1 control group at any given dilution 
factor (P>0.1).  
A) 
B) 
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Figure 5.6: IgA response of pMOhly1/HA1/STM1 vaccinated groups.  
A) specific IgA response against PR-8 virion; B) specific IgA response against Pichia-expressed 
rHA1. The results showed no statistically significant differences between the 
pMOhly1/HA1/STM1 vaccinated group over the control group at any given dilution factor 
(P>0.1).  
A) 
B) 
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5.3.4 Cell-mediated immune responses 
Chickens were sacrificed on the 35th day, which was two weeks after the second dose of 
vaccination. Splenocytes were prepared for the ELISpot assay as described in Section 5.2.8.3. 
The number of cytokine secreting cells in each group was compared using Student’s T tests. 
Results were reported as spot count with standard deviation (spot count + S.D.). 
Cell-mediated immune responses were measured by the production of IFN-γ by splenocytes 
in response to stimulation by either inactivated PR-8 virion and Pichia-expressed rHA1, and 
BSA as an internal negative control. Concanavalin A, a plant-based mitogen known to 
stimulate T-lymphocyte proliferation served as an internal positive control.  
 
Comparative analysis between chickens vaccinated with pHES/STM1 and pHES/HA1/STM1 
indicated that STM1 expressing influenza HA1 using pHES-vectored construct did not 
increase IFN-γ secretion following stimulation with either inactivated PR-8 virion (P>0.10) or 
Pichia-expressed rHA1 (P>0.10) (Figure 5.7).  
 
Analysis of IFN-γ secreting splenocytes obtained from chickens vaccinated with 
pMOhly1/STM1 and pMOhly1/HA1/STM1 indicated a statistically significant response  in 
splenocytes stimulated with inactivated PR-8 virion (P<0.01) and in splenocytes stimulated 
with Pichia-expressed rHA1 (P<0.05) when compared with the control as shown in Figure 5.8.  
 
These results indicate that STM1 expressing influenza HA1 using the pHES-vectored construct 
cannot induce an IFN-γ response, but pMOhly1-vectored construct can induce an IFN-γ 
response. In addition, splenocytes stimulated with inactivated PR-8 virion exhibited slightly 
elevated IFN-γ secretion compared to rHA1 stimulated splenocytes. Increased IFN-γ secretion 
might be induced by other immunostimulating components carried by the virion. 
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Figure 5.7: ELISpot assay of IFN-γ secreting T-lymphocytes from pHES/HA1/STM1 vaccinated 
chickens. 
Splenocytes from vaccinated chickens were stimulated with Pichia-expressed rHA1 or 
inactivated PR-8 virion, the number of positive IFN-γ secreting cells determined. Compared 
with the control group, chickens vaccinated with pHES/HA1/STM1 was unable to induce any 
statistically significantly different IFN-γ responses. (*P>0.10) 
 
 
 
 
* 
* 
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Figure 5.8: ELISpot assay of IFN-γ secreting T-lymphocytes from pMOhly1/HA1/STM1 
vaccinated chickens.  
Splenocytes from vaccinated chickens were stimulated with Pichia-expressed rHA1 or 
inactivated PR-8 virion, the number of positive IFN-γ secreting cells determined. Compared 
with the control group, chickens vaccinated with pMOhly1/HA1/STM1 construct yielded 
significantly higher spot counts.  
(**P<0.05, ***P<0.01) 
 
 
** 
*** 
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5.4 Discussion  
The use of live attenuated Salmonella as a vector to deliver heterologous antigen has been 
previously demonstrated [3, 150, 431]. The ability of the Salmonella vectors to target both 
cell-mediated and humoral immune responses and present heterologous antigen makes 
them an ideal candidate for the delivery of passenger antigen and induction of long-lasting 
immune responses [151, 152, 158]. The use of Salmonella-vectored vaccine carrier to deliver 
heterologous antigens for the prevention of avian influenza virus has been studied to a lesser 
extent, and currently there are no conclusive results available for potential 
commercialisation [311, 312, 314]. 
 
The aim of the work described in this chapter was to analyse the optimal antigen 
presentation of influenza HA1 in vivo from Salmonella STM1 in order to characterise the 
optimal expression system which can be further utilised for the efficient delivery of influenza 
HA1 by using STM1 as a vector.  
 
As described in the previous chapter, pHES and pMOhly1 vectors were engineered to express 
influenza HA1 in Salmonella STM1 and present these passenger proteins to different 
compartments for optimal immunogenicity. pHES encodes a modified ShdA autotransporter 
gene derived from S. Typhimurium LT-2, and the HA1 gene was cloned immediately 
downstream of N-terminal signal peptide for surface display of the fusion rHA1 protein after 
expression. pMOhly1 encodes the necessary components of the E. coli α-haemolysin 
secretion system, which secrete the fusion rHA1 into the extracellular compartment.  
 
Animal experiments demonstrated that STM1 expressing HA1 using the pHES vector loses its 
plasmid stability immediately after oral administration; whereas STM1 carrying the pMOhly1 
construct remained detectable for up to seven days after administration. For pHES-vectored 
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STM1 vaccines, the increased metabolic burden due to carriage of the pHES plasmid may 
have played an important role to the spontaneous loss of plasmid [129], which is not 
uncommon when the metabolic burden associated with plasmid replication over-attenuates 
the vaccine carrier [130]. Another possible explanation to the lack of plasmid detection after 
administration is the alteration of the surface-protein composition due to carriage of pHES 
vector, which may have had a significant impact on the retention of the vaccine carrier. It has 
been demonstrated in a mouse model that a serotype of S. Typhimurium strains harbouring 
mutated ShdA has reduced ability for intestinal persistence with reduced number and 
shorter period of faeces shedding compared to its isogenic parent strain [383, 386, 432]. 
Therefore, it is possible that the STM1 displaying a modified ShdA autotransporter protein on 
the surface hindered the vaccine’s ability to persist in vivo. Furthermore, as an IPTG-inducible 
plasmid vector, the fusion rHA1 could only be presented to chicken immune systems in a 
one-off fashion, which was achieved by IPTG-induction prior to administration. Take together, 
the spontaneous loss of plasmid, inability to persist inside chicken intestinal tract, and lack of 
repeated antigen presentation to chicken immune systems, the STM1 expressing HA1 using 
pHES vector was unable to elicit any HA1-specific immune responses. 
 
The STM1 expressing fusion rHA1 using the pMOhly1 vector, which was examined in this 
animal trial, has been shown to not induce any humoral immune responses including 
HA1-specific serum IgG, secretory IgA nor virus neutralising serum antibody response. 
However, cell-mediated immune response, as measured by enumeration of IFN-γ secreting 
splenocytes indicated significant elevation when stimulated by either Pichia-expressed rHA1 
(P<0.05) or inactivated PR-8 virion (P<0.01) compared with the control group.  
 
These findings indicate that the STM1 expressing HA1 using the pMOhly1 vector was unable 
to elicit antibody-mediated immune responses against influenza HA1. In contrast to our 
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findings, Liljebjelk and colleagues used a plasmid-based expression system, expressing 
codon-optimised H5N1 HA gene under the control of an anaerobically induced promoter in a 
S. Typhimurium Δaro mutant [312]. They found moderately elevated protective humoral 
immune responses in chickens via mucosal immunisation suggesting that the use of an in 
vivo inducible promoter, such as nir15, can potentially overcome the problem of toxicity of 
over expressed foreign protein or loss of expression plasmid. However, pMOhly1-vectored 
STM1 vaccines secrete foreign protein extracellularly, hence the accumulation of 
heterologous toxicity in the vaccine carrier is unlikely. One foreseeable disadvantage of using 
constitutive vectors for the purpose of delivering vaccine antigen is the continuous metabolic 
burden associated with protein expression, which could potentially over-attenuate the 
vaccine carrier, hence retarding vaccine immunogenicity. Furthermore, it has been reported 
by Hahn and von Specht, 2003 [390] that the level of protein expression from the haemolysin 
vector can be as low as 25 to 100 μg/L. 
 
Unlike the animal trial described in Chapter 3, where robust HA1-specific immune responses 
were elicited by subcutaneous administration of adjuvanted 25 μg of purified influenza HA1 
protein. The STM1 vaccine carriers expressing HA1 were unable to elicit any humoral 
immune responses.  
 
Evaluation of cell-mediated immune response from stimulated splenocytes indicated a 
positive response for the secretion of IFN-γ in the chickens vaccinated with STM1 expressing 
HA1 from pMOhly1 plasmid when compared with the control group, indicating that the rHA1 
antigen may be presented in a way to preferentially induce T-lymphocytes that secrete IFN-γ, 
indicative of a Th1-restricted type response in chickens.  
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As S. Typhimurium is a facultative intracellular pathogen, T-lymphocytes are essential 
components of the specific immune response. The bacterium-specific CD4+ and CD8+ 
T-lymphocytes are critical for a complete immune response against S. Typhimurium [121]. 
Following entry into the gut, the vaccine organisms are taken up by phagocytic cells, and the 
fusion rHA1 will be processed through the exogenous pathways. The exogenous pathway 
predominately presents antigen through MHC class II, leading to the activation of CD4+ T 
helper lymphocyte responses [415]. As shown in the results, the STM1 expressing HA1 from 
pMOhly1 plasmid induced a Th1 response, which is essential for the control of influenza 
infection by sustaining CD8+ T-lymphocyte response. It was unfortunate that Th2-type 
immune responses were not evaluated in this study due to unavailability of an anti-chicken 
IL-4 antibody for the ELISpot assay. However, the lack of antigen-specific humoral immune 
response suggests the lack of Th2 elicitation. Several factors such as type of Salmonella 
strains, type of mutation and the type of heterologous protein expressed play a decisive role 
in the generation of complete cell-mediated immune responses [433, 434].  
 
Another possible explanation to the sole production of low level IFN-γ is that, the STM1 
expressed pMOhly1/HA1 was processed through the endogenous pathway and directly 
presented by MHC class I molecules or cross-presented from the exogenous pathway, 
resulting in the activation of CD8+ Tc1 cells. Cross-presentation of exogenous antigens on 
MHC class I molecules is known to play an important role in the initiation of CD8+ 
T-lymphocyte responses [435]. The process is mainly carried out by specific dendritic cell 
subsets through an adaption of their endocytic and phagocytic pathways. Chin’ombe et al., 
2009 [436] reported a successful induction of CD8+ T-lymphocyte cytokine responses in orally 
immunised mice using attenuated an Salmonella vaccine strain expressing a green 
fluorescent protein model antigen. Such results highlight the potential of using attenuated 
Salmonella vaccine to induce antigen-specific CD8+ responses. The mechanisms of 
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Salmonella-expressed antigen being presented to the immune system by the MHC class I 
pathway to induce CD8+ responses is not yet fully understood. Nevertheless, it has been 
noticed that Salmonella have high tropism for DCs and these DCs have the ability to 
cross-prime exogenous antigens for induction of CD8+ T-lymphocyte responses [437-442]. 
Furthermore, DCs can also engulf the apoptotic cells from Salmonella infection, which may 
serve as another source of antigen that can be processed for the induction of CD8+ 
T-lymphocyte responses [441, 442]. Moreover, It has been reported that, during Salmonella 
infection, the Salmonella LPS stimulates TLRs on DCs, which leads to the production of IL-12 
[443]. IL-12 promotes IFN-γ production and activation of CD4+ Th1 responses. Therefore, it is 
possible that the presence of IL-12 induced by Salmonella LPS enables the STM1-expressed 
HA1 to stimulate Th1-type immune responses. 
 
It was observed that splenocytes stimulated with inactivated PR-8 virion exhibited slightly 
elevated IFN-γ secretion compared to rHA1 stimulated splenocytes. Butchko et al., 1978 [444] 
reported that non-infectious influenza virus type A strain H2N2 is a strong T- and B- 
lymphocyte mitogen. Furthermore, Anders et al., 1984 [445] showed that inactivated 
influenza type A subtype H1 induced low, but significant levels of T-lymphocyte proliferation 
in unprimed splenocytes from BALB/c mice. Further investigation by the authors 
demonstrated the virus-induced mitogenesis can be inhibited by monoclonal antibodies 
directed against hemagglutinin, which strongly suggests the mitogenic property of influenza 
hemagglutinin [445]. 
 
This study has shown that although attenuated S. Typhimurium STM1 holds many promising 
factors to be used as vaccine carrier, including elicitation of both CD4+ and CD8+ 
T-lymphocyte responses, the immunogenicity of such a system heavily depends on how the 
heterologous protein is expressed and delivered to the host. STM1 expressing fusion rHA1 
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using pHES vector has been shown to be ineffective in stimulating humoral and cell-mediated 
immune responses. It is possible that the inability to persist in vivo combined with the lack of 
repeated antigen presentation may contribute to this finding. However, STM1 expressing 
HA1 using pMOhly1 vector was able to elicit Th1-biased immune responses, but no humoral 
immune responses.  
 
Based on the findings of this chapter it remains possible that STM1 mutants can be used 
effectively as a carrier to deliver influenza antigen and confer protective immunity through 
oral immunisation. Nevertheless, the efficacy of such vaccine still requires enhancements by 
in-depth understanding of the host-to-vaccine interactions and mechanisms to increase the 
level of protein expression.  
 
 
 
 
 
 
 
 
 
 
 
  
 
Chapter 6 
Conclusion 
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Avian influenza virus is a continuous and re-emerging disease with a devastating impact on 
the global poultry industry and occasionally to the human population [163, 164]. Currently, 
the poultry industry heavily relies on enhancing biosecurity measures, frequent surveillance 
and restricting poultry movement to control and prevent an influenza epidemic [170, 177]. 
However, these basic control measures have failed to effectively control the virus spread, as 
sporadic outbreaks of avian influenza infections still happens on yearly basis [257]. In recent 
years, the introduction of prophylaxis vaccines for the prevention of influenza infections in 
the poultry industry have helped to limit the socioeconomic impact during these outbreaks, 
but several limitations and concerns associated with vaccine efficiency has been debated in 
the scientific community [169, 282]. Several noticeable limitations have resulted in 
suboptimal coverage of these vaccines, including the time-consuming production of the 
egg-based conventional inactivated whole-virus vaccine and labour-intensive parenteral 
administration [253]. The development of an efficacious vaccine to protect against avian 
influenza virus would improve the husbandry of poultry and increase the productivity of 
poultry farm, and most importantly minimise spill-over infections into the human population 
[170, 213].  
 
This study focused on using two different vaccine approaches to elicit immune responses 
that would be protective against influenza infections; the use of yeast-expressed influenza 
rHA1 protein as a subunit vaccine antigen, and the use of rHA1 protein delivered by 
attenuated Salmonella vectors. The advantage of using yeast-expressed influenza rHA1 as a 
subunit vaccine is its scalability and productivity [290]; whereas Salmonella-vectored 
influenza vaccine can be administered simply by mixing with drinking water or aerosol spray 
[98].  
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The codon-optimised influenza PR-8 HA1 gene was engineered for expression from P. 
pastoris as a soluble secretory molecule. The expression studies indicated that rHA1 was 
successfully expressed and secreted into the growth medium as soluble molecule, and the 
rHA1 yield was the highest concentration in BMMY medium after 72 hours growth. This 
result suggested the buffering mechanism and additional nutrients supplied in yeast extract 
and peptone were crucial for optimal expression of rHA1. In optimised expression conditions, 
the total rHA1 protein-yield was approximately 2.9 mg/L.  
 
The animal experiment conducted using rHA1 as subunit vaccine antigen indicated the 
successful elicitation of both humoral and cell-mediated immune responses. Immunised 
mice exhibited significantly elevated IgG responses specific to purified rHA1, and endpoint 
titres of 51200 were obtained from ELISA when compared with the control group. The 
virus-neutralising HI titre of the immunised mice was determined to be 7.4log2 ± 5.5log2; 
whereas serum collected from the control group exhibited no virus-neutralising ability.  
 
In an investigation conducted by Saelens et al., 1999 [235], where the entire influenza 
A/Victoria/3/75 (H3N2 subtype) HA gene was expressed from P. pastoris, immunised mice 
exhibited an elicitation of virus-specific IgG responses and complete survival from 
homologous 10 LD50 challenge. Our investigation has shown that the globular HA1 domain of 
the entire HA protein is enough to stimulate the production of a virus-specific IgG immune 
response, and also the induction of virus-neutralising antibody responses.  
 
Cell-mediated immune responses were examined using the ELISpot assay, and the results 
suggested a T-lymphocyte bias towards Th2 immunity, indicated by the elevated secretion of 
IL-4 from stimulated splenocytes. Splenocytes collected from the immunisEd mice failed to 
demonstrate statistically significant IFN-γ secretion when compared with the control group, 
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indicating the lack of Th1 immune elicitation. Such results suggested the rHA1 subunit 
vaccine would induce an antibody-mediated immune response. In the case of influenza virus 
infection, robust Th2 responses are crucial for the prevention of viral attachment and entry 
by the production of neutralising antibodies [446]. The lack of Th1 elicitation might result in 
the absence of CD8+ T-lymphocyte activation. Nevertheless, literature has suggested that 
CD8+ T-lymphocyte responses are predominantly responsible for delayed-type viral clearance 
rather than the prevention of viral infection [7, 297, 447]. Therefore, the inability to generate 
protective cytotoxic T-lymphocyte responses in mice does not necessarily mean the vaccine 
will not be protective against influenza infection.  
 
Live attenuated Salmonella bacteria such as STM1 provide a unique alternative in terms of 
heterologous antigen delivery and immune presentation. The STM1 mutant harbours an 
aroA gene mutation and is a well-characterised vaccine strain currently licensed for the 
prevention of Salmonella infection in livestock. Bachtiar et al., 2003 [3] have demonstrated 
its potential to deliver heterologous vaccine antigen expressed from plasmid and was found 
suitable as vaccine carrier for this purpose.  
 
In this study, pHES and pMOhly1 vectors were used to express the influenza HA1 gene in 
STM1 for surface display and extracellular secretion of the antigen. The pHES vector 
equipped with a modified ShdA autotransporter gene derived from S. Typhimurium LT-2, 
which can translocate the rHA1 onto STM1 surface [5]. On the other hand, pMOhly1 vector 
encodes the necessary components of the E. coli α-haemolysin secretion system, which can 
secrete the rHA1 extracelullarly [6].  
 
The influenza PR-8 HA1 gene was successfully extracted from the virus and engineered into 
STM1 for surface display using the pHES vector and extracellular secretion using the 
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pMOhly1 vector. The expression studies have confirmed that the rHA1 expressed in pHES 
vector was successfully translocated onto the STM1 outer-surface membrane, with an 
optimal expression time of three hours post-induction. Furthermore, the rHA1 expressed in 
pMOhly1 vector was detected in overnight culture medium, indicating the successful 
secretion into extracellular space. Having confirmed expression of these STM1 vaccine clones, 
an animal experiment was carried out to assess the immunogenicity of these vaccines in 
Broiler chickens.  
 
The results detailed in Chapter 5 indicated that the STM1 expressing the HA1 in the pHES 
vector failed to induce any detectable immune responses, which is probably attributed to its 
“one-off” antigen presentation due to the in vitro induced promoter. Furthermore, the pHES 
vaccine plasmid was undetectable immediately after immunisation, indicating the lack of 
plasmid retention in the chicken intestinal tract. It is possible that having the modified ShdA 
autotransporter gene expressed on the STM1 vaccine surface could severely influence the 
mechanisms to attach and colonise in vivo [386, 432], and the increase metabolic burden due 
to plasmid replication may have facilitated the spontaneous loss of plasmid [129]. 
Spontaneous loss of plasmid has been a challenge in the development of vaccine carriers; 
whilst the delivery of plasmid-borne S. Typhimurium vaccine carrier has been relatively 
successful, several reports have indicated a decreased efficacy due to plasmid instability 
[448-450]. Therefore, it is important to ensure the stability of the gene encoding the 
heterologous antigen to optimise the vaccine efficacy, and leading to the development of 
successful vaccine carriers.  
 
The STM1 expressing HA1 using the pMOhly1 vector was also unable to induce any 
detectable humoral immune responses, including serum IgG, faecal IgA and virus-neutralising 
antibody responses. However, the vaccine successfully elicited a Th1-biased immune 
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response, indicated by the secretion of IFN-γ after being stimulated with either 
Pichia-expressed rHA1 or inactivated PR-8 virion. It was unfortunate that Th2-type immune 
responses could not be examined in this study due to the unavailability of an anti-chicken 
IL-4 antibody for the ELISpot assay. 
 
Although these vaccine vectors are as yet less than ideal for field application, the outstanding 
safety profiles and the ability to induce antigen-specific immune responses suggested that 
the development of Salmonella-vectored influenza vaccines could be achieved in the future 
by better expression of heterologous antigens from the selected Salmonella vector [379]. 
 
To improve the immunogenicity of the HA1 antigen delivered by STM1, the expression level 
and plasmid stability must be enhanced in order to progress to any commercial application. 
The use of plasmid-based antigen delivery system are a problem for two main reasons;  
they do not ensure the stability of antigen expression in the absence of selective pressure 
(antibiotic), and are open to the possibility of environmental contamination of residual 
bacterial flora through horizontal transmission of plasmids [4, 379]. However, the alternative 
plan would require the use of chromosomal integration coupled with an in vivo induced 
promoter, but such an expression system would decrease the level of antigen expression by a 
further step [379, 451, 452]. Therefore, further studies are required for selection of stronger 
promoters, as well, a well-characterised vaccine strain for chromosomal insertion.  
 
Taken together, these results indicated that Pichia-expressed influenza rHA1 could induce not 
only virus-specific humoral immune responses but also stimulate Th2-type cell-mediated 
immunity, which could be protective against influenza infections. The STM1 expressing 
secretory rHA1 using pMOhly1 vector successfully induced Th1-biased cell-mediated immune 
responses, which is suggested to be important in delayed-type viral clearance [7, 447].  
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Although the results acquired in these studies were less than satisfactory, there were 
significant responses to the influenza antigen that suggested further investigation is required. 
It may be possible to induce a better well-balanced immune response against influenza virus 
by combining both the subunit rHA1 and the STM1 vaccine strain into a prime-boost vaccine 
scheme. Such a vaccine regime could ensure the elicitation of both humoral and 
cell-mediated immunity against influenza infections.  
 
Moreover, it has been demonstrated in the study that the STM1 vaccine carrier can elicit 
Th1-type immunity, hence it can potentially lead to help for the activation of CD8
+ 
T-lymphocyte responses against the heterologous protein. Ashraf et al., 2011 has 
demonstrated that after orally immunised mice with attenuated S. Typhimurium mutant 
carrying the influenza nucleoprotein, followed by three booster immunisations, the mice 
were completely protected against lethal influenza virus challenge. In addition, a 
Th1-restricted immune response was elicited against influenza nucleoprotein [311]. 
Therefore, it is possible to use the STM1 vaccine carrier to deliver a conserved influenza viral 
protein such as the ion channel M2e or the NP, which might elicit a more universal immunity 
against the influenza infection.  
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Appendix 1 
Lambda DNA digested with PstI run on a 1.5% agarose gel. 
 
 
 
Image obtained from Fermentas Life Science Pty. Ltd., Japan 
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Appendix 2 
Protein Marker, Broad Range (P7702), New England Biolabs, USA. 
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Appendix 3 
Precision Plus Protein TM All Blue Standards (#161-0373), BioRad Laboratories, USA. 
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Appendix 4 
ColorPlus™ Prestained Protein Marker (P7709), New England Biolabs, USA.  
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Appendix 5 
Precision Plus Protein TM Dual Color Standards (#161-0374), BioRad Laboratories, USA. 
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Appendix 6 
Precision Plus Protein TM KaleidoscopeTM Standards (#161-0375), BioRad Laboratories, USA. 
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Appendix 7 
Individual IgG response against Pichia-expressed rHA1 in immunised mice, correlating to the 
aggregated data shown in Figure 3.12. 
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Appendix 8 
ELISpot analysis of IL-4 and IFN-γ productions in stimulated T cells for individual mice, 
correlating to the aggregated data shown in Figure 3.13. and Figure 3.14. 
 
 
Each bar is the illustration of averaged duplicates of an immunised mouse. Three mice were 
included in each cytoline production assay. 
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Appendix 9 
Individual IgG response of pHES/STM1 and pHES/HA1/STM1 vaccinated chickens, correlating 
to the aggregated data shown in Figure 5.3. 
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